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Deposition of Aβ in amyloid plaques and accumulation of hyperphosphorylated tau in 
neurofibrillary tangles are hallmark pathologies of Alzheimer’s disease. Changes in 
APP processing alter Aβ generation and are likely to affect APP function, which may 
also contribute to Alzheimer’s disease. APP binds to adaptor protein Fe65 and one 
proposed function of this complex is to signal to the nucleus to regulate gene 
transcription. However, the mechanisms that regulate APP-Fe65 binding and the 
genes regulated by this pathway are poorly understood. Phosphorylation is a common 
mechanism for regulating protein-protein interactions and Fe65 is phosphorylated by 
several kinases, including ERK1/2. The first hypothesis investigated in this thesis is 
that BDNF signalling, which leads to ERK1/2 activation, stimulates Fe65 
phosphorylation to regulate its binding to APP. BDNF was found to induce 
ERK1/2-dependent phosphorylation of Fe65 and, in a variety of assays including the 
use of phosphomutants, BDNF-induced phosphorylation of Fe65 was shown to inhibit 
the binding of Fe65 to APP. Unpublished next generation sequencing of Fe65 knockout 
mouse brains suggested that Fe65 may affect the wnt signalling pathway, which 
regulates GSK3β activity. GSK3β is a kinase involved in the hyperphosphorylation of 
tau in Alzheimer’s disease. The second hypothesis tested in this thesis is that Fe65 
regulates genes that are linked to GSK3β activity and tau phosphorylation. RT-qPCR 
carried out on Fe65 knockout mouse brains and siRNA-treated rat cortical neurons 
found that expression of wnt receptor Fzd-1 was affected by loss of Fe65. Additionally, 
loss of Fe65 decreased both GSK3β activity and tau phosphorylation. These results 
show that Fe65 is involved with APP to function in a key process that can be regulated 
by BDNF, a treatment previously shown to be neuroprotective in Alzheimer’s disease 
models. Furthermore, they reaffirm the link between APP and Fe65 and link Fe65 to 
tau phosphorylation, which may be the first step in understanding the relationship 
between the two hallmark pathologies of Alzheimer’s disease.  
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Amino acids: single letter code and abbreviations 
 
Single letter code Abbreviation Amino Acid 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
X Xxx Any amino acid 






AD Alzheimer’s disease 
ADAM A disintegrin and metalloproteinase  
AICD APP intracellular domain 
ANOVA Analysis of variance 
Aph-1 Anterior pharynx-defective phenotype-1 
APLP Amyloid precursor-like protein 
apoE Apolipoprotein E 
ApoER2 ApoE receptor 2 
APP Amyloid precursor protein 
APS Ammonium persulfate 
ARF6 ADP-ribosylation factor 6 
ATM Ataxia telangiectasia mutated 
ATR Ataxia-telangiectasia- and Rad3-related 
Aβ Amyloid-β 
BACE1 β-amyloid cleaving enzyme 1 
BDNF Brain-derived neurotrophic factor 
c-Abl c-Abl tyrosine kinase 
CAT Chloramphenicol acetyltransferase 
cdk5 Cyclin-dependent kinase 5 
CHO Chinese hamster ovary 
CHO-TrkB CHO cells stably transfected with TrkB 
Dab1 Disabled-1 
DIV Days in vitro 
DMEM Dulbecco’s modified Eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNase Deoxyribonuclease 
E. coli Escherichia coli 
ECL Enhanced chemiluminescence 
EDTA Etylenediamintetraacetic acid 
EGTA Ethylene glycol-bis(β-aminoethylether)-N,N,N’,N’-
tetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ERK Extracellular regulated kinase 
ERα Estrogen receptor α 
FBS Fetal bovine serum 
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Fe65KO Fe65 knockout 
Fe65L Fe65-like 
Fzd1 Frizzled 1 
GRB2 Growth factor receptor-bound protein 2 
GSK3α/β Glycogen synthase kinase 3α/β 
GST Glutathione-S-transferase 
HBSS Hank’s balanced salt solution 
HEK Human embryo kidney 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
JIP1 c-jun N-terminal kinase-interacting protein 1 
JNK c-jun N-terminal kinase 
KPI Kunitz protease inhibitor 
LB Luria-Bertani 
LB-amp Luria-Bertani broth containing 100 µg/ml ampicillin 
LRP Low-density lipoprotein receptor-related protein 
LTP Long-term potentiation 
MAP Mitogen-activated protein 
MEK MAP kinase kinase 
Mena Mammalian enabled 
Mint munc-18 interacting 
mRNA Messenger RNA 
NFT Neurofibrillary tangles 
NGF Nerve growth factor 
NMDA N-methyl-D-aspartate 
OD Optical density 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PEN-2 PS enhancer 2 
PFA Paraformaldehyde 
PLA Proximity ligation assay 
PS Presenillin 
PTB Phosphotyrosine binding 
RIPA Radio-immunoprecipitation assay 
RNA Ribonucleic acid 
RT-qPCR Quantitative real-time PCR 
sAPPα/β Secreted APPα/β 
S.D. Standard deviation 
SDS Sodium dodecyl sulphate 
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SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SGK1 Serum- and glucocorticoid-induced kinase 1 
SH2 Src-homology-2 
siRNA Small interfering RNA 
TAE Tris-Acetate-EDTA 
TBS Tris buffered saline 
TCF/LEF T-cell factor/lymphoid enhancer factor 
TEMED Tetramethylethylenediamine 
Tris Tris(hydroxymethyl)aminomethane 
Triton-PBS 0.1 % (v/v) Triton X-100 in PBS 
TrkB Tyrosine receptor kinase B 





CHAPTER 1: INTRODUCTION 
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1.1 Alzheimer’s disease 
1.1.1 Prevalence and burden of Alzheimer’s disease  
Alzheimer’s disease (AD) is the most common cause of dementia. It is a progressive 
neurodegenerative disorder that affects over 850,000 people in the UK and 44 million 
sufferers worldwide (http://www.alzheimersresearchuk.org/). Due to a lack of effective 
treatments or cures, most patients live with AD for a number of years. During this time, 
disease symptoms become increasingly severe and more debilitating. This creates a 
huge burden on the carers and families and costs the UK alone £23 billion per year. 
The prevalence of AD is increasing and it is estimated that worldwide, 115.4 million 
people will be living with the disease by 2050 (World Health Organization, 2012). 
These alarming figures make it clear that finding a treatment for AD is of vital 
importance. 
 
There are several subclasses of AD that are categorised by age of onset, progression 
rate of disease and whether there is an underlying genetic cause. Over 90 % of AD 
cases are sporadic, late-onset disease occurring in those aged 65 and over 
(http://www.alzheimersresearchuk.org/). Unlike the rare, familial forms of disease, 
sporadic AD is not linked to a particular genetic mutation and does not show a 
predictable pattern of inheritance. Patients with AD usually present a syndrome of 
clinical symptoms. These can include problems with learning, remembering 
information, language usage, understanding complex tasks, visuospatial difficulties and 
personality changes. AD can be difficult to diagnose because there are several forms 
of dementia with overlapping symptoms. Also, some people develop mixed dementia, 
where more than one form of dementia is responsible for their cognitive decline 
(Jellinger and Attems, 2010). As many of the dementia diseases display similar 
biochemical abnormalities within the brain, studying AD may help to shed light on 
causes and treatments of other neurodegenerative diseases. 
 
1.1.2 Cellular pathology of AD 
AD was originally described in 1906 by Dr Alois Alzheimer as a range of symptoms 
observed in a 51 year-old patient. These symptoms included personality changes, 
memory loss and disorientation. Post-mortem investigation of the cortical tissue 
revealed atrophy and abnormal 'minute miliary foci' and 'tangles of fibrils’ (Stelzmann et 
al., 1995). The examination of brain samples from other AD patients over the last 
century has revealed that two hallmark pathologies – extracellular neuritic plaques and 
intracellular neurofibrillary tangles – are present in AD (see Figure 1.1). 
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Figure 1.1: The hallmark pathologies of AD. Silver stain of brain tissue showing 
(black arrowhead) a neuritic plaque and (white arrowhead) a neurofibrillary tangle. 
(Image from Serrano-Pozo et al., 2011). 
 
1.1.2.1 Neuritic plaques 
Neuritic plaques contain a core that mainly consists of aggregated amyloid-β (Aβ). Aβ 
exists mainly as a 40-42 amino acid peptide that is derived from the amyloid precursor 
protein (APP) by proteolytic cleavage (Zhang et al., 2011). Aβ40/42 peptides are 
produced by the same pathway but the longer peptide is more prone to aggregation 
and is believed to be the first form of Aβ deposited in plaques (Gravina et al., 1995; 
Jarrett et al., 1993; Roher et al., 1993). The neuritic plaques are heterogeneous and 
contain other proteins including acetylcholinesterase, apolipoproteins, growth factors 
and their receptors (Armstrong et al. 2008). Neuritic plaques are usually surrounded by 
degenerating neurites and can also contain processes from microglia, the immune cells 
of the brain (Dickson, 1997; Meyer-Luehmann et al., 2008; Pike et al., 1995). Neuritic 
abnormalities and microglial recruitment occur shortly after plaque formation, 
suggesting these are responses to either the plaques themselves or toxic molecules 
released by plaques (Meyer-Luehmann et al., 2008). In AD brains, neuritic plaques are 
found in the hippocampus and cortex, areas most vulnerable to disease. However, they 
are not exclusive to AD and can develop during normal ageing, although they are far 
fewer in number in these cases (Herrup, 2015; Morris et al., 1996; Snowdon et al., 
1997). 
 
1.1.2.2 Neurofibrillary tangles 
The other pathology of AD is the presence of intraneuronal neurofibrillary tangles 
(NFTs) comprising the microtubule-associated protein tau. There are six different tau 
isoforms in the human brain that are derived from alternative splicing of exons. The 
isoforms contain either three or four C-terminal microtubule-binding domains and none, 
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one or two N-terminal inserts (Noble et al., 2013; Wang and Mandelkow, 2015). Tau is 
predominantly expressed in neurons and is involved in regulating microtubule 
stabilisation and cytoskeletal dynamics and may play a role in regulating axonal 
transport (Elie et al., 2015; Wang and Mandelkow, 2015). Tau is a phosphoprotein that 
contains 85 potential phosphorylation sites (Noble et al., 2013; Wang and Mandelkow, 
2015). Regulation of tau phosphorylation is performed by many kinases and 
phosphatases and is important because tau is hyperphosphorylated in NFTs (Noble et 
al., 2013; Šimić et al., 2016). A number of serine/threonine and tyrosine kinases have 
been implicated in the hyperphosphorylation of tau in AD; particularly cyclin-dependent 
kinase 5 (cdk5)/p35 and glycogen synthase kinase 3 (GSK3; Hooper et al., 2008; 
Noble et al., 2013; Su and Tsai, 2011).  
 
Although both neuritic plaques and NFTs are hallmark pathologies of AD, the severity 
of tau pathology correlates best with disease progression and spread along vulnerable 
brain regions (Braak and Braak, 1991; Wilcock and Esiri, 1982). NFTs are found in a 
number of neurodegenerative disorders that display tau pathology termed tauopathies 
(Šimić et al., 2016; Spillantini and Goedert, 2013; Wang and Mandelkow, 2015). 
Aggregated tau may cause cellular dysfunction by loss of normal function or by gain of 
toxic function of insoluble tau oligomers. Indeed, tau appears to facilitate Aβ 
neurotoxicity (Ittner and Götz, 2011). However, NFTs may not be neurotoxic 
themselves as they can be present in cells for many years without causing cell death 
(Spillantini and Goedert, 2013; Wang and Mandelkow, 2015).  
 
How these two pathologies begin and escalate has been a key focus of AD research, 
with the rationale that the cause of disease should provide a target for therapeutic 
development. The majority of drug development has focussed on combating neuritic 
plaques, however all clinical trials to date on therapeutics intended to clear neuritic 
plaques from the brain have failed to ameliorate disease symptoms, even when plaque 
load has been successfully reduced (Doody et al., 2014; Herrup, 2015; Holmes et al., 
2008; Salloway et al., 2014). Along with evidence that both neuritic plaques and NFTs 
can be found in individuals without AD (Herrup, 2015; Lee et al., 2001; Morris et al., 
1996; Snowdon et al., 1997; Wang and Mandelkow, 2015), these failures imply that AD 
is more complex than originally thought. 
 
1.1.3 Genetics of AD 
Although the vast majority of AD cases are sporadic, research into the genetic causes 
of familial AD has helped to identify genes involved in the disease. Autosomal 
dominant mutations that cause early-onset, familial AD are found in one of three 
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genes: APP, PS1 (encoding presenilin 1; PS1) or PS2 (encoding presenilin 2; PS2). 
Mutations in MAPT, the gene encoding tau, do not cause AD but cause some forms of 
another inherited tauopathy called frontotemporal lobar degeneration with tau 
pathology (Goedert et al., 2012). 
 
1.1.3.1 APP 
The first genetic link discovered in AD was that patients with Down’s Syndrome 
(trisomy of chromosome 21) over the age of forty develop typical AD pathology. The 
APP gene is located on chromosome 21, so these patients carry three copies of APP, 
suggesting that an excess of APP protein can cause disease (St George-Hyslop et al., 
1987; Wisniewski et al., 1985). Indeed, duplication of the APP gene has since been 
found to cause familial AD (Rovelet-Lecrux et al., 2006; Sleegers et al., 2006). A 
number of autosomal dominant mutations of APP have also been shown to cause 
familial AD. These pathogenic mutations occur close to the Aβ domain of APP and act 
to enhance or alter Aβ production (www.alzforum.org; Schellenberg & Montine 2012; 
Tanzi 2012). In particular, some mutations increase total Aβ production, some 
mutations increase the relative levels of the more pathogenic Aβ42 peptide and some 
mutations make Aβ more prone to aggregation or more “amyloidogenic”. Interestingly, 
one APP mutation has been identified that protects against AD and this inhibits the 
production of Aβ (Jonsson et al., 2012). 
 
1.1.3.2 PS1 and PS2 
Mutations in PS1 and PS2 are the most common cause of familial AD. The presenilins 
form part of the γ-secretase complex that is involved in the proteolytic cleavage of APP 
to produce Aβ (De Strooper et al., 2010). Familial AD-linked PS1/2 mutations are 
loss-of-function mutations that alter the production of Aβ from APP by influencing the 
specificity of γ-secretase cleavage. PS1/2 mutations enhance generation of the more 
pathogenic Aβ42 peptide over the less pathogenic Aβ40 peptide (De Strooper and 
Annaert, 2010; Duff et al., 1996; Fernandez et al., 2014; Scheuner et al., 1996). 
 
1.1.3.3 MAPT 
The MAPT gene encodes tau and resides on chromosome 17. To date, no mutations in 
MAPT have been found that cause familial AD. Instead they lead to the development of 
some forms of frontotemporal lobar degeneration with tau pathology (Lee et al., 2001; 
Šimić et al., 2016; Spillantini and Goedert, 2013). MAPT mutations either alter the 
ability of tau to bind to microtubules or alter the ratio of tau isoforms via alternative 
splicing changes (Spillantini and Goedert, 2013). Both types of mutations enhance tau 
aggregation into intracellular NFTs. 
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1.1.3.4 Risk factor genes 
A number of other genes are now known to increase the risk of developing AD. The ε4 
allele of the APOE gene, encoding apolipoprotein E (apoE), is the strongest risk factor 
discovered to date for late-onset, sporadic AD. There are three APOE alleles: ε2, ε3 
and ε4. Individuals carrying one copy of the APOE-ε4 allele have a 3-fold increased 
risk, while people carrying two copies have a greater than 10-fold increased risk of 
developing sporadic AD (Corder et al., 1993; Genin et al., 2011; Kim et al., 2009; 
Verghese et al., 2011). In contrast, the ε2 allele of APOE is neuroprotective and 
carriers of this allele have a lower risk of AD (Corder et al., 1994; Hu et al., 2015). The 
exact mechanism of apoE pathogenicity is unknown but it may be involved in Aβ 
aggregation, clearance of Aβ, or tau phosphorylation (Castellano et al., 2011; Kim et 
al., 2009).  
 
In addition to APOE, recent genome-wide association studies have identified over 
twenty other genes that are associated with AD (Bertram et al., 2010; Harold et al., 
2009; Hollingworth et al., 2011; Karch et al., 2014; Lambert, 2013; Naj et al., 2011; 
Seshadri et al., 2010). These can be broadly grouped into genes involved in lipid 
metabolism, protein trafficking and inflammation (Karch and Goate, 2015; Schellenberg 
and Montine, 2012). Although the effect of these genes on the risk of developing AD is 
much lower than APOE, they may help to elucidate further pathways involved in 
disease. 
 
1.1.4 The amyloid cascade hypothesis 
As described above, the pathology of AD involves extracellular accumulation of Aβ in 
neuritic plaques and intracellular accumulation of tau in NFTs. Mutations in APP and 
PS1/2 alter APP processing to enhance Aβ production. These pathogenic mutations 
cause familial AD, which displays both neuritic plaques and NFTs. Mutations in MAPT 
cause related dementias, but do not initiate amyloid pathology. This evidence suggests 
that mismetabolism of APP can affect tau phosphorylation and supports the amyloid 
cascade hypothesis, which is the most widely accepted hypothesis for AD development 
and progression. The amyloid cascade hypothesis describes two key events that lead 
to the two hallmark pathologies of disease; 1) the altered processing of APP, leading to 
Aβ plaque formation and 2) the hyperphosphorylation of tau, leading to NFT 
development (see Figure 1.2). The hypothesis proposes that changes in APP 
metabolism occur prior to the hyperphosphorylation and aggregation of tau. In support 
of this hypothesis, familial AD cases are associated with mutations in the APP gene or 
PS1/2 genes (see section 1.1.3). These mutations fall into 3 classes; enhanced APP 
production, enhanced amyloidogenic processing or enhanced Aβ42 generation 
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(Schellenberg and Montine, 2012; Scheuner et al., 1996; Tanzi, 2012). In contrast, 
mutations in the gene encoding tau have not yet been linked to AD, but instead cause 
frontotemporal lobar degeneration and increase the risk of developing other 
tauopathies that have NFT pathology without neuritic plaque development (Goedert et 
al. 2012; Spillantini & Goedert 2013; Wang & Mandelkow 2015).  
 
Recently, soluble Aβ oligomers, rather than insoluble Aβ aggregates have been 
proposed as an alternative or complementary route to synapse loss and cell death from 
APP mismetabolism (Benilova et al., 2012). Monomeric Aβ can aggregate into soluble 
oligomers of varying molecular size that cause neurotoxicity (Sakono and Zako, 2010). 
However, there is some dispute over the physiological relevance of these findings, due 
to the high concentrations of Aβ required to induce cell death (Benilova et al., 2012; 
Hardy, 2009).  
 
The causative link between Aβ generation, or even general altered APP processing 
and tau hyperphosphorylation is still unknown. Indeed, most APP animal models do not 
develop tau pathology, requiring mutations of both APP (or APP processing-linked) and 
MAPT genes to fully model disease (Elder et al., 2010; Richardson and Burns, 2002). 
The hypothesis also does not explain how Aβ aggregates can be found in healthy 
individuals without tau pathology and why Aβ fails to correlate well with disease 





Figure 1.2: The amyloid cascade hypothesis. A diagram to show the outline of the 
amyloid cascade hypothesis.  
 
1.2 The amyloid precursor protein 
APP belongs to a small family of proteins comprising APP and amyloid precursor-like 
protein 1 and 2 (APLP1 and APLP2). These three proteins are very similar in structure 
and have overlapping expression patterns (Sprecher et al., 1993; Wasco et al., 1993, 
1992). The APP genes are highly conserved in mammals and APP-family knockout 
mouse models suggest some level of functional redundancy between APP and 
APLP1/2 (Eggert et al., 2004; Heber et al., 2000; Herms et al., 2004; Müller and Zheng, 
2012; Slunt et al., 1994). 
 
APP is a type-1 transmembrane protein containing an N-terminal signal sequence (17 
residues), a large extracellular domain that is stabilised by disulfide bonds and is 
glycosylated, a transmembrane domain (23 residues) and a small intracellular domain 
(47 residues; Dyrks et al., 1988; Kang et al., 1987; Oltersdorf et al., 1989). The Aβ 
encoding sequence is located in the extracellular and transmembrane domains (Dyrks 
et al. 1988; see Figure 1.3). The APP gene is located on chromosome 21 at position 
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21q21.3 (Goldgaber et al., 1987; Kang et al., 1987; Robakis et al., 1987; Tanzi et al., 
1987) and undergoes alternative splicing of exons to generate a number of different 
isoforms. Three major isoforms of APP are produced, which contain 695, 751 or 770 
amino acids. The two longer isoforms contain a Kunitz protease inhibitor (KPI) domain 
that is capable of inhibiting serine proteases such as trypsin (Petersen et al., 1994; 
Tanzi et al., 1988) and may play a role in blood coagulation and wound repair 
(Schmaier et al., 1993; Smith et al., 1990). APP770 also contains an Ox2 domain (see 
Figure 1.3), which may be involved in cell-surface binding (Dawkins and Small, 2014), 
although very little is known about the function of this domain. APP695 is the main APP 
isoform expressed in brain tissue, while APP751 and APP770 are expressed ubiquitously 
throughout many cell types (Kitaguchi et al., 1988; Oltersdorf et al., 1989; Ponte et al., 
1988; Tanzi et al., 1988; Zhang et al., 2011). 
 
Figure 1.3: The structure of the APP isoforms. A) The labelled domains of the APP 
isoforms are the signal sequence (SS), Kunitz protease inhibitor (KPI), Ox2, amyloid-β 
(Aβ) and the APP intracellular domain (AICD). TM indicates the transmembrane region 
of the APP proteins B) APP695 domain details including the sequence of the AICD, the 
YENPTY binding domain that interacts with Fe65 (red) and the epitope to which CT-17 
(the C-terminal APP antibody used in this thesis) was raised against (blue line; Cousins 




APP is most abundantly expressed in the brain, heart and spleen, although it is also 
found in other peripheral tissues (Kitaguchi et al., 1988; Tanzi et al., 1988, 1987). 
Within the brain, APP is particularly localised to the cerebral cortex and hippocampus, 
areas that are affected in AD (Arai et al., 1991; Bahmanyar et al., 1987). The 
subcellular localisation of APP is linked to both its complex processing pathways and 
its proposed functions. APP is found in the endoplasmic reticulum and Golgi apparatus, 
which is where it is synthesised and post-translationally modified (Haass et al., 1992; 
Marquez-Sterling et al., 1997). It is also localised to the plasma membrane and to 
secretory vesicles and endosomes that transport APP to and from the cell surface 
(Schubert et al., 1991; Sisodia, 1992; van der Kant and Goldstein, 2015). APP is 
transported through axons by fast, anterograde transport in a kinesin-1-dependent 
manner and in developing axons, it is thought to play a role in cell motility (Cheung et 
al., 2014; Fu and Holzbaur, 2013; Koo et al., 1990; Marquez-Sterling et al., 1997; Moya 
et al., 1994; Stokin et al., 2005; Vagnoni et al., 2012). APP is also found in vesicles in 
the presynaptic terminals of many synapses, where it may function in synapse 
development and synaptic transmission (Lee et al., 2010; Priller et al., 2006; Schubert 
et al., 1991; Tyan et al., 2012; van der Kant and Goldstein, 2015; Weyer et al., 2011).  
 
1.2.1 APP proteolytic processing 
APP can be proteolytically processed via two mutually exclusive pathways (Figure 1.4). 
These pathways consist of a sequence of cleavage events by a combination of three 
enzymes or enzyme complexes that are termed secretases. α-secretase cleavage 
occurs within the extracellular Aβ domain of APP (Lys16 of the Aβ sequence), 
precluding the generation of the Aβ peptide (Anderson et al., 1991; Esch et al., 1990; 
Sisodia, 1992; Sisodia et al., 1990; Wang et al., 1991). Alternatively, APP can be 
processed by β-secretase. β-secretase cleaves full-length APP at two sites; between 
Met596 and Asp597 or between Tyr606 and Glu607, which are both at the N-terminus of the 
Aβ encoding sequence (APP695 numbering; Deng et al., 2013; Seubert et al., 1993; 
Shoji et al., 1992; Sinha et al., 1999). Once α- or β-secretase cleavage has occurred, 
the remaining membrane-tethered C-terminal APP fragment is sequentially cleaved by 
γ-secretase at the C-terminus of the Aβ sequence (Haass et al. 2012; Figure 1.4). The 
APP processing pathway that involves cleavage of APP by α- and γ-secretase is the 
non-amyloidogenic pathway and it precludes Aβ generation. The amyloidogenic APP 
processing pathway involves β- and γ-secretase cleavage of APP and releases the Aβ 
peptide. A recent study reported a new processing event driven by η-secretase 
cleavage of APP between Asn504 and Met505 followed by α- or β-secretase cleavage, 




Figure 1.4: APP processing occurs via two mutually exclusive pathways.  APP 
processing via the non-amyloidogenic pathway creates three peptides; secreted APPα 
(sAPPα), p3 and APP intracellular domain (AICD). The amyloidogenic pathway 
generates secreted APPβ (sAPPβ), the amyloidogenic fragment amyloid-β (Aβ), which 
is involved in amyloid plaques and AICD.  
 
The majority of APP is metabolised via the non-amyloidogenic pathway. This produces 
a soluble extracellular N-terminal fragment (sAPPα), a C-terminal APP intracellular 
domain (AICD) and a small peptide termed p3. Processing by the amyloidogenic 
pathway produces a soluble N-terminal domain (sAPPβ), AICD and Aβ (Haass et al., 
2012). The low sequence specificity of γ-secretase accounts for the creation of varying 
lengths of Aβ peptide (Zhang et al., 2011). These cleavage events may also occur in 
different cellular compartments (Hartmann et al., 1997). sAPPβ and Aβ fragments are 
then secreted from the cell (Chow et al., 2010; Haass et al., 2012). The processing 
pathways are differentially localised within the cell, suggesting that APP trafficking to 
and from the cell surface may play a vital role in determining the balance of α- and 
β-processing of APP (Haass et al., 2012). This may also explain why AICD from the 
amyloidogenic pathway is reported to regulate gene transcription, while AICD 
generated from the non-amyloidogenic pathway is not (Belyaev et al., 2010; Goodger 
et al., 2009). 
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1.2.2 APP secretases 
Because of their influence on the fate of APP, much research has been carried out to 
identify the secretase enzymes responsible for the cleavage of APP. β-secretase has 
been identified as β-amyloid cleaving enzyme 1 (BACE1). BACE1 is a type-1 
membrane-spanning aspartyl protease that is active in the low pH environment of the 
endosomal/lysosomal system and Golgi, where it cleaves APP (Shoji et al., 1992; 
Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). γ-secretase is a multiprotein 
complex consisting of aspartic proteases PS1/2, PS enhancer 2 (PEN-2), nicastrin and 
anterior pharynx-defective phenotype-1 (Aph-1). PEN-2, nicastrin and Aph1 are 
believed to be chaperone proteins or involved in targeting the γ-secretase complex to 
its substrates (Strooper et al. 2012). α-secretase has still not been fully identified but it 
has recently been reported to be a metalloprotease of the a disintegrin and 
metalloproteinase (ADAM) family. ADAM9, ADAM10 and ADAM17 are all capable of 
α-secretase cleavage of APP and there appears to be some functional redundancy 
among these proteins (Kuhn et al., 2010; Vingtdeux and Marambaud, 2012). In 
addition, a BACE1 homologue, BACE2, may also cleave APP at the α-secretase site, 
although BACE2 is only expressed at very low levels in neurons (Basi et al., 2003; 
Bennett et al., 2000; Yan et al., 2001). 
 
1.2.3 APP functions 
The precise function of APP is unknown. APP, APLP1 and APLP2 knockout mice are 
viable and display only minor phenotypes of reduced body weight and locomotor 
deficits (Heber et al., 2000; Shariati and De Strooper, 2013). APP/APLP1 double 
knockout mice are also viable but double knockout of either APP or APLP1 with APLP2 
causes death shortly after birth. Despite this, these double knockouts show no obvious 
histopathological abnormalities (Heber et al., 2000; Shariati and De Strooper, 2013). 
 
While the APP knockout mice are viable, they show neuronal abnormalities such as 
reduced synaptic density, increased neurite branching and an increase in defective 
synapses (Li et al., 2010; Wang, 2005). This suggests that APP plays a role in neurite 
outgrowth and synapse formation, which is supported by evidence that loss of APP 
reduces neurite length while exogenous APP and AICD augments neurite growth 
(Allinquant et al., 1995; Koo et al., 1993; Milward et al., 1992; Qiu et al., 1995; Zhou et 
al., 2012). In addition to this, sAPPα acts as a trophic support molecule for elongating 
processes (Milward et al., 1992; Ohsawa et al., 1999; Tyan et al., 2012; Young-Pearse 
et al., 2008). APP also enhances cell surface expression of a receptor for nerve growth 
factor (NGF), another trophic support factor for developing neurites (Matrone et al., 
2011; Milward et al., 1992; Patapoutian and Reichardt, 2001; Wallace et al., 1997) and 
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finally, APP is involved in the regulation of actin cytoskeleton dynamics in growth cones 
via its interaction with Fe65 (Cheung et al., 2014; Sabo et al., 2003). In contrast, others 
report that loss of APP enhances outgrowth (Young-Pearse et al., 2008) and inhibits 
cell proliferation and neurogenesis (Ghosal et al., 2010; Ma et al., 2008). These 
conflicting data suggest that both too much and too little APP can be detrimental to 
normal neuronal development.  
 
APP also appears to play an important role in calcium signalling during synaptic 
transmission (Gautam et al., 2015; Leissring et al., 2002; Wang, 2005). Both APP 
overexpressing and knockout mice show enhanced susceptibility to seizures in 
response to stress (Koike et al., 2012; Vogt et al., 2011), and have a large proportion of 
non-functioning synapses (Wang, 2005). This may be due to impaired APP-mediated 
calcium signalling at synapses or the misregulation of cell surface receptors. APP 
interacts with N-methyl-D-aspartate (NMDA) glutamate receptors and increases their 
cell surface expression (Cousins et al., 2009), which enhances calcium signalling and 
synaptic transmission (Carroll and Zukin, 2002; Lau and Zukin, 2007). In contrast to 
full-length APP, Aβ has the opposite effect on NMDA receptors and instead promotes 
receptor endocytosis (Snyder et al., 2005).  
 
Another key function of APP is its role in the regulation of gene expression. It carries 
out this role in conjunction with its binding partner Fe65 (Borg et al., 1996; Bressler et 
al., 1996; Cao and Südhof, 2004, 2001; Fiore et al., 1995; McLoughlin and Miller, 1996; 
Trommsdorff et al., 1998; Zambrano et al., 1997). Although there is strong evidence 
that APP and Fe65 are involved in modulating gene transcription, the genes that are 
affected by this signalling pathway are not consistently reported (Belyaev et al., 2009; 
Grimm et al., 2015; Kim et al., 2003; Lau et al., 2008; Pardossi-Piquard et al., 2005; 
Perkinton et al., 2004; Ryan and Pimplikar, 2005; von Rotz et al., 2004; Xu et al., 
2011). The regulation of gene transcription by APP and Fe65 is discussed in more 
detail in section 1.3.2. 
 
APP has also been implicated in intracellular axonal transport via kinesin-1 (van der 
Kant and Goldstein, 2015), although others have disputed this finding (Brunholz et al., 
2012). There is also evidence linking APP with metal homeostasis (Ayton et al., 2013). 
In addition, the longer, KPI domain-containing isoforms may also function in regulating 
blood clotting and wound repair (Dawkins and Small, 2014). 
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1.2.4 APP interacting proteins  
A large number of proteins have been shown to bind to APP (van der Kant and 
Goldstein, 2015; Van Gassen et al., 2000). The best-characterised APP interacting 
proteins are those that bind to the 682YENPTY687 motif in the intracellular domain of 
APP. These proteins interact with APP via phosphotyrosine binding (PTB) domains or 
src-homology-2 (SH2) domains and include Fe65 family proteins, disabled-1 (Dab1), 
X11 family proteins, c-jun N-terminal kinase (JNK) interacting protein (JIP1), ShcA/C 
and growth factor receptor-bound protein 2 (GRB2; van der Kant & Goldstein 2015). 
 
The Fe65 protein family comprises Fe65, Fe65-like 1 and Fe65-like 2 (Fe65L1 and 
Fe65L2). They are all adaptor or scaffolding proteins that contain a number of 
protein-protein interaction domains, through which, they mediate the assembly of 
protein complexes. The best-studied family member is Fe65, which is the topic of this 
thesis and its structure, function and binding to APP are discussed in more detail in 
section 1.3. 
 
Dab1 is another adaptor protein that interacts with APP via its YENPTY domain 
(Homayouni et al., 1999; Howell et al., 1999), outcompeting Fe65 for binding (Kwon et 
al., 2010). Both APP and Dab1 are involved in cell migration (Young-Pearse et al., 
2007), possibly by pathways that involve apoE receptors. Interactions between APP 
and apoE receptors are thought to play a role in modulating lipoprotein metabolism 
(Hoe and Rebeck, 2008). Fe65 may also be involved in this pathway as it can bind to 
apoE receptor 2 (ApoEr2) and low-density lipoprotein receptor-related protein (LRP) 1 
(Hoe et al., 2006; Kinoshita et al., 2001; Pietrzik et al., 2004; Trommsdorff et al., 1998).  
 
The X11 or munc-18 interacting (Mint) family proteins comprise three adaptor proteins 
(X11α, X11β and X11γ) that contain a PTB domain that interacts with the YENPTY 
domain of APP. X11α and X11β are neuron-specific isoforms, while X11γ is 
ubiquitously expressed (Rogelj et al., 2006). The X11s may facilitate an interaction 
between APP and the γ-secretase complex to regulate APP processing (Lau et al., 
2000a; Mueller et al., 2000). X11β and Fe65 compete for YENPTY binding, with APP 
preferentially interacting with Fe65 (Lau et al., 2000b). The X11s may also function in 
APP trafficking via binding to calsyntenin-1 (also known as alcadein α1), a kinesin-1 
light chain ligand (Araki et al., 2003). X11β may act as a Golgi coat protein to load APP 
onto calsyntenin-1-containing vesicles for axonal transport on kinesin-1 motors 
(Vagnoni et al., 2012). 
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JIP1 is also thought to be involved in APP transport as it interacts with both APP and 
kinesin-1 light chain (Fu and Holzbaur, 2013; Matsuda et al., 2001; Muresan and 
Muresan, 2005; Scheinfeld et al., 2002), although there is conflicting evidence 
regarding this (Vagnoni et al., 2013). JIP1-dependent transport may facilitate the role of 
APP in neuronal outgrowth by delivering APP to neurite terminals (Muresan and 
Muresan, 2005). JIP1 may also enhance the phosphorylation of APP at Thr668 by JNK 
(Inomata et al., 2003; Kimberly et al., 2005). This has been shown to impact other 
protein interactions with APP, including weakening the APP-Fe65 complex (Ando et al., 
2001; Barbagallo et al., 2010; Nakaya and Suzuki, 2006) and enhancing APP-JIP1 
binding (Muresan and Muresan, 2005). 
 
ShcA, ShcC and GRB2 adaptor proteins are all capable of interacting with APP via 
binding to the YENPTY domain of APP (Russo et al., 2005, 2002; Zhou et al., 2004). 
ShcA-GRB2-APP complexes are reported to be upregulated in AD and may be 
involved in enhancing extracellular regulated kinase (ERK) 1/2 signalling (Nizzari et al., 
2007; Russo et al., 2002; Venezia et al., 2006), although the physiological relevance of 
this function is unclear. There is also evidence that these adaptor proteins may be 
involved in regulating APP processing (Nizzari et al., 2007; Xie et al., 2007). 
 
Phosphorylation of specific APP residues regulates these protein-protein interactions. 
Both X11s and Fe65 bind to unphosphorylated YENPTY domains while Shc proteins 
have phosphorylation-dependent binding (Borg et al., 1996). Phosphorylation of Tyr682 
(YENPTY) on APP facilitates ShcA/C binding by inhibiting the interaction between APP 
and Fe65 (Tarr et al., 2002a, 2002b) and reducing JIP1 binding (Tamayev et al., 2009). 
In contrast, phosphorylation of Tyr687 (YENPTY) does not alter APP interactions but 
instead regulates endocytosis and processing of APP (Rebelo et al., 2007; Takahashi 
et al., 2008). Despite being upstream of the YENPTY motif of APP, phosphorylation at 
Thr668 also inhibits APP-Fe65 binding (Ando et al., 2001; Barbagallo et al., 2010; 
Nakaya and Suzuki, 2006), although this is not consistently reported (Chang et al., 
2006; see Figure 1.3B). 
 
1.3 Fe65 
Fe65 is a member of a small family of adaptor proteins comprising Fe65, Fe65L1 and 
Fe65L2. All three proteins contain an N-terminal WW domain and two C-terminal PTB 
domains (see Figure 1.5; Bork & Sudol 1994; Bork & Margolis 1995). Through these 
three domains, the Fe65s can bind to other proteins and act as scaffolds for the 
formation of larger complexes (see section 1.3.1). WW domains recognise proline-rich 
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ligands containing a conserved sequence of PPXY or PPLP, while the PTB domains 
bind to proteins containing phosphotyrosine motifs. The Fe65s show at least some 
level of functional redundancy (Chow et al., 2015a; McLoughlin and Miller, 2008; 
Minopoli et al., 2012). For example, all members of the Fe65 family can interact with 
APP family members via their second C-terminal PTB domain (PTB2; Bressler et al., 
1996; Duilio et al., 1998; Guénette et al., 1996; Li et al., 2008; Mcloughlin et al., 1999). 
While Fe65 family members share structural and functional similarities, they differ in 
their patterns of protein expression. Fe65 is most highly expressed in neurons with the 
Fe65L1/2 proteins showing a more widespread, peripheral localisation (Bressler et al., 
1996; Duilio et al., 1991).  
 
Fe65 knockout (Fe65KO) and Fe65L1 knockout mice are viable and show no obvious 
phenotype (Guénette et al., 2006). Fe65/Fe65L1 double knockout mice occur at a 
lower than predicted frequency, are smaller and often display bilateral circling 
(Guénette et al., 2006). Fe65 has been better characterised than Fe65L1 or Fe65L2. 
The Fe65 gene is located on chromosome 11 at position 11q15 (Bressler et al., 1996). 
It undergoes alternative splicing to create two Fe65 isoforms that vary in length by  
2 residues, located within the PTB1 domain. The longer of these two isoforms is 
exclusively expressed in neurons and is the most abundant form found in the brain, 
while the shorter isoform is expressed in non-neuronal cells and is found in both brain 
and peripheral tissues (Duilio et al., 1991; Hu et al., 1998, 1999). An N-terminally 
truncated 60 kDa isoform of Fe65 is also expressed in cells and is generated by 
proteolytic cleavage (Cool et al., 2010; Domingues et al., 2011; Guénette et al., 2006; 
Hu et al., 2005; McLoughlin and Miller, 2008).  
 
Fe65 mRNA is predominantly expressed in the brain, particularly in the hippocampus, 
cerebellum and cortex (Bressler et al., 1996; Kesavapany et al., 2002; Simeone et al., 
1994). Fe65 is primarily expressed in neurons but it has also been detected in some 
astrocytes within the hippocampus (Kesavapany et al., 2002). There is limited evidence 
regarding expression changes of Fe65 in AD brain tissue, but a small-scale study of 
post-mortem brain samples found an increase of Fe65 in late stage AD. The same 
study found a co-localisation of Fe65 with neurofibrillary tangles but not amyloid 
plaques (Delatour et al., 2001). The subcellular localisation of Fe65 within neurons is 
diffuse, with a high proportion of protein found in the cytoplasm. It co-localises with 
APP at plasma membranes (Cao and Südhof, 2001; Lau et al., 2000b; Minopoli et al., 
2001; Sabo et al., 1999) and is also concentrated in growth cones of developing 
neurons (Cheung et al., 2014). Some Fe65 is also found in the nucleus, the majority of 
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which is phosphorylated (Lau et al., 2000b; Minopoli et al., 2001; Zambrano et al., 
1998). 
 
Fe65 is a phosphoprotein and is phosphorylated on Ser175, Ser228, Ser287, Ser347, Ser459, 
Ser517, Tyr547, Ser566, Ser610, Ser699 and Thr709. The kinases that phosphorylate these 
sites are ERK1/2 (Ser175, Ser287, Ser347 and Thr709), ataxia telangiectasia mutated 
(ATM) and ataxia-telangiectasia- and Rad3-related (ATR) protein kinases (Ser228), 
serum- and glucocorticoid-induced kinase 1 (SGK1; Ser566 and Ser610) and c-Abl 
tyrosine kinase (c-Abl; Tyr547; Chow et al., 2015b; Franz-Wachtel et al., 2012; Jowsey 
and Blain, 2015; Lau et al., 2008; Lee et al., 2008; Perkinton et al., 2004; Standen et 
al., 2003). These post-translational modifications can alter the binding affinity of Fe65 
to its interacting partners (see section 1.3.2). 
 
 
Figure 1.5 The structure of the Fe65 proteins. The protein-protein interaction 
domains of the Fe65s are the WW domain and phosphotyrosine binding domains 1 
and 2 (PTB1 and PTB2). Also indicated are the phosphorylation sites of Fe65 (Ser228, 
Ser459, Ser517, Tyr547, Ser566, Ser610 and Ser699) and the four ERK1/2 phosphorylation 
sites of Fe65 (Ser175, Ser287, Ser347 and Thr709) that are investigated in this thesis are 
shown in red.  
 
1.3.1 Fe65 binding proteins 
As stated above, Fe65 contains three protein-protein interaction domains, the 
N-terminal WW domain and two C-terminal PTB domains. Through these, Fe65 binds 
to a number of other proteins and facilitates the assembly of multi-protein complexes 
(Chow et al., 2015a). APP binds to PTB2 and is the best-characterised Fe65 binding 
protein, but two other proteins have also been reported to bind at this site (see Table 
1.1). The best-studied ligands that bind to Fe65 PTB1 are histone acetyltransferase 
Tip60, LRP1 and transcription factor CP2/LSF/LBP1, although a number of different 
proteins can interact with PTB1 (see Table 1.2). The third interaction motif of Fe65 is 
the WW domain, which binds to proline-rich ligands (Salah et al., 2012). Several Fe65 
WW domain-interacting proteins have been described (see Table 1.3), of which, 
mammalian enabled (Mena) and c-Abl are the best characterised.  
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Fe65 has also been reported to interact with other proteins including Bloom syndrome 
protein, calsyntenin-1, Dab1, Megalin, Notch, protein phosphatase 1γ, Rac1, 
sarcoplasmic/ER Ca2+ ATPase 2 and synaptic vesicle glycoprotein 2A (Alvira-Botero et 
al., 2010; Araki et al., 2004; Chow et al., 2015a; Kim et al., 2012; Kwon et al., 2010; 
Nensa et al., 2014; Rebelo et al., 2013; Schrötter et al., 2013; Wang et al., 2011). The 
precise interaction domains of Fe65 to which they bind are unknown and they may 
interact indirectly through multiprotein complexes. 
 
Table 1.1: Proteins reported to interact with the Fe65 PTB2 domain 
PTB2 ligand Reference(s) 
APP (Borg et al., 1996; Bressler et al., 1996; 
Fiore et al., 1995; McLoughlin and Miller, 
1996; Zambrano et al., 1997) 
Dexras1 (Lau et al., 2008) 
Estrogen receptor α (ERα) (Bao et al., 2007; Sun et al., 2014) 
 
 
Table 1.2: Proteins reported to interact with the Fe65 PTB1 domain. 
PTB1 ligand Reference(s) 
ADP-ribosylation factor 6 (ARF6) (Cheung et al., 2014) 
ApoEr2 (Hoe et al., 2006) 
CP2/LSF/LBP1 (Kim et al., 2003; Zambrano et al., 1998) 
LRP1 (Kinoshita et al., 2001; Pietrzik et al., 2004; 
Trommsdorff et al., 1998) 
Tau (Barbato et al., 2005) 
Teashirt (Kajiwara et al., 2009) 
Tip60 (Cao and Südhof, 2001; Stante et al., 2009) 




Table 1.3: Proteins reported to interact with the Fe65 WW domain. 
WW ligand Reference(s) 
c-Abl (Perkinton et al., 2004; Zambrano et al., 2001) 
GSK3β (Lee et al., 2008b) 
Huntingtin (Chow et al., 2012) 
Mena (Ermekova et al., 1997; Sabo et al., 2001) 
Neuronal precursor cell expressed 
developmentally downregulated 4-2 
(Telese et al., 2005) 
P2X receptor P2X2 subunit (Masin et al., 2006) 
Nucleosome assembly factor SET (Telese et al., 2005) 
 
1.3.2 Fe65 functions 
A heavily researched role of Fe65 is in the regulation of gene transcription. It carries 
out this role in a complex with AICD after γ-secretase cleavage of APP. AICD was 
originally thought to be able to regulate gene transcription alone, in a similar manner to 
Notch. Like APP, Notch is a type-1 transmembrane protein that undergoes proteolytic 
cleavage by γ-secretase to produce an intracellular domain. Once released, the Notch 
intracellular domain translocates to the nucleus where it binds to transcription factors 
and regulates the expression of Notch responsive genes (Kopan and Ilagan, 2009). 
Many studies have shown that after γ-secretase cleavage, AICD also translocates to 
the nucleus, where it is involved in regulating gene transcription (Alves da Costa et al., 
2006; Belyaev et al., 2009; Cao and Südhof, 2004, 2001; Kajiwara et al., 2009; Kim et 
al., 2003; Lau et al., 2008; Li et al., 2010; Ma et al., 2008; McLoughlin and Miller, 2008; 
Müller et al., 2007; Nakaya and Suzuki, 2006; Pardossi-Piquard et al., 2005; Perkinton 
et al., 2004; Robinson et al., 2014; Schrötter et al., 2013; von Rotz et al., 2004; Xu et 
al., 2011). In contrast to the Notch intracellular domain however, AICD is relatively 
small (~50 residues). While AICD has been shown to interact directly with Mediator, an 
RNA polymerase II subunit (Xu et al., 2011), it may require its interaction with Fe65 to 
facilitate the recruitment of other nuclear proteins to create a complex that can regulate 
gene transcription of target genes. Fe65 may also be required for the nuclear 
translocation of AICD (Cao and Südhof, 2001; Kinoshita et al., 2002). Contrary to this 
however, some studies report that APP-Fe65 nuclear signalling is not involved in gene 
transcription (Hébert et al., 2006; Waldron et al., 2008)  
 
The route of AICD-Fe65 nuclear signalling is unclear. γ-secretase cleavage of APP 
could release AICD-bound Fe65 from the transmembrane fragment of APP, allowing 
nuclear translocation of the AICD-Fe65 complex. Alternatively, Fe65 could dissociate 
from full-length APP, perhaps triggered by phosphorylation events that weaken the 
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interaction between the two proteins (Ando et al., 2001; Barbagallo et al., 2010; Chow 
et al., 2015b; Nakaya and Suzuki, 2006; Zhou et al., 2009). This would allow Fe65 to 
translocate to the nucleus alone, where it could bind to nuclear AICD fragments. The 
translocation of Fe65 is not AICD-dependent (Kim et al., 2003) and while several 
studies report that nuclear trafficking of AICD requires Fe65 (Cao and Südhof, 2001; 
Kinoshita et al., 2002), this does not always appear to be the case (Nakaya and 
Suzuki, 2006).  
 
While AICD is produced from both proteolytic processing pathways of APP, there is 
evidence that only β-secretase processed AICD is transcriptionally active (Belyaev et 
al., 2010; Waldron et al., 2008). This is perhaps due to the location of the protein 
fragment after β-secretase processing in the endosomal/lysosomal system, rather than 
α-secretase processing at the cell surface. The shift in equilibrium in APP processing 
seen in AD means that there is likely to be more transcriptionally active AICD present 
in cells, along with an increase in Fe65 (Delatour et al., 2001; Zhang et al., 2011). 
 
Two extracellular proteins have been reported to regulate gene transcription via 
APP-Fe65 nuclear signalling. TAG1 binds to APP and enhances γ-secretase-mediated 
release of AICD and promotes gene transcription (Ma et al., 2008). F-spondin is a 
secreted signalling molecule that also binds to the extracellular domain of APP. In 
contrast to TAG1, F-spondin inhibits AICD-Fe65 signalling by preventing 
β-secretase-mediated processing of APP, which may reduce the amount of 
transcriptionally active AICD available (Belyaev et al., 2010; Ho and Südhof, 2004). 
 
A number of genes have been proposed to be regulated by APP-Fe65 signalling (see 
Table 1.4) and some of these genes are linked to AD pathogenesis. Most of this work 
has focussed on genes regulated by AICD, while the role of Fe65 has been less well 




Table 1.4: Genes reported to be positively regulated by APP-Fe65 signalling. 
Gene(s) Reference(s) 
GSK3β (Kim et al., 2003; Lau et al., 2008; 
Perkinton et al., 2004) 
APP (von Rotz et al., 2004) 
Neprilysin (Belyaev et al., 2009; Grimm et al., 2015; 
Pardossi-Piquard et al., 2005; Xu et al., 
2011) 
KAI1 (Baek et al., 2002; Bao et al., 2007; Ryan 
and Pimplikar, 2005) 
p53 (Alves da Costa et al., 2006) 
Microtubule associated monooxygenase, 
calponin and LIM domain containing 2, 
Fibronectin 1 
(Müller et al., 2007; Xu et al., 2011) 
BACE1, Tip60 (von Rotz et al., 2004) 
Insulin like growth factor binding protein 
3, Solute carrier family 7 member 5, Actin 
α2, Transgelin, Tropomyosin 1, RAB3B 
(Müller et al., 2007) 
Transthyretin, Klotho (Li et al., 2010) 
BLM, Minichromosome maintenance 
complex component 3 
(Schrötter et al., 2013) 
Caspase 4, apoptosis-related cysteine 
peptidase 
(Kajiwara et al., 2009) 
Aquaporin (Xu et al., 2011) 
 
Exactly how the APP-Fe65 complex regulates gene transcription has not been fully 
elucidated and the mechanism of action may differ between target genes. The 
best-studied mechanism of gene regulation by APP-Fe65 is of neprilysin, a protein 
involved in the degradation of Aβ (Saido and Leissring, 2012). AICD binds directly to 
both promoter regions of the neprilysin gene and recruits Fe65, Tip60 and Mediator. 
This complex acts as a transcriptional activator and enhances neprilysin expression in 
an APP-dependent manner (Belyaev et al., 2009; Grimm et al., 2015; Pardossi-Piquard 
et al., 2005; Xu et al., 2011). However, high-throughput methods of quantifying gene 
expression changes failed to detect changes to neprilysin expression (Giliberto et al., 
2008; Müller et al., 2007), and others report a similar lack of neprilysin expression level 
changes in transfected cells (Hébert et al., 2006; Waldron et al., 2008).  
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The APP-Fe65-Tip60 complex also regulates the expression of the tetraspanin KAI1. In 
this system, a repressor complex binding to the KAI1 promoter region normally inhibits 
KAI1 expression. When this repressor is replaced by the APP-Fe65-Tip60 complex, 
RNA polymerase II is recruited and gene expression increases (Baek et al., 2002; 
Ryan and Pimplikar, 2005). Expression of KAI1 also requires an interaction between 
the APP-Fe65-Tip60 complex and SET (Telese et al., 2005). Oestrogens negatively 
regulate this complex by enhancing ERα recruitment. ERα displaces Tip60 from the 
APP-Fe65-Tip60 complex and prevents KAI1 expression (Bao et al., 2007). As with 
neprilysin expression however, there are also reports to the contrary, which do not 
show an increase in KAI1 expression in response to overexpression of AICD or AICD 
and Fe65 (Giliberto et al., 2008; Hébert et al., 2006; Müller et al., 2007; Waldron et al., 
2008).  
 
APP-Fe65 nuclear signalling does not only enhance gene transcription but can reduce 
expression of target genes as well. The expression of stathmin 1, F-actin capping 
protein and thymidylate synthase is inhibited by the APP-Fe65 complex (Bruni et al., 
2002; Müller et al., 2013). For these genes, the APP-Fe65 complex may be acting as a 
repressor, rather than an activator. The inhibition of thymidylate synthase involves the 
Fe65-CP2/LSF/LBP1 interaction (Bruni et al., 2002). Interestingly, stathmin 1 and 
F-actin capping protein are involved in regulating cytoskeleton dynamics, a process 
that both APP and Fe65 have also been implicated in regulating (Müller et al., 2013; 
Sabo et al., 2003, 2001). 
 
Phosphorylation of both APP and Fe65 can regulate their interaction. Phosphorylation 
of Thr668 and Tyr682 on APP inhibits its binding to Fe65 (Ando et al., 2001; Barbagallo et 
al., 2010; Nakaya and Suzuki, 2006; Zhou et al., 2009), as does phosphorylation of 
Fe65 at Ser610 (Chow et al., 2015b). As Fe65 binds to both full-length APP and AICD 
and these interactions have different consequences, it is unclear what effect 
destabilising the interaction may have on APP-Fe65-mediated gene transcription. 
Reducing the interaction between full-length APP and Fe65 may enhance Fe65 
nuclear translocation, but reducing the interaction between Fe65 and AICD in the 
nucleus may reduce transcription of target genes. 
 
The APP-Fe65 complex is not solely modulated by phosphorylation events. A number 
of other Fe65 binding partners have been identified as regulators of Fe65-mediated 
gene transcription. These include Dexras1, calsyntenin-1, Tip60, ERα, the intracellular 
domain of LRP1 and Teashirt (Araki et al., 2004; Bao et al., 2007; Kajiwara et al., 2009; 
Kinoshita et al., 2003; Lau et al., 2008). The ways in which these proteins modulate 
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Fe65 function varies from preventing Fe65-protein interactions, such as LRP1 
competing with APP for Fe65 binding and sequestering Tip60 (Kinoshita et al., 2001; 
Mulvihill et al., 2011), to activating other pathways that inhibit gene transcription, such 
as Teashirt, which increases histone deacetylase activity to act in opposition to Tip60 
(Kajiwara et al., 2009). 
 
1.3.3 Other functions of Fe65 
A number of other functions have been ascribed to Fe65. Another nuclear function of 
Fe65 is regulating the repair of deoxyribonucleic acid (DNA) damage. Cells derived 
from Fe65KO mice are more sensitive to DNA damage, suggesting that Fe65 may also 
be involved in DNA repair pathways (Minopoli et al., 2007). Fe65 is required for 
effective DNA repair and binds to chromatin to facilitate the recruitment of Tip60 and 
other repair proteins to DNA damage sites (Minopoli et al., 2007; Stante et al., 2009). 
In this role, Fe65 inhibits cell death (Nakaya et al., 2008), however, other studies 
suggest that overexpression of Fe65 enhances apoptosis (Vázquez et al., 2009). 
 
Other functions of Fe65 relate to cell motility in neuronal development and neurite 
outgrowth. While Fe65KO mice have no anatomical abnormalities (Guénette et al., 
2006; Wang et al., 2004, 2009), they show enhanced neurogenesis (Ma et al., 2008), 
suggesting a role for Fe65 in the regulation of developing neurons. Simultaneous 
knockout of Fe65 and Fe65L1 results in neuronal migration defects similar to those 
seen in APP family knockout mouse models (Guénette et al., 2006; Herms et al., 
2004). As with APP mouse models, this suggests that there is functional redundancy 
between the Fe65 family proteins. Fe65KO mice show impairments in 
hippocampal-dependent learning and long-term potentiation (LTP) indicating that while 
Fe65 may not play an essential role in brain development, it is required for normal 
hippocampal learning and memory (Guénette et al., 2006; Wang et al., 2004, 2009).  
 
Another function of Fe65 is the regulation of protein degradation via the 
ubiquitin-proteasome system (UPS). Fe65 stabilises the intracellular domain of APP 
(Huysseune et al., 2007; Pietrzik et al., 2004; Waldron et al., 2008; Walsh et al., 2003), 
although this may only be the case for exogenous AICD (Kimberly et al., 2001; Nakaya 
and Suzuki, 2006). Fe65 also protects full-length APP, apoptotic factor p53 and mutant 
huntingtin from UPS-mediated degradation. Decreasing the degradation of proteins 
contributes to their accumulation in cells. Considering the functions of these proteins, 
this may be one mechanism by which Fe65 enhances gene transcription, apoptosis 
and mutant huntingtin aggregation (Chow et al., 2015b, 2012; Nakaya et al., 2008).  
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Evidence that Fe65 positively regulates cell motility and neurite outgrowth in cellular 
models corroborates a role for Fe65 in neuronal development. Overexpression of Fe65 
and APP increases the rate of cell migration (Sabo et al., 2001) and Fe65 interacts with 
Mena, ARF6 and Rac1, proteins involved in regulating actin cytoskeleton dynamics 
(Cheung et al., 2014; Ermekova et al., 1997; Sabo et al., 2001; Wang et al., 2011). In 
addition to this, Fe65, APP and Rac1 co-localise in extending lamellipodia (Sabo et al., 
2001; Wang et al., 2011) and Fe65 stimulates Rac1 activation via small GTPase ARF6, 
to augment neurite outgrowth (Cheung et al., 2014; see Chapter 5). 
 
1.3.3.1 ARF6 
ARF6 is a member of the Ras superfamily of small GTPases. These GTPases are 
members of signalling cascades and cycle between inactive GDP bound and active 
GTP bound conformational states. GTPase activating proteins (GAPs) accelerate the 
hydrolysis of bound GTP to GDP, inactivating the GTPase, while guanine nucleotide 
releasing proteins (GNRPs) promote dissociation of GDP, allowing uptake of GTP and 
activation of the GTPase (Cherfils and Zeghouf, 2013). ARF6 KO mice are embryonic 
lethal, indicating that, while ARF6 belongs to a large family of similar proteins, there is 
not enough redundancy between protein functions to rescue the loss of ARF6. 
Conditional ARF6 KO mice have deficient myelination of neurons, which has been 
linked to ARF6-dependent impairments of the migration of cells responsible for axon 
myelination (Akiyama and Kanaho, 2015). In addition, ARF6 has been linked to many 
functions including cytoskeletal organisation and membrane trafficking in endocytosis 
and exocytosis (Akiyama and Kanaho, 2015; Cheung et al., 2014; Gillingham and 
Munro, 2007). Chapter 5 describes novel work to which I contributed which showed 
that Fe65 binds to ARF6 to stimulate neurite outgrowth. This work has now been 
published and the paper is presented in the Appendix. 
 
1.3.4 Fe65 and APP processing 
The effects of Fe65 on APP processing and Aβ production have been studied by 
several groups but the results are conflicting. In cultured cells, Fe65 overexpression 
increases APP cell surface presentation (Hoe et al., 2006; Sabo et al., 1999) and 
several studies report increases in sAPPα secretion (Dumanis et al., 2012; Hoe et al., 
2006; Pietrzik et al., 2004; Suh et al., 2011). Conversely, some report that APP 
processing is decreased by Fe65 overexpression (Ando et al., 2001; Kwon et al., 
2010). The effect of Fe65 on Aβ production is also unclear. While most studies show 
that Fe65 decreases amyloidogenic processing of APP (Ando et al., 2001; Hoe et al., 
2006; Kwon et al., 2010; Wiley et al., 2007; Xie et al., 2007), increased Aβ production 
has also been detected in response to exogenous Fe65 expression (Sabo et al., 1999). 
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This may be due to cell-specific responses as these studies were carried out in a 
variety of cell types. 
 
Mice overexpressing APP and Fe65 show reduced levels of APP processing and Aβ 
production (Santiard-Baron et al., 2005). Fe65 overexpression also reduces the 
amount of APP Thr668 phosphorylation (Santiard-Baron et al., 2005), which is 
consistent with a reduction of APP processing (Ando et al., 2001; Lee et al., 2003; Liu 
et al., 2003). However, Fe65KO mouse models can also have decreased Aβ secretion 
(Guénette et al., 2006; Suh et al., 2011; Wang et al., 2004), suggesting that the role of 
Fe65 in APP processing is not simple. One possible reason for this is that Fe65 may 
have a dominant negative impact on APP and its interacting partners. This may explain 
why both loss and gain of Fe65 appears to decrease Aβ production (Pietrzik et al., 
2004). 
 
Mice overexpressing Fe65 and AICD develop AD-like tau pathology (Ghosal et al., 
2009), potentially linking an alteration in APP processing (which, in these mice, is 
mimicked by elevated AICD production) to the development of tau 
hyperphosphorylation and aggregation into NFTs. These mice also show enhanced 
levels of GSK3β activity (Ryan and Pimplikar, 2005).  
 
To summarise, the precise roles of Fe65 on APP processing, Aβ production and tau 
phosphorylation are not properly understood and some of the data are conflicting. 
Further work is needed to determine what role, if any, Fe65 may have in AD. 
 
1.4 Signalling pathways in Alzheimer’s disease 
Along with APP-Fe65 signalling, disruption of other signalling pathways has been 
linked to AD. These include JNK stress-activated signalling (Yarza et al., 2016), 
signalling via inflammatory factors (McCaulley and Grush, 2015) and insulin signalling 
(Ferreira et al., 2014; Liu et al., 2011). Two signalling pathways relevant to this thesis 
are the brain-derived neurotrophic factor (BDNF) and wnt pathways described below. 
 
1.4.1 BDNF signalling 
BDNF is an extracellular growth factor that is expressed highly in the brain, and 
interestingly, in areas that are affected by neuron loss in AD (Hofer et al., 1990; Murer 
et al., 1999; Murray et al., 1994; Phillips et al., 1990). BDNF is secreted from excitatory 
neurons and binds to membrane-bound tyrosine receptor kinase B (TrkB), which is 
presented on the cell surface of both excitatory and inhibitory neurons (Arancibia et al., 
 40 
2008; Huang and Reichardt, 2001). This activates TrkB and initiates downstream 
signalling to the ERK, phosphoinositide 3-kinase/Akt and phospholipase C pathways 
(Kaplan and Miller, 2000; Numakawa et al., 2010; Figure 1.6). BDNF-mediated signal 
transduction is important for neuron survival, differentiation and LTP (Alderson et al., 
1990; Arancibia et al., 2008; Bonni et al., 1999; Ghosh et al., 1994; Kang and 
Schuman, 1995; Knüsel et al., 1992; Korte et al., 1995; Lindholm et al., 1996; 
Patterson et al., 1996). 
 
One of the intracellular cascade pathways that BDNF-TrkB activation initiates is the 
ERK1/2 mitogen-activated protein (MAP) kinase cascade (Yang et al., 2013). This 
involves activation of the small GTPase Ras and sequential activation of kinases RAF, 
MAP kinase kinase (MEK) and ERK. ERK can then phosphorylate various proteins 
including the activation of transcription factors (Seger and Krebs, 1995). The MAP 
kinase cascade is a global signalling pathway that has been linked to many cellular 
processes (Yang et al., 2013).  
 
                                 
Figure 1.6: The BDNF signalling pathways. BDNF binds to receptor TrkB and 
activates several intracellular pathways: PI3K, the ERK MAP kinase cascade and 
PLCγ. 
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A number of lines of evidence link BDNF signalling with AD. BDNF knockout mice have 
reduced hippocampal synaptic transmission and synaptic density, increased cell death 
and impaired LTP, while mice overexpressing BDNF have increased LTP (Barco et al., 
2005; Lindholm et al., 1996; Patterson et al., 1996). The phenotypes of BDNF-deficient 
mice can be rescued by exogenous application of BDNF (Lindholm et al., 1996; 
Patterson et al., 1996). Addition of BDNF also restores synaptic density and 
hippocampal-dependent memory deficits in AD mouse models (Blurton-Jones et al., 
2009; Nagahara et al., 2009). These findings are consistent with data from cellular 
models showing that BDNF increases synaptic density and protects against cell death 
(Alderson et al., 1990; Blurton-Jones et al., 2009; Ghosh et al., 1994; Knüsel et al., 
1992; Lindholm et al., 1996; Nagahara et al., 2009).  
 
Expression of both BDNF and TrkB is reduced in disease-vulnerable areas in AD 
(Conner et al., 1997; Durany et al., 2000; Ferrer et al., 1999; Murer et al., 1999; 
Narisawa-Saito et al., 1996; Phillips et al., 1991; Pláteník et al., 2014). In addition to 
this, BDNF can be detected in neuritic plaques, particularly in the dystrophic neurites 
surrounding the Aβ core. This indicates either a possible protective response by the 
brain or sequestration of BDNF by neuritic plaques (Ferrer et al., 1999; Murer et al., 
1999). Indeed, BDNF protects neurons from Aβ-induced toxicity (Arancibia et al., 2008; 
Nagahara et al., 2009), although it has no effect on plaque development or clearance. 
This may be due to a lack of TrkB expression in some neurons (Ferrer et al., 1999; 
Murer et al., 1999). Both the decrease of BDNF seen in AD and apparent sequestering 
of the limited neurotrophin to neuritic plaques may contribute to neuronal degradation 
via withdrawal of the cell-survival function of BDNF. Recently BDNF has been identified 
as a target of the wnt signalling pathway via β-catenin and T-cell factor/lymphoid 
enhancer factor (TCF/LEF)-mediated gene transcription (Fragoso et al., 2011; Seitz et 
al., 2010; Yi et al., 2012). There is evidence that β-catenin nuclear signalling may be 
impaired in AD (Zhang et al. 1998; Nishimura et al. 1999), so disruption of the wnt 
signalling pathway may contribute to decreased levels of BDNF expression in AD 
(Conner et al., 1997; Durany et al., 2000; Ferrer et al., 1999; Murer et al., 1999; 
Narisawa-Saito et al., 1996; Phillips et al., 1991; Pláteník et al., 2014). 
 
BDNF also shows neuroprotective effects against neuron death induced by entorhinal 
cortex damage. BDNF treatment increases cell survival and partially restores LTP and 
learning deficits in both mice and non-human primates with entorhinal cortical lesions 
(Ando et al., 2002; Nagahara et al., 2009). These findings are promising as they 
suggest that BDNF treatment may be effective even after synapse loss and neuronal 
death, which is currently the only stage at which AD can be diagnosed. Finally, BDNF 
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expression is increased in response to physical exercise and enhances learning ability 
(Adlard and Cotman, 2004; Adlard et al., 2004), which is consistent with physical 
exercise being a neuroprotective environmental factor for AD (Adlard et al., 2005).  
 
Fe65 has been identified as a substrate for ERK1/2, which phosphorylates Fe65 on at 
least 4 residues (Standen et al., 2003). However, the biological effect of Fe65 
phosphorylation at these sites and how ERKs might be activated to phosphorylate 
Fe65 are unknown. Phosphorylation of both APP and Fe65 at other sites influence the 
APP-Fe65 interaction and this may impact the ability of the complex to regulate gene 
transcription (Ando et al., 2001; Barbagallo et al., 2010; Chow et al., 2015b; Nakaya 
and Suzuki, 2006; Zhou et al., 2009). Whether BDNF induces the phosphorylation of 
Fe65 via the MAP kinase cascade, and what effect this has on the APP-Fe65 
interaction has not yet been studied, but it may provide insight into an intracellular 
mechanism for the neuroprotective action of BDNF. 
 
1.4.2 Wnt signalling  
Wnts are a large family of secreted glycoproteins that act in an autocrine and paracrine 
fashion (Clevers and Nusse, 2012). They bind to specific cell surface receptors called 
Frizzled (Fzd) that are coupled to LRP5/6 co-receptors. Receptor-ligand binding 
activates the intracellular domains of the receptors and initiates either the canonical or 
non-canonical wnt signalling pathway (MacDonald et al., 2009). There are 19 wnt 
ligands and 10 Fzd receptors and the specific combination of wnt ligand and Fzd 
receptor may determine which pathway is activated, although the relationships 
between them have not all been comprehensively described (Clevers and Nusse, 
2012; Niehrs, 2012). The canonical pathway leads to changes in gene transcription. 
The non-canonical planar cell polarity pathway regulates the cytoskeleton and the 
non-canonical Ca2+ pathway regulates Ca2+ homeostasis (Niehrs, 2012). 
 
In the canonical pathway, in the absence of wnt signal, GSK3 is present in a multimeric 
protein complex termed the ‘destruction complex’ also containing Axin, casein kinase I 
and adenomatous polyposis coli (Kimelman and Xu, 2006). The destruction complex is 
constitutively active and leads to phosphorylation of the nuclear signalling molecule 
β-catenin. This phosphorylation targets β-catenin for degradation by the UPS (Clevers 
and Nusse, 2012; Kimelman and Xu, 2006). Wnt-Fzd binding activates the cytoplasmic 
protein, dishevelled, which causes dissociation of the destruction complex. This allows 
β-catenin to translocate and accumulate in the nucleus where it binds to TCF/LEF 
transcription factors and activates transcription of a large number of target genes 
(Behrens et al., 1996; http://web.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes; 
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Schuijers et al., 2014; Figure 1.). The canonical wnt pathway regulates a variety of 
functions including development, LTP, synapse formation, neurogenesis and cell 




Figure 1.7: The wnt signalling pathway. In the absence of wnt signal, GSK3, Axin, 
casein kinase I (CK1) and adenomatous polyposis coli (APC) are present in the 
constitutively active destruction complex, which targets β-catenin (β-cat) for 
degradation. Wnt-Fzd binding activates dishevelled (dsh), resulting in dissociation of 
the destruction complex, which allows β-catenin to translocate and accumulate in the 




The canonical wnt pathway is of particular interest in the field of AD as it regulates the 
activity of GSK3, one of the kinases involved in the phosphorylation of tau (Hernández 
et al., 2010; Hooper et al., 2008). It forms the basis of the GSK3 hypothesis of AD 
which proposes that GSK3 hyperactivity is responsible for tau hyperphosphorylation 
(Hooper et al. 2008). Unlike other pathways of GSK3 regulation, the wnt signalling 
pathway does not appear to inactivate the two GSK3 isoforms (GSK3α and GSK3β) via 
Ser21/9 phosphorylation (on GSK3α and GSK3β respectively; Ding et al., 2000). Two 
mechanisms of GSK3 inactivation that have been proposed are LRP-mediated 
inhibition of the GSK3 active site and endocytosis of LRP-GSK3 complexes into 
vesicles (Metcalfe and Bienz, 2011).  
 
In addition to GSK3 inactivation, β-catenin has been shown to be neuroprotective 
against Aβ toxicity (Alvarez et al., 2004; Chacón et al., 2008; De Ferrari et al., 2003). 
There is also evidence that wnt signalling is impaired in AD. β-catenin degradation is 
increased in familial AD cases caused by PS1 mutations (Zhang et al., 1998) and its 
nuclear translocation is also disrupted (Nishimura et al., 1999). Reductions of β-catenin 
in AD may limit the ability of cells to resist Aβ neurotoxicity (He and Shen, 2009). This 
may be catalysed by a concomitant Aβ-induced rise in expression of Dikkopf-1, a 
negative regulator of the wnt signalling pathway (Caricasole et al., 2004; Killick et al., 
2014; Purro et al., 2012). 
 
1.5 Hypotheses and aims 
Abnormal metabolism of APP is strongly linked to the pathogenesis of AD but much of 
the research supporting this link is focused on Aβ and not on APP function. There is 
evidence that the APP-Fe65 complex signals to the nucleus to regulate gene 
transcription and this provides a complementary route in which defects in APP 
metabolism might contribute to AD. However, the mechanisms that regulate binding of 
Fe65 to APP and the genes that are regulated by this signalling pathway are unclear. 
Phosphorylation is a common mechanism for regulating protein-protein interactions 
and ERK1/2 has recently been shown to phosphorylate Fe65.  
 
The studies presented in this thesis address two related hypotheses:   
1. That BDNF signalling, which leads to activation of ERK1/2 in neurons, stimulates 
Fe65 phosphorylation to regulate its binding to APP 
2. That Fe65 regulates genes that are linked to GSK3α/β activity and tau 
phosphorylation. 
The aims of this thesis were to begin to test these hypotheses.  
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CHAPTER 2: MATERIALS AND METHODS 
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2.1 Materials 
Unless otherwise stated, all chemicals and reagents were purchased from 
Sigma-Aldrich (Dorset, UK). Solutions and buffers were prepared using ultrapure H2O 
from a Milli-Q purification system (Merck Millipore; Watford, UK). When required, 
sterilisation was carried out using a 0.2 µm pore Nalgene filter (ThermoFisher 
Scientific; Loughborough, UK) or by autoclaving at 121 °C and 101 kPa for 20 min. 
 
2.1.1 Antibodies 
Primary antibodies were obtained from Abcam (Cambridge, UK), BD Biosciences 
(Oxford, UK), Cell Signaling (Leiden, The Netherlands), DAKO (Cambridge, UK), 
Millipore, R&D Systems (Abingdon, UK), Santa Cruz (Heidelberg, Germany), 
Sigma-Aldrich or made in house and are detailed in Table 2.1.  
Table 2.1: Primary antibodies used in these studies. 
Antigen Species Manufacturer Dilution 
APP (CT-17) Rabbit In house (Cousins et 
al., 2009) 
1:5000 (WB) 
  1:400 (PLA) 




Fe65 (2877) Rabbit Cell Signaling 
Technology 
1:1000 (WB) 
Fe65 (4H324) Mouse Abcam 1:5000 (WB exogenous) 
1:1000 (WB endogenous) 
1:400 (PLA) 




Fe65 (C60) Rabbit In house  
(Lau et al., 2000b) 
1:1000 (WB) 




Rabbit Cell Signaling 
Technology 
1:1000 (WB) 
Fzd1 (AF1120) Rabbit R&D Systems 1:500 (WB) 
Table continued overleaf 
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Table 2.1: Primary antibodies used in these studies (continued). 
Antigen Species Manufacturer Dilution 
Fzd1 (sc-30428) Goat Santa Cruz 
Biotechnology 
1:500 (WB) 
Pan Fzd (sc-9169) Rabbit Santa Cruz 
Biotechnology 
1:500 (WB) 
GAPDH (14C10) Rabbit Cell Signaling 
Technology 
1:20000 (WB) 
GSK3α (9338) Rabbit Cell Signaling 
Technology 
1:1000 (WB) 
GSK3β (610201) Mouse BD Biosciences 1:1000 (WB) 
Phospho-GSK3β 
(Ser9; 9336 
Rabbit Cell Signaling 
Technology 
1:1000 (WB) 
LRP6 (C5C7) Rabbit Cell Signaling 
Technology 
1:1000 (WB) 
Myc (9B11) Mouse Cell Signaling 
Technology 
1:2000 (WB) 
Tau (A0024) Rabbit DAKO 1:10000 (WB) 
Phospho-Tau 
(Ser202; CP13) 
Mouse Gift from Peter Davies 
(Albert Einstein College 
of Medicine, USA) 
1:400 (WB) 
α-Tubulin (T6199) Mouse Sigma-Aldrich 1:20000 (WB) 
Wnt3a (2391) Rabbit Cell Signaling 
Technology 
1:750 (WB) 
WB = western blot, PLA = proximity ligation assay, IP = co-immunoprecipitation 
 
Secondary antibodies used in western blotting were polyclonal goat anti-mouse, 
polyclonal goat anti-rabbit or polyclonal rabbit anti-goat immunoglobulins conjugated to 
horseradish peroxidase. Secondary antibodies were obtained from DAKO and used at 
a dilution of 1:8000.  
 
2.1.2 Enzyme-linked immunosorbent assays (ELISA) 
Total tau and Ser199 phosphorylated tau ELISA kits were purchased from ThermoFisher 
Scientific. The Phospho/Total GSK3β ELISA kit was purchased from Meso Scale 
Diagnostics (Maryland, USA) and measured both total GSK3β and GSK3β 




2.1.3 Plasmid vectors 
Table 2.2: Mammalian and bacterial expression plasmids used in these studies. 
Construct Vector Reference 
APP pCI-neo (Mcloughlin et al., 1999) 
Fe65 pCI-neo (Lau et al., 2000b) 
Fe65-myc pCI-neo (Lau et al., 2000b) 
Fe65QuadA* pCI-neo (Standen et al., 2003) 
Fe65QuadE* pCI-neo (Standen et al., 2003) 
ARF6-myc pCI-neo (Cheung et al., 2014) 
Chloramphenicol 
acetyltransferase (CAT) 
pCI-neo (Lau et al., 2002) 
Glutathione-S-transferase 
(GST) 
pGEX-5X-1 (Standen et al., 2001) G.E. 
Healthcare  
(Buckinghamshire, UK) 
GST-APPC pGEX-5X-1 (Standen et al., 2001) 
GST-ARF6 pCI-neo (Cheung et al., 2014) 
GST-Fe65WW pCI-neo (Cheung et al., 2014) 
GST-Fe65PTB1 pCI-neo (Cheung et al., 2014) 
GST-Fe65PTB2 pCI-neo (Cheung et al., 2014) 
Fe65ΔPTB1 pCMV (Cao and Südhof, 2001) 
Fe65ΔPTB2  pCMV (Cao and Südhof, 2001) 
*Fe65QuadA and Fe65QuadE phosphorylation mutants contain mutations at Ser175, Ser287, 
Ser347 and Thr709 to alanine and glutamic acid respectively. 
 
 
2.2 General biochemical reagents 
Luria-Bertani (LB) agar and LB broth were obtained from Life Technologies Ltd 
(Paisley, UK). The HiSpeed plasmid purification midi kit, RNeasy mini kit and 
RNase-free DNase I set were obtained from Qiagen (Manchester, UK). The protein 
assay kit was obtained from Bio-Rad (Hertfordshire, UK). REDExtract-N-AmpTM tissue 
polymerase chain reaction (PCR) kit was purchased from Sigma-Aldrich. 
 
2.2.1 General tissue culture reagents 
Fetal Bovine Serum (FBS), L-glutamine (200 mM) and trypsin-etylenediamintetraacetic 
acid (EDTA) solution (0.05 % (v/v)/0.02 % (v/v) in phosphate buffered saline; PBS) 
were supplied by G.E. Healthcare. Opti-MEM reduced serum medium, Ham's F12 
medium, Dulbecco’s modified Eagle medium (DMEM), DMEM/Ham’s F12 medium, 
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Hank’s balanced salt solution without Ca2+ and Mg2+ (HBSS (-/-)), HBSS with Ca2+ and 
Mg2+ (HBSS (+/+)), Neurobasal media, B-27 supplement, AlbuMAX-I, 
penicillin/streptomycin (100x), Lipofectamine and Lipofectamine 2000 were supplied by 
Life Technologies Ltd. Blasticidin (powder, prepared to a stock solution of 1500 µg/ml 
in DMEM/Ham’s F12 medium) was obtained from Santa Cruz and Zeocin (100 mg/ml) 
was from Invivogen (Toulouse, France). Deoxyribonuclease (DNase) I, soybean trypsin 
inhibitor, Trypan blue (0.4 %) and plasticware were from Sigma-Aldrich. 
 
2.2.2 Mammalian cell culture and transfection 
Table 2.3: Growth media and transfection reagents for cell lines. 







4.5 g/L glucose 
2 mM L-glutamine  
0 % (v/v) FBS 
Lipofectamine 2000 Life Technologies 
Ltd 
FuGene 6 Roche 




4.5 g/L glucose 
2 mM L-glutamine 
10 % (v/v) FBS  
5 µg/ml Blasticidin 
200 µg/ml Zeocin 
Lipofectamine 2000 Life Technologies 
Ltd 
Human embryo 
kidney (HEK) 293 
cells 
DMEM 
4.5 g/L glucose 
2 mM L-glutamine 
10 % (v/v) FBS  




2.2.3 Cell treatments 
BDNF was from PeproTech (London, UK), K252a was from Sigma-Aldrich, U0126 was 
from Millipore. Accell small interfering RNAs (siRNAs) specific to APP (#13 and #16), 
Fe65 (#14), Fzd1 (pool) and non-targeting control (#1) siRNAs were purchased from 




Table 2.4: siRNA sequences used to achieve Fe65 and APP knockdown in rat 
cortical neurons. 
siRNA Target Sequence 
Fe65 #14 GUGGCAGUCAACAAUUGUA 
APP #13 GCACUAACUUGCACGACUA 
APP #16 CGGUGAAGACAAAGUCGUA 




Non-targeting control UGGUUUACAUGUCGACUAA 
 
 
2.2.4 Duolink proximity ligation assay (PLA) 
The Duolink PLA kits used were In Situ detection reagents (orange), In Situ wash 
buffers (fluorescence) and In Situ PLA probe kits for rabbit PLUS and mouse MINUS 
PLA probes. All Duolink PLA kits were obtained from Sigma-Aldrich. 
 
2.2.5 Quantitative real-time PCR (RT-qPCR) 
The kits and plasticware used in the RT-qPCR studies were purchased from 
PrimerDesign (Southampton, UK) and include nanoScript2 reverse transcription kit, 
PrecisionPLUS mastermix with inert blue dye, GeNorm reference gene analysis kit and 
custom primers (detailed in 2.3.12.4). 
 
2.3 Methods 
2.3.1 General microbiology methods 
2.3.1.1 Storage and growth of E. coli for DNA purification 
Escherichia coli (E. coli) transformed with plasmids of interest were stored at -80°C in 
sterile 25 % (v/v) glycerol solution in LB broth (20 g/L, autoclaved) containing  
100 µg/ml filter-sterilised ampicillin (LB-amp) for selection of the plasmid vector. For 
bacterial growth, E. coli containing the plasmid of interest were grown on LB agar  
(32 g/L, autoclaved) plates containing 100 µg/ml filter-sterilised ampicillin for selection 
of the plasmid vector. Selection plates were incubated at 37 °C for 16 h. Single 
bacterial colonies picked from these selection plates were used to inoculate 5 ml 
aliquots of LB-amp. These starter cultures were incubated at 37 °C for 8 h in a shaking 
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incubator at 220 rpm before being used to inoculate 100 ml LB-amp cultures that were 
incubated for a further 16 h at 220 rpm. 
 
2.3.1.2 Plasmid DNA purification 
Plasmid DNA was purified from bacterial cultures using a HiSpeed plasmid purification 
midi kit (Qiagen) as per the manufacturer’s instructions. The concentration of plasmid 
DNA was quantified by measuring absorbance at 260 nm using a NanoDrop 1000 
spectrophotometer (ThermoFisher Scientific) and the 260/280 nm absorbance ratio 
was used to determine DNA purity; pure DNA has a ratio of 1.8. Plasmid DNA was 
stored at -20 °C until required. 
 
2.3.1.3 Agarose gel electrophoresis 
To prepare agarose gels, 1-1.5 % (w/v) agarose (Ultra pure, electrophoresis grade; Life 
Technologies Ltd) was heated in 1x Tris-Acetate-EDTA (TAE) buffer containing 40 mM 
Tris(hydroxymethyl)aminomethane (Tris), 0.11 % (v/v) acetic acid and 1 mM EDTA, 
buffered to pH 8.0 with NaOH. This solution was poured into a gel bed containing a 
15-well comb and ethidium bromide was added to a working concentration of  
300 ng/ml before the gel set. The set gel was then moved to an electrophoresis tank 
and submerged in 1x TAE buffer. Ribonucleic acid (RNA) or PCR samples were diluted 
with loading buffer containing 0.04 % (w/v) Bromophenol blue and 6.6 % (w/v) sucrose, 
loaded into the wells and run at 100-150 V. DNA and RNA in agarose gels were 
visualised under ultraviolet light using a GelDoc-It™ Imaging system (Ultra-Violet 
Products; Cambridge, UK). 
 
2.3.2 Mammalian cell culture and transfection 
2.3.2.1 Passaging, freezing and defrosting cells 
Cell cultures were grown in the appropriate growth medium (see Table 2.3) in a 
humidified incubator at 37 °C with 5 % CO2. Cells were passaged when they reached 
approximately 80 % confluency. To passage, cells were washed twice with PBS 
containing 0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium 
chloride, pH 7.4 and incubated with enough trypsin-EDTA solution to cover the base of 
the culture vessel for 5-10 min until the cells had detached from the culture vessel. The 
cell suspension was triturated using a 5 ml pipette to achieve a single-cell suspension 
before 4-7.5 ml of the appropriate growth medium was added to inactivate the trypsin 
treatment (4 ml for 25 cm2 flasks, 7.5 ml for 75 cm2 and 175 cm2 flasks). The cell 
suspension was further diluted and distributed to sterile culture vessels as required. 
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For cryopreservation, cells were grown and passaged as normal but instead of further 
dilution, cells were pelleted by centrifugation at 1000 g for 5 min and resuspended in  
7 ml freeze medium containing 70 % (v/v) growth medium, 20 % (v/v) FBS and 10 % 
(v/v) dimethyl sulfoxide (DMSO). Cells were immediately divided into 1 ml aliquots in 
cryovials, placed into a polystyrene box and incubated at -80 °C to freeze gradually. 
After 24 h, frozen cells were moved to liquid nitrogen for long-term storage. 
 
To defrost, cells were thawed rapidly in a 37 °C water bath and diluted in 10 ml of the 
appropriate growth medium (see Table 2.3). The cell suspension was spun at 1000 g 
for 3 min and freeze medium was replaced with 5 ml of fresh growth medium. 
Defrosted cells were initially plated in a 25 cm2 flask and incubated in a humidified 
incubator at 37 °C with 5 % CO2 for 24 h before being passaged and moved to a larger 
culture vessel as appropriate. 
 
2.3.2.2 Transient transfection of cell lines 
2.3.2.2.1 Lipofectamine 2000 
CHO-TrkB cells were plated in 6-well and 12-well plates to achieve approximately 80 % 
confluence before being transfected with Lipofectamine 2000 as per the manufacturer’s 
instructions. For each well of a 6-well plate, 1 µg total DNA and 2.5 µl Lipofectamine 
2000 transfection reagent were diluted in 100 µl Opti-MEM and 0.5 µg total DNA and 
1.25 µl Lipofectamine 2000 were diluted in 100 µl Opti-MEM per well for 12-well plates. 
For CHO-TrkB cells, antibiotic-containing medium was aspirated from cells and 
replaced with antibiotic-free medium prior to transfection. After the DNA-transfection 
reagent complexes were distributed onto cells, plates were incubated in a humidified 
incubator at 37 °C with 5 % CO2 for a further 24 h before being harvested for analysis. 
 
2.3.2.2.2 Lipofectamine 
CHO cells were transfected in 6-well plates plated to achieve approximately  
80 % confluence using Lipofectamine as per the manufacturer's instructions. For each 
well, 2 µg total DNA and 4 µl Lipofectamine transfection reagent were diluted in 266 µl 
Opti-MEM. Cells were incubated in a humidified incubator at 37 °C with 5 % CO2 for a 
further 24 h before being harvested for analysis. 
 
2.3.2.2.3 FuGene 6 
CHO cells used in the experiments described in Chapter 5 were transfected with 
FuGene 6 as per the manufacturer’s instructions. Cells were incubated in a humidified 
incubator at 37 °C with 5 % CO2 for a further 24 h before being harvested for analysis. 
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2.3.2.3 Rat primary cortical neuron cell culture 
All work involving animals was conducted in accordance with the UK Animals 
(Scientific Procedures) Act 1986. Cortices were harvested from the brains of embryonic 
day 18 Sprague-Dawley rat pups (Charles River Laboratories; Kent, UK). Cortices 
were pooled and washed with HBSS (-/-) and incubated in 70 µl 2.5 % trypsin-EDTA in 
5 ml HBSS (-/-) at 37 °C for 30 min. An equal volume of filter-sterilised DNase I solution 
containing 10 µg/ml DNase I in HBSS (+/+) was added to achieve a final concentration 
of 5 µg/ml before media was aspirated. To dissociate cells, 1 ml triturating solution 
containing 1 % (w/v) AlbuMAXTM I, 0.5 mg/ml soybean trypsin inhibitor and 10 µg/ml 
filter-sterilised DNase I in HBSS (+/+) was added. The solution was triturated with 
flame-polished glass Pasteur pipettes until a single-cell suspension was achieved. The 
dissociated cells were diluted with phenol red-free Neurobasal medium supplemented 
with 2 % (v/v) B27 supplement, 2 mM L-glutamine, 100 IU/ml penicillin and 100 µg/ml 
streptomycin to a volume of 1 ml per pup dissected. Cells were strained through a  
70 µm cell strainer before being counted using a haemocytometer. To ensure that only 
live cells were counted, a small sample was diluted 1:10 in Trypan Blue prior to 
counting. 
 
For biochemical studies, neurons were plated at 8.0 x 105 cells per well in 12-well 
plates coated with 0.01 % (w/v) poly-D-lysine. For immunofluorescence and PLAs, 
neurons were plated at 2.5 x 104 cells per well in 12-well plates containing 18 mm 
coverslips (Marienfield; Lauda-Königshofen, Germany) coated with 0.01 % (w/v) 
poly-D-lysine. Cells were maintained in a humidified incubator at 37 °C with 5 % CO2 in 
Neurobasal medium supplemented with 2 % (v/v) B27 supplement, 2 mM L-glutamine, 
100 IU/ml penicillin and 100 µg/ml streptomycin. 
 
2.3.3 Cell treatments 
2.3.3.1 BDNF, K252a and U0126 cell treatments 
Cells were treated with 25 ng/ml BDNF prepared as a 25 µg/ml stock solution in 
filter-sterilised PBS containing 0.5 % bovine serum albumin for 15 or 30 min. K252a 
was prepared as a 200 µM stock in DMSO and applied at 200 nM 10 min prior to 
BDNF treatment. U0126 was prepared as a 20 mM stock in DMSO and applied at  
20 µM 15 min prior to BDNF treatment. Neurons were treated with BDNF on the third 
day of in vitro culture (days in vitro 3; DIV3). CHO and CHO-TrkB cells were transiently 
transfected with Fe65 24 h prior to BDNF treatment (as described in section 2.3.2.2). 
During treatments, cells were incubated in a humidified incubator at 37 °C with 5 % 
CO2. Following incubation, cells were washed twice with PBS and lysed for sodium 
dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (SDS-PAGE) and western 
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blotting. Cells were grown in 12-well plates and lysed in 75 µl sample buffer containing  
50 mM Tris-HCl pH 6.8, 2 % (w/v) SDS, 0.1 % (w/v) bromophenol blue, 20 % (v/v) 
glycerol. 5 % (v/v) β-mercaptoethanol and complete EDTA-free protease inhibitor 
cocktail (Roche, West Sussex, UK). Samples were heated for 5 min at 95 °C and 
frozen at -20 °C until required. For co-immunoprecipitation and GST pull-down assays, 
cells were grown in 6-well plates and lysed in 500 µl lysis buffer containing 50 mM 
Tris-citrate, 150 mM NaCl, 1 % (v/v) Triton X-100, 5 mM ethylene 
glycol-bis(β-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA), 5 mM EDTA, 
complete EDTA-free protease inhibitor cocktail. For Duolink PLA studies, cells were 
washed and fixed as described in section 2.3.9. 
 
2.3.3.2 siRNA treatment 
Accell siRNAs were reconstituted in siRNA resuspension buffer containing 60 mM KCl, 
6 mM HEPES pH 7.5 and 200 mM MgCl2 to a concentration of 100 µM as per the 
manufacturer’s instructions and stored at -20 °C until required. DIV3 cortical neurons 
were treated with 1 µM siRNA as per the manufacturer’s protocol. Briefly, resuspended 
siRNA was added to the cells at a final concentration of 1 µM and cells were incubated 
for a further 4 days in a humidified incubator at 37 °C with 5 % CO2. For APP siRNAs, 
where two individual siRNAs were combined, a 50:50 ratio of each siRNA was used to 
create a total concentration of 1 µM (see Table 2.4). 
 
To harvest for SDS-PAGE and western blotting, cells were washed twice with PBS and 
scraped into 50 µl lysis buffer (see section 2.3.3.1). Total protein concentration was 
measured by Bio-Rad protein assay (described in section 2.3.4) and samples were 
diluted as appropriate to ensure equal protein loading for SDS-PAGE and western 
blotting. 
 
To harvest for RT-qPCR, cells were washed twice with PBS and scraped into 350 µl 
buffer RLT containing 1 % (v/v) β-mercaptoethanol (from Qiagen RNeasy mini kit). The 
cell lysates were homogenised using a rotor-stator homogeniser (Ultra Turrax T8; IKA, 
Germany) for 3 x 10 s bursts on ice and samples were stored at -80 °C until the rest of 
the RNeasy kit protocol was performed (described in section 2.3.12.1). 
 
2.3.4 Determination of protein concentration (Bio-Rad protein assay) 
Protein concentrations were quantified using a Bio-Rad protein assay kit (Hertfordshire, 
UK), which is based on the Bradford method of quantifying protein concentration 
(Bradford, 1976). The assay was performed as per the manufacturer’s instructions. 
Samples were run in triplicate on a 96-well plate alongside a freshly prepared bovine 
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serum albumin protein standard curve. Absorbance for each sample was measured at 
595 nm on a Victor3 Multilabel Counter spectrophotometer (PerkinElmer; Coventry, 
UK). 
 
2.3.5 SDS-PAGE and western blotting 
Prior to SDS-PAGE, samples were heated in sample buffer (described in 2.3.3.1) for 5 
min at 100 °C. For SDS-PAGE, samples were separated on 8 or 10 % (v/v) 
polyacrylamide gels (see Table 2.5) in running buffer containing 25 mM Tris, 192 mM 
glycine, 0.1 % (w/v) SDS for 1.5–5 h at 100 V. Samples were run alongside Precision 
Plus ProteinTM Dual Xtra Standards (Bio-Rad) as markers for protein molecular 
masses.  
 
Table 2.5: Polyacrylamide gel recipes for SDS-PAGE. 
Gel Component Concentration 
8 % Resolving gel Tris-HCL pH 8.8 372 mM 
30 % (w/v) acrylamide/methylene 
bisacrylamide  
(37.5:1 ratio; acrylamide 30 %) 
8 % (v/v) 
SDS 0.1 % (w/v) 
Ammonium persulfate (APS) 0.1 % (w/v) 
Tetramethylethylenediamine 
(TEMED) 
0.1 % (v/v) 
10 % Resolving gel Tris-HCL pH 8.8 372 mM 
Acrylamide 30 % 10 % (v/v) 
SDS 0.1 % (w/v) 
APS 0.1 % (w/v) 
TEMED 0.1 % (v/v) 
5.6 % Stacking gel Tris-HCL pH 6.8 117 mM 
Acrylamide 30 % 5.6 % (v/v) 
SDS 0.1 % (w/v) 
APS 0.1 % (w/v) 




After separation by SDS-PAGE, proteins were transferred to Protran nitrocellulose 
membrane (0.45 µm pore; G.E. Healthcare) using a Bio-Rad Transblot system. 
Membranes were then incubated in blocking solution containing 5 % (w/v) skimmed 
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milk powder, 0.1 % (v/v) Tween 20 in Tris-buffered saline containing 20 mM Tris;  
137 mM NaCl; buffered with HCl to pH 7.6 (TBS) for 1 h before being incubated for  
16 h with primary antibody diluted appropriately with blocking solution (see Table 2.1). 
Blots were then washed for 10 min in 0.01 % (v/v) Tween 20 in TBS three times and 
incubated with the relevant horseradish peroxidase-coupled secondary antibody at a 
dilution of 1:8000 in blocking solution for 1 h. Western blots were then developed using 
an enhanced chemiluminescence system (ECL) comprising ECL Western Blotting 
Detection Reagents and Amersham Hyperfilm ECL (G.E. Healthcare). Hyperfilm was 
fixed and developed using a Konica Minolta SRX-101A Developer (Banbury, UK). 
 
2.3.5.1 Densitometry and statistical analysis of western blots 
Quantification of protein levels detected by SDS-PAGE and western blotting was 
carried out by densitometry. Developed ECL hyperfilms were digitalised using an 
Epson Perfection V700 Photo flatbed scanner (Hertfordshire, UK). ImageJ was used to 
measure the optical density (OD) of each protein band and the background density, 
which was subtracted from every sample value. Loading controls were run when 
possible to be used to account for inaccuracies when loading the samples into the gel. 
ODs for each sample were normalised to the expression level of the loading control for 
that particular sample. All OD values were then normalised to the mean OD of the 
control sample group. Statistical analyses were performed using Mann-Witney tests 
using Excel (Microsoft Corporation) and Prism 6 (GraphPad Software Inc.) and for all 
statistical tests, p < 0.05 was considered statistically significant. Where appropriate, bar 
charts were plotted using mean values and standard deviation (S.D.) was shown with 
error bars. 
 
For co-immunoprecipitation and GST pull-down assays where a loading control could 
not be used, an input sample was run alongside precipitated or pulled-down (output) 
samples. The input samples measure relative amounts of the proteins of interest 
present in each reaction so can be used to account for variation in protein levels 
between samples. For these experiments, ODs of each output sample were normalised 
to the level of protein expression detected in the input of each sample. For GST 
pull-down assays, these values were then further normalised to the mean of the control 
group. For co-immunoprecipitations, the amount of protein co-immunoprecipitated was 
also normalised to the amount of ‘bait’ protein immunoprecipitated as variation in 
available ‘bait’ could also influence the amount of protein that could be 
co-immunoprecipitated from samples. As with GST pull-down analyses, treatment 
values were further normalised to the mean of the control group. Statistical analyses 
were performed Excel and Prism 6 and for all statistical tests, p < 0.05 was considered 
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statistically significant. BDNF treated samples were compared using Wilcoxon 
signed-rank tests and Fe65 phosphorylation mutants were compared using Kruskal-
Wallis tests followed by Dunn’s multiple comparisons tests using Fe65WT as the control 
group for pairwise comparison. Where appropriate, bar charts were plotted using mean 
values and S.D. was shown with error bars. 
 
2.3.6 Co-immunoprecipitation 
Co-immunoprecipitation assays were performed at 4 °C or on ice to minimise protein 
degradation. For experiments described in Chapter 3, cells were washed with ice-cold 
PBS and scraped into lysis buffer (see section 2.3.3.1). The samples were sonicated 
with 5 pulses at 40 % cycle duty using a Vibra-Cell™ (Sonics & Materials, Inc., 
Connecticut, USA), before 10 % of the sample was heated in sample buffer (see 
section 2.3.3.1) for 5 min at 95 °C and then stored at -20 °C. The rest of the sample 
was centrifuged at 13,000 g for 20 min at 4 °C to pellet cellular debris. The total protein 
concentration of the supernatant was measured via Bio-Rad protein assay (described 
in section 2.3.4) and the samples were diluted to 1 µg/µl with autoclaved water. 
Typically, 300-500 µg total protein was used per immunoprecipitation and samples 
were rotated for 16 h at 4 °C with 1.5-2.5 µg of the appropriate antibody (see Table 
2.1). Following washing, the samples were then rotated with 30 µl Protein G Sepharose 
Fast Flow beads (50 % (v/v) slurry in 0.1 % (v/v) Triton X-100 in PBS; Triton-PBS) for 2 
h at 4 °C to allow antibody binding. The beads were then pelleted by centrifugation at 
3,000 g for 5 s at 4 °C and were washed four times with 1 ml Triton-PBS to remove 
unbound protein. The beads were heated in 50 µl sample buffer for 5 min at 95 °C to 
elute the sepharose bead-bound proteins and the sample was moved to a fresh 
eppendorf tube and stored at -20 °C until analysis via SDS-PAGE and western blotting 
was carried out. For experiments described in Chapter 5, CHO cells were transfected 
with the appropriate GST construct, lysed and treated as above with the exception that 
the samples were not sonicated prior to centrifugation and the antibody was captured 
by incubating with protein A-Agarose beads (Sigma) for 2 hr at 4 °C.  
 
2.3.7 GST fusion protein pull-down assay 
2.3.7.1 GST fusion-protein bead preparation 
E. coli transformed with plasmids containing either GST or GST-APPC were grown on 
LB agar selection plates containing 100 µg/ml ampicillin and used to make starter 
cultures (described in section 2.3.1.1). Working cultures of 200 ml LB-amp were 
inoculated with 2 ml of the starter cultures and incubated at 220 rpm, 37 °C until the 
optical density measured at 600 nm reached approximately 0.8 (0.6-1.0), indicating 
that mid-log phase growth had been achieved. Optical density was measured using an 
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Ultospec 3000 UV/visible spectrophotometer (G.E. Healthcare). Isopropyl 
β-D-1-thiogalactopyranoside (IPTG) was made up to a stock of 1M and added to 
cultures to a final concentration of 0.4 mM to induce recombinant protein expression. 
Bacterial cultures were incubated for a further 2 h at 220 rpm at 37 °C. The bacteria 
were cooled for 10 min on ice before being pelleted via centrifugation at 3,000 g for   
10 min at 4 °C. The pellet was resuspended in 10 ml radio-immunoprecipitation assay 
(RIPA) buffer containing 0.1 % (w/v) SDS, 0.1 % (v/v) Triton X-100 and 1 % (w/v) 
sodium deoxycholate in TBS and incubated for 30 min on ice. Samples were sonicated 
on ice for 15 s at full power, 50 % cycle duty, then cellular debris was pelleted by 
centrifugation at 8,000 g for 10 min at 4 °C. The supernatant was incubated on a 
rotator for 90 min at 4 °C with 750 µl of a 50 % (v/v) slurry of glutathione sepharoseTM 
4B beads in PBS (G.E. Healthcare) to allow protein adherence before the beads were 
pelleted by centrifugation at 3,000 g for 1 min at 4 °C. The beads were washed three 
times in 1 ml Triton-PBS to remove unbound protein. The beads were finally 
resuspended in 750 µl Triton-PBS to create a 50 % (v/v) slurry.  
 
To check that GST and GST-APPC had coupled to the glutathione sepharoseTM 4B 
beads, 2 µl beads were heated in 20 µl SDS-PAGE sample buffer (described in section 
2.3.3.1) for 5 min at 95 °C and the protein eluate was run on a 10 % polyacrylamide gel 
for 1 h at 100 V (described in section 2.3.5). The polyacrylamide gel was fixed for 1 h in 
fixing buffer containing 50 % (v/v) methanol and 10 % (v/v) glacial acetic acid and 
stained for 2 h in 50 % (v/v) methanol, 1 % (v/v) glacial acetic acid and 0.1 % (v/v) 
Coomassie Brilliant Blue. It was then destained for 3 h in destaining solution containing 
40 % methanol and 10 % (v/v) glacial acetic acid to remove background staining. 
Protein bands were imaged using an Epson Perfection V700 Photo flatbed scanner. 
 
2.3.7.2 GST fusion-protein pull-down assay 
GST pull-down assays were performed at 4 °C or on ice to minimise protein 
degradation. For experiments described in Chapter 3, CHO-TrkB cells were transfected 
as appropriate (described in section 2.3.2.2) and treated with BDNF as appropriate 
(described in section 2.3.3.1) before cells were washed with ice-cold PBS and scraped 
into lysis buffer (see section 2.3.3.1). The samples were sonicated on ice with 5 pulses 
at 40% cycle duty before 10 % of the sample was collected as the input sample and 
heated in SDS-PAGE sample buffer (see section 2.3.3.1) for 5 min at 95 °C before 
being stored at -20 °C. The rest of the sample was centrifuged at 13,000 g for 20 min 
at 4 °C to pellet cellular debris. The total protein concentration of the supernatant was 
calculated via Bio-Rad protein assay (described in section 2.3.4) and the samples were 
diluted to 1 µg/µl. Typically, 300-500 µg total protein was used per GST pull-down. 
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Samples were incubated with 30 µl of either GST coupled glutathione sepharoseTM 4B 
beads or GST-APPC coupled glutathione sepharoseTM 4B beads on a rotator for 2 h at 
4 °C. The beads were then pelleted by centrifugation at 3,000 g for 15 s at 4 °C. The 
beads were washed four times with 1 ml Triton-PBS and the retained protein eluted 
from the beads into 50 µl sample buffer. The protein solution was heated for 5 min at 
95 °C and frozen at -20 °C until required. For experiments described in Chapter 5, 
CHO cells were transfected with the appropriate GST construct, lysed and treated as 
above with the exception that the samples were not sonicated prior to centrifugation 
and they were incubated with unconjugated glutathione sepharoseTM 4B beads for 1 hr. 
 
2.3.8 ELISA 
2.3.8.1 Total tau and phosphorylated tau ELISA 
Total tau levels were measured using the ThermoFisher Scientific tau (total) ELISA kit 
and tau phosphorylated at Ser199 was measured using the ThermoFisher Scientific tau 
(pS199) ELISA kit. ELISAs were performed on DIV3 rat cortical neurons treated with 
siRNAs (described in section 2.3.3.2). To perform the ELISAs, cells were washed twice 
with PBS and incubated in 100 µl ELISA cell extraction buffer containing 10 mM Tris, 
pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM sodium fluoride, 20 mM 
sodium pyrophosphate, 2 mM sodium orthovanadate, 1 % (v/v) Triton X-100, 10 % 
(v/v) glycerol, 0.1 % (w/v) SDS, 0.5 % (w/v) sodium deoxycholate, 1 mM 
phenylmethylsulfonyl fluoride and complete EDTA-free protease inhibitor cocktail for  
30 min at 40 °C. Following incubation, the samples were spun at 13,000 g for 10 min at 
4 °C and supernatants were collected and diluted 1:500 prior to application to the 
ELISA plate. The kits were used as per the manufacturer’s instructions and the 
provided tau standard curves were run alongside samples. The ELISA plates were 
read at 450 nm on a Victor3 Multilabel Counter spectrophotometer. 
 
2.3.8.2 Total GSK3β and phosphorylated GSK3β ELISA 
Both total GSK3β and GSK3β phosphorylated at Ser9 were measured using the Meso 
Scale Diagnostics phospho/total GSK-3β whole cell lysate ELISA kit. ELISAs were 
performed on DIV3 rat cortical neurons treated with siRNAs (described in section 
2.3.3.2). Cells were washed twice with PBS and incubated in 100 µl ELISA cell 
extraction buffer (described in 2.3.8.1) for 30 min at 40 °C. The samples were spun at 
13,000 g for 10 min at 4 °C. Cell lysates were then diluted 1:50 prior to application to 
the ELISA plate. The kits were used as per the manufacturer’s instructions and no 
standards were supplied for standard curves so relative OD values were compared. 
The ELISA plate was read at 450 nm on a Victor3 Multilabel Counter 
spectrophotometer. 
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2.3.8.3 Statistical analysis of ELISA data 
Relative tau phosphorylation was analysed using Excel by calculating phosphorylated 
tau as a proportion of total (including phosphorylated) tau levels. These values were 
then normalised to the control mean. In a similar manner, relative GSK3β 
phosphorylation was analysed by calculating phosphorylated GSK3β as a proportion of 
total (including phosphorylated) GSK3β. Again, these values were then normalised to 
the control mean before statistical analyses were carried out. Statistical analyses were 
carried out using Mann-Witney tests. All statistical analyses were performed using 
Excel and Prism 6 and for all statistical tests p < 0.05 was considered statistically 
significant. Where appropriate, bar charts were plotted using mean values and S.D. 
was shown with error bars. 
 
2.3.9 Immunofluorescence 
Rat cortical neurons were plated out as described in section 2.3.2.3 and grown to DIV3 
in a humidified incubator at 37 °C with 5 % CO2. Following the incubation period, media 
was aspirated from cells, which were then washed with PBS. Cells were fixed in 4 % 
(w/v) PFA in PBS for 15 min before being washed twice with PBS. Coverslips were 
washed once with quenching solution containing 50 mM NH4Cl and then incubated in 
quenching solution for 15 min. Cells were then washed again with PBS and 
permeabilised by incubation in 0.2 % (v/v) Triton X-100 in PBS for 3 min. After 3 further 
washes with PBS cells were blocked in 5 % FBS in PBS for 30 min before being 
incubated with the appropriate primary antibodies for 1 hr. Coverslips were washed 
three times with 5 % FBS and incubated in the appropriate secondary antibody for 45 
min. Again, coverslips were washed three times with 5 % FBS followed by incubation 
with 0.1 µg/ml DAPI stain for 15 min. Finally, cells were washed five times in PBS to 
remove all excess stain and mounted onto glass coverslips using Fluorecent Mounting 
Medium (DAKO). Images were captured using a Leica DM5000B microscope with 63x 
HCX PL Fluotar phase objective (Milton Keynes, UK). For intensity correlation analysis, 
images were analysed using ImageJ with the Intensity Correlation Analysis plugin 
(described in Cheung et al., 2014). Statistical analysis was carried out using 
one-sample t-tests using Excel and Prism 6. 
 
2.3.10 Duolink PLA  
In situ PLAs were used to monitor the APP-Fe65 interaction (Söderberg et al., 2006; 
Weibrecht et al., 2010). Cells were fixed using paraformaldehyde (PFA) cross-linking 
and probed with primary antibodies followed by secondary antibodies coupled to 
specific oligonucleotides. If the antigens are situated close enough (within 30 nm), 
these oligonucleotides hybridize and initiate rolling-circle amplification of fluorescent 
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oligonucleotides. These fluorescent signals can then be detected and used to quantify 
the interaction between the two labelled proteins of interest (Figure 2.1). 
 
For PLAs, CHO-TrkB cells were plated out to achieve ~5 % confluence in 12-well 
plates containing 18 mm diameter glass coverslips (Marienfield) and grown for 48 h in 
a humidified incubator at 37 °C with 5 % CO2. Following the incubation period, media 
was aspirated from cells, which were then washed with PBS. Cells were fixed in 4 % 
(w/v) PFA in PBS for 15 min before being washed twice with PBS. Coverslips were 
washed once with quenching solution containing 50 mM NH4Cl and then incubated in 
quenching solution for 15 min. Cells were then washed again with PBS and 
permeabilised by incubation in 0.2 % (v/v) Triton X-100 in PBS for 3 min. After 3 further 
washes with PBS, PLAs were performed as per the Duolink In Situ PLA protocol using 
the Duolink In Situ range of: detection reagents (orange), wash buffers (fluorescence) 
and PLA probe kits. All incubation steps were carried out in a humidity chamber 
pre-heated to 37 °C. Briefly, coverslips were incubated in Duolink blocking solution at 
37 °C for 30 min. Coverslips were then incubated in primary antibodies (see Table 2.1) 
diluted 1:400 in Duolink antibody diluent for 1 h at 37 °C and washed three times in  
5 ml PBS for 5 min. The coverslips were then incubated in Rabbit PLUS and mouse 
MINUS Duolink PLA probes used at a dilution of 1:5 in Duolink blocking solution at  
37 °C for 1 h. Following this incubation period, the coverslips were washed twice in  
5 ml Duolink wash buffer A containing 10 mM Tris, 150 mM NaCl and 0.05 % (v/v) 
Tween 20 for 5 min then incubated in 40 µl Duolink ligase solution containing 1 U 
ligase at 37°C for 30 min. Coverslips were washed twice in 5 ml Duolink wash buffer A 
for 2 min and incubated in 40 µl Duolink amplification solution containing 0.5 U 
polymerase at 37 °C for 100 min. From this stage on, foil was used to protect the 
photosensitive reaction from light at all steps. Coverslips were washed in 0.5 µg/ml 
DAPI in Duolink wash buffer B containing 200 mM Tris and 100 mM NaCl for 10 min, 
followed by a further wash in 5 ml Duolink wash buffer B for 10 min and 5 ml Duolink 
wash buffer B diluted 1:100 with autoclaved H2O for 1 min. Finally, coverslips were 
mounted onto microscope slides using fluorescence mounting medium (DAKO) and 
stored at 4 °C until required. 
 
For PLA analyses, images were captured using a Leica DM5000B microscope with 63x 
HCX PL Fluotar phase objective. For CHO-TrkB cells, a single image could not capture 
all the in-focus PLA signals (seen as fluorescent dots) so a z-stack of 6-12 images per 
cell was compiled as necessary and analysed using ImageJ with the ‘Extended Depth 
of Field’ plug-in (Forster et al., 2004). For primary cortical neurons, depth of field was 
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not an issue so a single image was taken. The number of fluorescent dots present in 
each cell was counted using the ‘Analyze Particles’ function of ImageJ. 
 
 
Figure 2.1: A diagram to show the Duolink PLA process. A) Primary antibodies are 
used to label the proteins of interest in fixed, permeabilised cells. B) Proprietary 
secondary antibodies that are conjugated to complementary oligonucleotides bind to 
the primary antibodies. C) If the PLA probes bind to antibodies within 30 nm of each 
other, they hybridise during the ligation step. D) The hybridised oligonucleotides act as 
primers for rolling-circle amplification of fluorescent oligonucleotides that can be 
visualised as a single red dot under a fluorescent microscope. 
 
2.3.10.1 Statistical analysis of PLA data 
Raw data of individual experiments were checked for normality using the 
Kolmogorov-Smirnov test and equal variance was determined using F tests. For BDNF 
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experiments, data were normalised to the untreated control sample and the normalised 
data for BDNF treated cells from three independent experiments were pooled and 
compared using Mann-Witney tests. Data from control experiments were analysed 
using one-way ANOVA followed by Dunnett’s multiple comparisons test using 
APP+Fe65+PLA probes as the control group for pairwise comparison. All statistical 
analyses were performed using Excel and Prism 6 and for all statistical tests, p < 0.05 
was considered statistically significant. 
 
2.3.10.2 Neurite length measurements 
Rat cortical neurons were grown to DIV2 before being transfected with EGFP 
alongside the appropriate constructs. Neurons were immunostained (see section 2.3.9) 
to verify that both constructs had been transfected successfully before being chosen 
for analysis. The longest neurite of each cell examined was measured 24 hr after 
transfection. The length was determined as the distance from the tip of the growth cone 
to the cell body and was quantified using ImageJ using the NeuronJ plug-in (Cheung et 
al., 2014). Data were analysed using one-way ANOVA followed by Bonferroni post hoc 
test. All statistical analyses were performed using Excel and Prism 6 and for all 
statistical tests, p < 0.05 was considered statistically significant. 
 
2.3.11 Fe65KO transgenic mice 
2.3.11.1 PCR genotyping of Fe65 knockout mice 
Fe65KO mice were as originally described (Guénette et al., 2006) and maintained on a 
C57BL/6 genetic background. To identify transgenic littermates, DNA from ear or tail 
tissue was extracted using REDExtract-N-AmpTM tissue PCR kit as per the 
manufacturer’s instructions. For PCR, 4 µl of the extracted DNA sample was added to 
10 µl REDExtract-N-AmpTM PCR reaction mix and 4 pmol of the appropriate primers 
(see Table 2.6) in a final volume of 20 µl. Together these primers detect both wild-type 
(WT) and the targeted mutant Fe65 alleles. The PCR was run in a G-Storm 
thermocycler (Somerset, UK; see Table 2.7). To visualise PCR genotyping results,  
10 µl of the reaction was run on a 1.5 % (w/v) agarose gel for 20 min (see section 
2.3.1.3). 
 







Table 2.7: Fe65KO mouse PCR genotyping program. 
Step Cycles Time (min) Temperature (°C) 








Extension/Elongation 1 5 72 




2.3.11.2 Tissue harvesting from Fe65KO mice 
Brains were harvested from Day 0 male mouse pups. The brain hemispheres were 
separated via a sagittal cut and each hemisphere was snap-frozen in liquid nitrogen 
separately for later processing. PCR genotyping was carried out on tail tissue from 
carcasses to identify WT and Fe65KO pups (described in section 2.3.11.1). One 
hemisphere of each brain sample was homogenised in 200 µl extra strong lysis buffer 
containing 10 mM Tris-HCl, pH 7.5, 75 mM NaCl, 0.5% (w/v) SDS, 20 mM sodim 
deoxycholate, 1 % (v/v) Triton X-100, 1 mM sodium pyrophosphate, 2 mM sodium 
orthovanadate, 1.25 mM sodium fluoride, 10 mM EDTA and complete EDTA-free 
protease inhibitor cocktail per 10 mg brain and processed for SDS-PAGE and western 
blotting to analyse protein expression (as described in section 2.3.5).  
 
2.3.12 RNA isolation, reverse transcription and SYBR Green RT-qPCR 
2.3.12.1 RNA isolation 
The remaining mice brain hemispheres (described in section 2.3.11.2) were processed 
using the RNeasy mini kit (Qiagen) used in conjunction with the suggested on-column 
DNase treatment using the RNase-free DNase I set (Qiagen). Brain samples were 
homogenised in 350 µl Buffer RLT containing 1 % (v/v) β-mercaptoethanol per 10 mg 
of tissue using a rotor-stator homogeniser (Ultra Turrax T8). All tissue was kept on ice 
to minimise protein and messenger RNA (mRNA) degradation and samples were 
stored in aliquots at -80 °C until required. Following homogenisation, the RNeasy mini 
kit was used as per the manufacturer's instructions. RNA was eluted off the column by 
incubation in 50 µl ribonuclease-free water. The eluted RNA was then re-applied to the 
column, incubated and spun as before to ensure maximum yield. The concentration of 
RNA yield was determined by measuring its absorbance at 260 nm using a NanoDrop 
1000 spectrophotometer. The 260/280 ratio was used to determine RNA purity; pure 
RNA has a ratio of 2.0. To assess RNA quality and check for genomic DNA 
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contamination and RNA degradation, 0.1-0.2 µg RNA was run on a 1 % (w/v) agarose 
gel (see section 2.3.1.3). RNA samples were stored at -80 °C until required to preserve 
RNA quality. 
 
2.3.12.2 Reverse transcription 
RNA was reverse transcribed to cDNA using the nanoScript2 reverse transcription kit 
(PrimerDesign) as per the manufacturer's instructions using the supplied oligo-dT 
primers to enhance primer annealing to the 3’ polyA tail of mRNA. Incubation steps 
were performed using a G-storm thermocycler. cDNA samples were stored at -20 °C 
until required (for a maximum of 12 months). Reverse transcription-null controls were 
run alongside reverse transcription reactions and these contained all the same 
reagents and samples as full reactions with the exception of the reverse transcriptase 
enzyme. 
 
2.3.12.3 GeNorm reference gene analysis 
The GeNorm reference gene analysis kit (PrimerDesign) was used to identify 
appropriate reference genes to use for relative quantification of mRNA expression. For 
GeNorm analysis, 12 reference genes were analysed (see Table 2.9). Reference gene 
RT-qPCR was carried out in duplicate on 4 WT and 4 Fe65KO mouse brain samples. 
To reduce inter-run variability, all samples for each gene were run on the same plate. 
SYBR Green RT-qPCR was carried out using PrecisionPLUS mastermix 
(PrimerDesign) containing inert blue dye as per the manufacturer's instructions. Each 
20 µl reaction contained 300 nM primer mix, 1 x PrecisionPLUS mastermix and 25 ng 
cDNA. SYBR Green RT-qPCR was performed using an ABI 7900HT Fast Real-Time 
PCR system (ThermoFisher Scientific) using 384-well BrightWhite RT-qPCR plates 
(PrimerDesgin) and adhesive optical seals. The amplification protocol used is 
described in Table 2.8. Results were collected and analysed using SDS 2.3 (ABI) and 
Prism 6 and GeNorm analysis was carried out using qbase+ 3.0 software (Biogazelle; 
Zwijnaarde, Belgium; Vandesompele et al. 2002). 
 
2.3.12.4 SYBR green RT-qPCR 
For relative quantification of mRNA expression of seven genes of interest, mouse brain 
samples and cell lysates of siRNA treated rat cortical neurons were analysed via SYBR 
Green RT-qPCR as described in section 2.3.12.3. RT-qPCR was carried out using 
technical triplicates alongside no-template controls and reverse transcription-null 
controls (described in section 2.3.12.2). Custom primers for mouse genes (see Table 
2.10) and rat genes of interest (see Table 2.11) were purchased from PrimerDesign 
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and were guaranteed to have greater than 90 % efficiency to be suitable for relative 
quantification analysis using the 2-ΔΔCt method (Livak and Schmittgen, 2001). 
 
Table 2.8: RT-qPCR amplification program. 
Step Cycles Time (sec) Temperature (°C) 




Data collection 60 60 






Table 2.9: GeNorm reference gene primer details. Specific primer sequences 
were not disclosed by PrimerDesign. 
Gene Anchor Nucleotide Context Length Sequence (bp) 
18S 134 99 
ACTB 597 94 
ATP5B 1115 142 
B2M 202 159 
CANX 2827 127 
CYC1 514 203 
EIF4A2 876 215 
GAPDH 793 180 
RPL13A 691 180 
SDHA 2018 181 




Table 2.10: Primer sequences used for RT-qPCR on Fe65KO mouse brain 
samples. 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
APP TGGCGGTGAAGACAAAGTAGT CCATCCTCCACATCCTCATCAT 
Fzd1 CCCGCCCATTCCAGATCC ATCTCAAATAAGCAGCATCAGG
AA 
GSK3α CCCCCAGGCTACCACTCC AGGGAAGGGAAGACGAGAGA 






Wnt3 GGCGAGATTCTGTGTCCAAG CGGGGCTCTGTCCTACTTC 
 
 
Table 2.11: Primer sequences used for RT-qPCR on siRNA treated rat cortical 
neurons. 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 






Fzd1 CCCGCCCATTCCAGATCC ATCTCAAATAAGCAGCATCAGGAA 
 
 
2.3.12.5 Analysis of RT-qPCR data 
RT-qPCR results were analysed using SDS 2.3, Excel and Prism 6. First the 
dissociation curve raw data were analysed using SDS 2.3 to check that no primer 
dimers were formed during the PCR experiment for any of the primers used. Technical 
replicates differing by >0.5 Ct (number of cycles taken for SYBR Green fluorescence to 
reach a threshold level) were excluded from analyses and biological replicates were 
excluded if they did not have ≥2 replicate data points. Relative quantification was 
calculated using the 2-ΔΔCt method (Livak and Schmittgen, 2001) using GAPDH/ATP5B 
as reference genes. Specifically, the following equation was used: ΔΔ!" = (!"!"#  −  !"!"#)!"#$% ! − (!"!"#  −  !"!"#)!"#$% !" 
Where CtGOI = Ct for gene of interest, CtREF = average Ct of reference genes, mouse x 
is any biological sample and mouse WT is the mean change in expression of the gene 
of interest normalised to the reference genes in the WT mouse brain samples. 
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Statistical analyses were performed using Mann-Whitney tests on 2-ΔCt values (Livak 
and Schmittgen, 2001) as appropriate. Bar charts were plotted with 2-ΔΔCt values 
normalised to the mean of the control group and S.D. was shown with error bars. All 
statistical analyses were performed using Excel and Prism 6 and for all statistical tests, 
p < 0.05 was considered statistically significant. 
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CHAPTER 3: BDNF INDUCES ERK1/2 PHOSPHORYLATION OF 
FE65 TO REGULATE ITS BINDING TO APP
 70 
3.1 Introduction 
Fe65 is of interest to the field of AD research because it is a major binding partner of 
APP. This interaction occurs between the second PTB domain of Fe65 and the 
YENPTY motif on the intracellular domain of APP. The APP-Fe65 complex has been 
implicated in several cellular processes, including cell motility, apoptosis and gene 
transcription (see section 1.3.2). Binding between APP and Fe65 is regulated by 
phosphorylation of both proteins at specific sites. Phosphorylation of APP at Tyr682 and 
Thr668 inhibits the interaction between APP and Fe65 (Ando et al., 2001; Barbagallo et 
al., 2010; Nakaya and Suzuki, 2006; Tarr et al., 2002a, 2002b). In addition, 
phosphorylation of Fe65 on Ser610 by SGK1 can also impair APP-Fe65 binding and 
inhibits amyloidogenic processing of APP (Chow et al., 2015b; Lee et al., 2008a). Fe65 
is also phosphorylated on Tyr547 within its second PTB domain, although this does not 
impact the APP-Fe65 interaction but instead stimulates APP-Fe65 mediated 
transcription (Perkinton et al., 2004). Finally, Fe65 is phosphorylated on N-terminally 
located Ser228 by ATM/ATR protein kinases (Jowsey and Blain, 2015). In contrast to 
Tyr547 phosphorylation, Ser228 phosphorylation inhibits APP-Fe65 mediated 
transcription, but has no effect on the ability of Fe65 to bind to APP (Jowsey and Blain, 
2015). 
 
Fe65 is also phosphorylated at Ser175, Ser287, Ser347 and Thr709 by ERK1/2 (Standen et 
al. 2003; Figure 1.3.1), however, the functional effects of this phosphorylation on 
APP-Fe65 binding have not yet been investigated. In addition, the regulatory 
mechanisms that control phosphorylation of these sites by ERK1/2 is also unknown. 
One well characterised mechanism of ERK1/2 activation within the nervous system 
involves stimulation of TrkB signalling by BDNF (Yang et al., 2013). Interestingly, 
BDNF has been proposed as a potential therapy for AD as it can restore synaptic 
defects in animal models of disease and ameliorate cognitive impairments, but the 
precise mechanisms underlying these effects are not clear (Blurton-Jones et al., 2009; 
Nagahara et al., 2013, 2009).  
 
In this chapter, the effect of BDNF on phosphorylation of Fe65 by ERK1/2 was studied. 
The consequences of this BDNF-mediated Fe65 phosphorylation on the interaction 
between APP and Fe65 were also explored. Finally, Fe65 phosphorylation mutants 
were utilised to investigate how phosphorylation of Fe65 at ERK1/2-specific sites 
regulates its binding to APP. For experiments investigating the binding of Fe65 to APP, 
assays were required that can reliably quantify subtle changes in binding between the 
two proteins. Whilst immunoprecipitation and pull-down assays have been used 
 71 
previously to detect the APP-Fe65 interaction, they have been used mainly to detect 
whether or not binding occurs, rather than for measuring quantitative changes in 
binding. Therefore, the first stage of these experiments was to establish several 
complementary assays that are able to detect the APP-Fe65 interaction quantitatively 
and to optimise them for the proteins of interest. The second stage of this investigation 
was to use these assays to determine how phosphorylation of Fe65 affects its binding 





3.2.1 Commercial antibodies detect Fe65 on western blots 
As a number of experiments in this investigation relied on detection of Fe65 by western 
blotting, an appropriate Fe65 antibody needed to be identified. Homemade antibodies 
have previously been generated that recognise Fe65 (Kesavapany et al., 2002), but 
these were damaged in a freezer defrost accident. Commercial Fe65 antibodies 
sc-19751 (Santa Cruz), 4H324 (Abcam), 2877 (Cell Signaling Technology) and a 
homemade Fe65 antibody, C60 (Lau et al., 2000b), were used to probe western blots 
of cell lysates from CHO cells transiently transfected with either chloramphenicol 
acetyltransferase (CAT) from E. coli as a control vector (Ctrl) or Fe65 plasmid vector 
(described in Table 2.2). Fe65 was strongly detected by both 4H324 and 2877 
antibodies at both concentrations tested. The western blots probed with C60 showed a 
specific band detected at the correct molecular weight for Fe65, however, the large 
amount of non-specific staining also seen suggested that the concentrations tested for 
this antibody were too high. Finally, the sc-19751 antibody only detected a very weak 
Fe65 signal at the concentrations tested (Figure 3.1). For all further western blots, 





Figure 3.1: Commercial antibodies detects Fe65 on western blots.  
CHO cells transiently transfected with CAT (Ctrl) or Fe65 plasmid vectors were lysed  
24 hr post-transfection and western blotted for Fe65. The four antibodies tested were 
sc-19751 (Santa Cruz), 4H324 (Abcam), C60 (Homemade) and 2877 (Cell Signaling 
Technology). Each antibody was tested at a dilution of 1:500 and 1:1000 in 5 % BSA 
for Fe65 transfected cells and 1:1000 in 5 % BSA for control transfected cells. 




3.2.2 Detection of the APP-Fe65 interaction 
The studies described below were aimed at determining how BDNF and 
phosphorylation of Fe65 on the ERK1/2-responsive sites (Ser175, Ser287, Ser347 and 
Thr709) affected its binding to APP. Reliable assays to detect and quantify the 
APP-Fe65 interaction firstly needed to be established. In addition, while many studies 
have demonstrated the interaction between transfected APP and Fe65 (for example, 
Borg et al., 1996; Bressler et al., 1996; Lau et al., 2008), detecting an interaction 
between endogenous APP and Fe65 has proved more difficult. To resolve this, 
proximity ligation assays (PLAs) were also established to study this interaction in 
untransfected cells (Söderberg et al., 2006). 
 
 
3.2.2.1 The APP-Fe65 interaction can be detected by co-immunoprecipitation 
involving Fe65, but not APP C-terminal immunoprecipitating antibodies 
To work up reliable immunoprecipitation assays to detect and quantify binding of 
transfected APP and Fe65, HEK293 and CHO cells were transiently transfected with 
CAT (Ctrl), APP, myc epitope-tagged Fe65 (Fe65-myc), APP+Fe65-myc, wild-type 
Fe65 (Fe65WT) or APP+Fe65WT plasmid vectors (described in Table 2.2). 
Immunoprecipitations were then performed with three different antibodies. 9B11, an 
antibody that detects the myc-tag, Fe65 antibody sc-19751 and C-terminal APP 
antibody CT-17. Western blots of total cell lysate inputs revealed that all cells were 
appropriately transfected. Extended exposures of these input blots with the APP and 
Fe65 antibodies enabled detection of endogenous proteins in non-transfected cells (not 
shown for all blots; Figure 3.2). Western blots of the immunoprecipitates revealed an 
interaction between APP and Fe65 in APP+Fe65 co-transfected cells following 
immunoprecipitation with 9B11 or the Fe65 antibody (Figure 3.2A, B). The absence of 
signal in control, APP or Fe65 only transfected cell immunoprecipitates in these 
experiments demonstrates the specificity of the assays. However, while the APP 
antibody immunoprecipitated APP, no bound Fe65 could be detected (Figure 3.2C). 
The signal for Fe65 pulled down in APP+Fe65-myc co-transfected cells is relatively 
weaker than the signal for Fe65 pulled down in singly, Fe65-myc transfected cells 
(Figure 3.2A). This could be due to pipetting error resulting in fewer beads being added 
to the sample or issues with eluting the protein from the beads after 
co-immunoprecipitation. For all co-immunoprecipitation assays, the APP signal is 
normalised to the amount of Fe65 precipitated to ensure that any fluctuations in signal 




Immunoprecipitation assays involving pull-down of Fe65 via the myc tag, or by using 
an Fe65 antibody detected binding of APP in transfected cells  
(Figure 3.2A, B). However, immunoprecipitation assays using antibody CT-17 pulled 
down APP, but not any bound Fe65 (Figure 3.2C). CT-17 was generated by 
immunisation of rabbits with a peptide comprising the 17 C-terminal amino acids of 
APP (see Figure 1.3B). This contains the C-terminal YENPTY motif, which is also the 
binding site of Fe65. One possible explanation for CT-17 failing to 
co-immunoprecipitate APP-bound Fe65 is that CT-17 cannot recognise APP-Fe65 
complexes because Fe65 blocks access to the CT-17 epitope, resulting in only 
unbound APP being precipitated. Due to the success of sc-19751 in detecting the APP-
Fe65 interaction without the use of an epitope tag, future co-immunoprecipitations were 





Figure 3.2: The APP-Fe65 interaction can be detected by co-immunoprecipitation 
involving Fe65, but not APP C-terminal antibodies. 
A) HEK293 cells were transiently transfected with CAT (Ctrl), APP, Fe65-myc or 
APP+Fe65-myc plasmid vectors as indicated. Fe65-myc was immunoprecipitated using 
antibody 9B11 that recognises the myc tag. B), C) CHO cells were transiently 
transfected with CAT control vector (Ctrl), APP, Fe65WT or APP+Fe65WT as indicated. 
B) Fe65WT was immunoprecipitated using Fe65 antibody sc-19751. C) APP was 
immunoprecipitated using CT-17, a C-terminal APP antibody. Input samples and 
immunoprecipitates were analysed by western blotting. Fe65 was detected using 




3.2.2.2 The APP-Fe65 interaction can be detected by GST pull-down assays 
involving the APP cytoplasmic domain 
To work up methods for detecting the APP-Fe65 interaction by GST-APPC pull-down 
assays, a construct of APP that contains only the 46 C-terminal residues (including the 
YENPTY motif) fused to Glutathione S-Transferase (GST) was expressed in E. coli 
(vector described in Table 2.2) and recombinant GST-APPC was then used to isolate 
Fe65 from transfected cells (Standen et al. 2001). GST and GST-APPC fusion protein 
expression was induced with IPTG and E. coli lysates were analysed by coomassie 
blue staining of SDS-PAGE gels. Expression of both constructs was enhanced by 
IPTG induction of E. coli as seen by the appearance of 26 kDa GST and 30 kDa 
GST-APPC species (Figure 3.3A). Proteins were then purified on glutathione sepharose 
4B beads. Protein samples eluted from GST and GST-APPC beads were also analysed 
by coomassie staining of SDS-PAGE gels, which verified correct expression of the two 
recombinant proteins (Figure 3.3A).  
 
Pull-down experiments with GST and GST-APPC beads were then performed from cell 
lysates of CHO cells stably expressing TrkB (CHO-TrkB) transiently transfected with 
CAT (Ctrl) or Fe65WT plasmid vectors (described in Table 2.2). Input, GST and 
GST-APPC pull-downs were separated by SDS-PAGE and analysed by western 
blotting. Fe65 was detected in input samples of cells transfected with Fe65WT but not 
control vector (Figure 3.3B). GST-APPC pulled-down Fe65 in cells transfected with 
Fe65WT but not control cells, while GST alone did not pull-down Fe65 from either cell 
lysate (Figure 3.3B). These experiments demonstrate the specificity of the GST-APPC 
pull-down assay but show that it is only capable of detecting interactions between 




Figure 3.3: The APP-Fe65 interaction can be detected by GST pull-down assays 
involving the APP cytoplasmic domain. 
A) E. coli transformed with either GST or GST-APPC expressing plasmids were 
induced to express protein with 0.4 mM IPTG treatment. Total lysates from uninduced 
and IPTG-induced E. coli were analysed by coomassie staining of SDS-PAGE gels. 
GST and GST-APPC recombinant proteins were purified using glutathione sepharose 
4B beads and also analysed by coomassie blue staining of SDS-PAGE gels (Beads). 
B) CHO-TrkB cells were transiently transfected with CAT control vector (Ctrl) or Fe65WT 
as indicated. Fe65WT was pulled-down from cell lysates by glutathione sepharose 4B 
beads coupled with either GST or GST-APPC and analysed by western blotting. Fe65 




3.2.2.3 Interaction of endogenous APP and Fe65 can be detected by proximity 
ligation assays 
The assays described above detect binding of exogenous Fe65 to APP. To detect 
binding of endogenous Fe65 to APP in situ within cells, PLAs for APP and Fe65 were 
established. CHO-TrkB cells were fixed and permeabilised before being probed with 
APP and Fe65 primary antibodies. PLA probes were used instead of fluorescently 
labelled secondary antibodies to detect interactions between the two labelled proteins. 
PLA probes are antibodies coupled to complementary oligonucleotides (one for each of 
the two primary antibodies) that, when situated within approximately 30 nm of each 
other, hybridise and serve as primers for rolling-circle amplification of fluorescent 
oligonucleotides. The resulting fluorescent signals appear as distinct dots that 
correspond to interacting protein pairs. The numbers of these fluorescent dots were 
then quantified via fluorescence microscopy and used as a measure of the strength of 
the protein-protein interaction between APP and Fe65 (Söderberg et al., 2006). PLAs 
are now being used in an increasing number of studies to quantify protein-protein 
interactions (Weibrecht et al., 2010). 
 
For these studies, Fe65 was labelled with mouse antibody 4H324 and APP with rabbit 
antibody CT-17. Control experiments in CHO-TrkB cells were performed to 
demonstrate the specificity of the assays. These involved primary antibodies and no 
PLA conjugates (Primary), no primary antibodies and both PLA conjugates (PLA), APP 
antibody CT-17 and both PLA conjugates (APP+PLA), Fe65 antibody 4H324 and both 
PLA conjugates (Fe65+PLA) and finally, Fe56 and APP antibodies with both PLA 
conjugates (Primary+PLA). Stained cells were imaged in z-stacks and the ‘Extended 
Depth of Field’ plugin of Image J was used for focus stacking. The ‘Analyze Particles’ 
plugin of Image J was used to quantify PLA signal dots. None or very few signals were 
detected in control experiments involving primary antibodies only, only one primary 
antibody or PLA probes only. However, robust signals were obtained when both 
primary antibodies and PLA probes were present (Figure 3.4). These results verify that 





Figure 3.4: Interaction of endogenous APP and Fe65 can be detected by 
proximity ligation assays. 
CHO-TrkB cells were fixed, permeabilised and labelled with APP and Fe65 primary 
antibodies (Primary), mouse plus and rabbit minus Duolink PLA probes (PLA), APP 
and both PLA probes (APP+PLA), Fe65 and both PLA probes (Fe65+PLA) or both 
primary antibodies and both PLA probes (Primary+PLA). A) Photos were acquired on a 
fluorescence microscope and z-stack images compiled with the ‘Extended Depth of 
Field’ plugin of Image J. APP was labelled using CT-17 and Fe65 was labelled using 
4H324 primary antibodies. Scale bar = 10 µM. B) Bar chart shows the mean number of 
dots observed in each cell for each treatment group. Dots were recorded from images 
using the ‘Analyze Particles’ plugin of Image J. A minimum of 8 cells were analysed per 
treatment for control experiments. Statistical analysis was performed using one-way 
ANOVA followed by Dunnett’s multiple comparisons test (error bars show S.D.,  
*** = p < 0.001, n = 8). 
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3.2.3 BDNF activates ERK1/2 and induces Fe65 phosphorylation in CHO cells 
expressing TrkB 
CHO cells are a common cell line for biochemical studies as they are easily maintained 
and can be transfected with a high level of efficiency. However, they are not a neuronal 
cell line and so are unlikely to express TrkB and respond to BDNF treatment. 
CHO-TrkB cells that stably express the BDNF receptor were therefore used (kind gift 
from Professor Pat Doherty; originally from Life Technologies). As the aim of this 
investigation was to measure the effect of BDNF signalling on Fe65 phosphorylation, 
the ability of CHO cells and CHO-TrkB cells to respond to BDNF treatment was first 
determined. Lysates from CHO cells treated with either vehicle (Ctrl) or BDNF  
(25 ng/ml for 15 min) were analysed by SDS-PAGE and western blotting. On 
SDS-PAGE, Fe65 migrates as three major species and these are known to be due to 
differential phosphorylation states. The fastest migrating species represents non- or 
low-phosphorylated Fe65 while the slower migrating species represent phosphorylated 
Fe65 (Standen et al., 2003; Zambrano et al., 1998). The migration patterns of Fe65 
and the levels of total ERK1/2 and ERK1/2 phosphorylated on its dual Thr/Tyr 
regulatory sites were monitored in cells treated with BDNF. Phosphorylation of ERK1/2 
by MEK on these regulatory sites is required for activity, so the strength of 
phosphorylated ERK1/2 (pERK) signals represents the level of active ERK1/2. BDNF 
had no effect on Fe65 phosphorylation as measured by band migration (Figure 3.5A). 
Similarly pERK and total ERK levels were also unaffected, demonstrating that the MAP 
kinase cascade was not activated by BDNF treatment in CHO cells (Figure 3.5A). 
These results are consistent with the absence of TrkB expression in this cell line. 
 
To determine whether CHO-TrkB cells respond to BDNF, cells were treated with either 
vehicle (Ctrl) or BDNF (25 ng/ml for 15 min). To confirm specificity of the BDNF 
treatment, some cells were also pre-treated with K252a, a potent inhibitor of TrkB 
(Knüsel and Hefti, 1992), or U0126, to prevent ERK activation. K252a inhibits TrkB 
signal transduction by preventing autophosphorylation of the receptor in response to 
ligand binding, while U0126 disrupts ERK1/2 signalling by inhibiting MEK, the upstream 
activator of ERK1/2 (Favata et al., 1998; Knüsel and Hefti, 1992; Ohmichi et al., 1992). 
As before, Fe65 migration, pERK and total ERK levels were monitored by western 
blotting. In CHO-TrkB cells, BDNF treatment caused an increase in the relative 
amounts of the slowest migrating Fe65 species and a reduction in the amount of the 
fastest migrating Fe65 species (Figure 3.5B). This change in Fe65 migration pattern on 
SDS-PAGE is consistent with BDNF treatment inducing Fe65 phosphorylation. Cells 
treated with BDNF also had higher levels of pERK but unaltered levels of total ERK 
(Figure 3.5B), indicating that the MAP kinase cascade was activated in these cells. As 
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expected, the effect of BDNF on Fe65 and pERK was abolished in cells pre-treated 
with K252a or U0126 (Figure 3.5B), indicating that BDNF-induced phosphorylation of 
Fe65 is TrkB- and ERK1/2-dependent. As CHO-TrkB cells responded to BDNF, this 
cell line was considered to be appropriate for further studies. 
 
To complement the above studies, phosphorylation mutants of Fe65 involving the 
ERK1/2 sites were studied. Fe65 contains four ERK1/2-responsive phosphorylation 
sites; Ser175, Ser287, Ser347 and Thr709 (Standen et al. 2003; see Figure 1.5). Two Fe65 
phosphomutants were used to investigate how BDNF and ERK1/2 affected Fe65. 
Fe65QA is a phospho-precluding mutant that contains substitution mutations to alanine 
at each of the four ERK-responsive sites to prevent phosphorylation. Fe65QE contains 
substitutions of these phosphorylation sites to glutamic acid, which has been shown to 
mimic the effect of constitutive phosphorylation in many studies (for example, Ackerley 
et al. 2003; Vagnoni et al. 2011). These mutants have been described previously 
(Standen et al., 2003). Lysates from cells transiently transfected with Fe65WT, Fe65QA 
or Fe65QE were analysed by western blotting to confirm that the Fe65 phosphorylation 
mutants show distinct migration patterns. In accordance with previous reports (Standen 
et al., 2003; Zambrano et al., 1998), Fe65QA displayed an altered pattern of migration 
on SDS-PAGE with an increase in the amount of the faster migrating, 
non-phosphorylated species. Conversely, Fe65QE displayed increased amounts of the 
slower migrating species (Figure 3.5C). These data also demonstrate that the Fe65 






Figure 3.5: BDNF activates ERK1/2 and induces Fe65 phosphorylation in CHO 
cells expressing TrkB. 
A) CHO cells were treated with vehicle (Ctrl) or BDNF (25 ng/ml) for 15 min as 
indicated. Lysates were probed for Fe65, pERK and total ERK by western blotting. B) 
CHO-TrkB cells were treated with vehicle (Ctrl), BDNF (25 ng/ml) for 15 min, K252a 
(200 nM) or U0126 (20 µM) as indicated. Where appropriate, K252a and U0126 
treatments were administered 10 min and 15 min prior to BDNF respectively. Samples 
were then analysed by SDS-PAGE and western blotting for Fe65, pERK and total ERK. 
C) Lysates from CHO-TrkB cells transfected with Fe65WT, Fe65QA or Fe65QE 
(phosphomutants containing mutations of ERK-phosphorylated residues Ser175, Ser287, 
Ser347 and Thr709) were probed on western blots for Fe65. Fe65 was detected with 
4H324, pERK was detected with 9102 and total ERK was detected with M12320 for all 
treatment groups. Molecular mass markers are shown. 
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3.2.4 BDNF activates ERK1/2 and induces Fe65 phosphorylation in rat cortical 
neurons 
While CHO-TrkB cells are useful for biochemical studies, they are not neuronal cells 
and do not naturally respond to BDNF. To confirm that BDNF is also capable of 
inducing Fe65 phosphorylation in neurons, rat primary cortical neurons were treated 
with either vehicle (Ctrl) or BDNF (25 ng/ml for 15 min) and samples were analysed by 
SDS-PAGE and western blotting for Fe65, pERK and total ERK. Treatment of cells with 
BDNF induced an increase in the relative levels of the slower migrating, 
phosphorylated Fe65 species and a decrease in the faster migrating, 
non-phosphorylated Fe65 species. Consistent with the findings from CHO-TrkB cells, 
these changes were at least partially prevented by pre-treatment with the TrkB 
signalling inhibitor K252a or the MEK inhibitor U0126 (Figure 3.6). These results show 
that BDNF induces endogenous Fe65 phosphorylation in cortical neurons by activating 




Figure 3.6: BDNF activates ERK1/2 and induces Fe65 phosphorylation in rat 
cortical neurons. 
A) DIV 5 rat cortical neurons were treated with either vehicle (Ctrl), BDNF (25 ng/ml) for 
15 min, K252a (200 nM) or U0126 (20 µM) as indicated. Where appropriate, K252a 
and U0126 treatments were administered 10 min and 15 min prior to BDNF 
respectively. The western blot migration pattern of Fe65 was monitored in cell lysates 
from each treatment group. Fe65 was detected with 4H324, pERK was detected with 
9102 and total ERK was detected using M12320 for all treatment groups. Molecular 
mass markers are shown. 
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3.2.5 BDNF treatment shows no significant effect on APP-Fe65 binding in 
co-immunoprecipitation and GST-APPC pull-down assays from CHO-TrkB 
cells 
The results in sections 3.2.3 and 3.2.4 show that BDNF induces phosphorylation of 
Fe65 via ERK1/2. Four different Fe65 ERK1/2 phosphorylation sites have been 
identified (Ser175, Ser287, Ser347 and Thr709; Standen et al. 2003), but the functional 
consequences of this phosphorylation is unknown. As APP is well characterised as a 
binding partner of Fe65 (Borg et al., 1996; Bressler et al., 1996; Fiore et al., 1995; 
McLoughlin and Miller, 1996), one possibility is that BDNF-induced phosphorylation of 
Fe65 via ERK1/2 affects its binding to APP. Phosphorylation is a common mechanism 
for regulating protein-protein interactions and phosphorylation of Fe65 on another site 
(Ser610) has been shown to alter its binding to APP (Chow et al., 2015b). 
 
To investigate whether BDNF influences the interaction between APP and Fe65, 
biochemical studies were performed using CHO-TrkB cells. Co-immunoprecipitation 
assays were carried out on cells transfected with either CAT (Ctrl), or APP+Fe65 
plasmid vectors (described in Table 2.2) and treated with vehicle or BDNF (25 ng/ml for 
30 minutes). While 15 min treatment with BDNF consistently activated ERK1/2 and 
induced phosphorylation of Fe65 (see Figure 3.5 and 3.6), optimisation experiments 
indicated that 30 min BDNF treatment was required to detect robust changes to the 
APP-Fe65 interaction (data not shown), so for all further experiments discussed, BDNF 
was applied to cells for 30 min. 
 
 Fe65 was immunoprecipitated with antibody sc-19751 and SDS-PAGE and western 
blotting was used to detect the amount of co-immunoprecipitated APP. Probing of total 
cell lysates for APP, Fe65 and pERK demonstrated that the cells were appropriately 
transfected and that BDNF treatment activated ERK1/2 (Figure 3.7A). Analyses of the 
immunoprecipitates showed that BDNF treatment had no significant effect on the 
interaction between APP and Fe65 (Figure 3.7B), although there is a non-significant 
trend towards a decrease in binding after BDNF treatment.  
 
The migratory shift in Fe65 described in sections 3.2.3 and 3.2.4 cannot be observed in 
western blots of co-immunoprecipitation samples and GST pull-down samples. This is 
because the gels were not run to separate the individual species of Fe65 to facilitate 
densitometry analysis of protein pull down. Instead, to confirm that BDNF treatment 
was successful, western blots were also probed for pERK as an indicator of 




To complement these studies, GST-APPC pull-down assays were performed from CAT 
control vector (Ctrl) or Fe65 transfected CHO-TrkB cells treated with either vehicle or 
BDNF (25 ng/ml for 30 minutes). The recombinant GST-APPC used in these assays is 
not phosphorylated (protein phosphorylation does not occur in standard E. coli strains), 
so any BDNF-induced changes to binding of Fe65 to APP in these pull-down assays 
cannot be attributed to altered phosphorylation of APP. As such, any changes are 
more likely to be due to changes in Fe65 phosphorylation. Western blots of inputs 
demonstrated that the cells were transfected with Fe65 and that BDNF induced 
activation of ERK1/2 (Figure 3.8A). Consistent with co-immunoprecipitation findings, 
BDNF treatment showed a non-significant trend towards a reduction in the amount of 
Fe65 pulled-down by GST-APPC (Figure 3.8B). 
 
These studies show that treatment of CHO-TrkB cells with BDNF induces 
phosphorylation of Fe65 and, although findings did not reach a level of significance, 
they show a consistent trend towards BDNF reducing binding between APP and Fe65. 
This occurs in both co-immunoprecipitation and GST-APPC pull-down assays. The 
finding that BDNF reduces binding of Fe65 to APP in the GST-APPC pull-down assays 
eliminates the possibility that this effect is due to BDNF acting on APP, for example by 





Figure 3.7: BDNF treatment has no effect on APP-Fe65 binding in 
co-immunoprecipitation assays from CHO-TrkB cells.  
A) CHO-TrkB cells were transiently transfected with CAT (Ctrl) or APP+Fe65WT plasmid 
vectors and treated with vehicle or BDNF (25 ng/ml) for 30 min as indicated. Fe65 was 
immunoprecipitated using sc-19751 and bound APP was analysed by western blotting. 
Fe65 was detected using 4H324, APP using CT-17 and pERK using 9102. Molecular 
mass markers are shown. B) Bar chart shows relative APP levels bound to Fe65 in the 
immunoprecipitates. Signals on western blots were quantified by densitometry and 
bound APP signals were normalised to immunoprecipitated Fe65 signals. Data from 
BDNF treated cells were then normalised to vehicle treated controls and statistical 
analysis was carried out using Wilcoxon-signed ranks test (error bars show S.D., n.s. = 





Figure 3.8: BDNF treatment has no effect on APP-Fe65 binding in GST-APPC 
pull-down assays from CHO-TrkB cells.  
A) CHO-TrkB cells were transiently transfected with CAT control vector (Ctrl) or Fe65WT 
and treated with either vehicle or BDNF (25 ng/ml) for 30 min as indicated. Fe65 was 
pulled down with GST-APPC-conjugated glutathione sepharose 4B beads and bound 
Fe65 was analysed by western blotting. Fe65 was detected using 4H324 and pERK 
was detected by 9102. Molecular mass markers are shown. B) Bar chart shows relative 
Fe65 levels bound to GST-APPC. Signals on western blots were quantified by 
densitometry and data from BDNF treated cells were normalised to vehicle treated 
controls. Statistical analysis was carried out using Wilcoxon-signed ranks test (error 




3.2.6 BDNF treatment reduces binding between endogenous APP and Fe65 in 
proximity ligation assays in both CHO-TrkB cells and rat cortical neurons 
The above studies show that BDNF reduces the interaction between exogenous APP 
and Fe65. To determine whether BDNF has a similar effect on endogenous APP and 
Fe65, PLAs were used. CHO-TrkB cells were treated with either vehicle or BDNF  
(25 ng/ml for 30 minutes) and PLAs were performed using primary antibodies to detect 
APP (CT-17) and Fe65 (4H324). BDNF treatment significantly reduced the number of 
PLA signals detected in cells compared to vehicle treatment (Figure 3.9). PLAs were 
then performed in rat cortical neurons treated with either vehicle or BDNF (25 ng/ml for 
30 minutes). Again, BDNF treatment significantly reduced the number of PLA signals 
(Figure 3.10). These experiments complement the results from the 
co-immunoprecipitation and GST-APPC pull-down assays, showing that treatment with 
BDNF reduces binding of APP and Fe65. Importantly, these PLAs demonstrate that 
this is the case for endogenous APP and Fe65 and, more specifically, endogenous 





Figure 3.9: BDNF treatment of CHO-TrkB cells reduces binding between 
endogenous APP and Fe65. 
A) CHO-TrkB cells were fixed, permeabilised and labelled with APP and Fe65 primary 
antibodies and PLAs carried out. Microscopy images were acquired and z-stack 
images compiled with the ‘Extended Depth of Field’ plugin of Image J. The number of 
dots observed in each cell was recorded from images using the ‘Analyze Particles’ 
plugin of Image J. APP was labelled using CT-17 and Fe65 was labelled using 4H324 
primary antibodies. Scale bar = 10 µM. B) Bar chart shows relative number of PLA 
signals (dots) counted per cell. Data were normalised to vehicle treated controls and 
statistical analysis was carried out using a Mann-Witney test (error bars show S.D., *** 





Figure 3.10: BDNF inhibits binding between endogenous APP and Fe65 in 
primary cortical neurons. 
A) DIV 3 rat cortical neurons were fixed, permeabilised and labelled with APP and 
Fe65 primary antibodies and PLAs carried out. Microscopy images were acquired and 
z-stack images compiled with the ‘Extended Depth of Field’ plugin of Image J. The 
number of dots observed in each cell was recorded from images using the ‘Analyze 
Particles’ plugin of Image J. APP was labelled using CT-17 and Fe65 was labelled 
using 4H324 primary antibodies. Scale bar = 10 µM. B) Bar chart shows relative 
number of PLA signals (dots) counted per cell. Data were normalised to vehicle treated 
controls and statistical analysis was carried out using a Mann-Witney test (error bars 
show S.D., *** = p < 0.0001, n = 164).  
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3.2.7 The Fe65 phospho-mimicking mutant has reduced binding to APP in 
GST-APPC pull-down assays 
The results in sections 3.2.3-3.2.6 show that BDNF treatment induces phosphorylation 
of Fe65 via ERK1/2 and that BDNF treatment reduces the interaction between APP 
and Fe65. This was shown in both CHO-TrkB cells and cortical neurons using three 
different techniques. Together, these results indicate that BDNF induces 
phosphorylation of Fe65 by ERK1/2 and affects its binding to APP. However, they do 
not eliminate the possibility that BDNF alters the APP-Fe65 interaction via other routes. 
For example, BDNF may induce phosphorylation of other proteins that bind to APP 
such as the X11s and this may indirectly influence APP binding to Fe65. In addition, 
they do not definitively demonstrate that phosphorylation of Fe65 on its four ERK1/2 
sites alters its binding to APP. 
 
To investigate whether the effects of BDNF treatment on the APP-Fe65 interaction are 
indeed due to phosphorylation at one or more of the four identified ERK1/2 
phosphorylation sites of Fe65 (Ser175, Ser287, Ser347 and Thr709), the ability of Fe65 
phospho-mimicking and phospho-precluding mutants to bind to APP was studied. 
Co-immunoprecipitation assays were carried out on CHO-TrkB cells transfected with 
either CAT control vector (Ctrl), APP+Fe65WT, APP+Fe65QA or APP+Fe65QE. Fe65 was 
immunoprecipitated with antibody sc-19751 and SDS-PAGE and western blotting was 
used to detect the amount of co-immunoprecipitated APP. Input samples probed for 
APP and Fe65 demonstrated that the cells were transfected as required (Figure 
3.11A). Analyses of the immunoprecipitates found that the Fe65 phospho-mimicking 
mutant (Fe65QE) showed a non-significant trend towards impaired binding to APP 
compared to Fe65WT. Interestingly the phospho-precluding mutant (Fe65QA) showed a 
non-significant trend towards increased binding to APP compared to Fe65WT (Figure 
3.11B).  
 
To complement these studies, GST-APPC pull-down assays were also performed on 
CHO-TrkB cells transfected with CAT control vector (Ctrl), Fe65WT, Fe65QA or Fe65QE. 
Western blots of inputs confirmed that the cells were appropriately transfected with 
Fe65 constructs (Figure 3.12A). Consistent with the non-significant trend seen in 
co-immunoprecipitation assays, Fe65QE showed reduced binding to GST-APPC 
compared to Fe65WT and this change was significantly different as detected by GST 
pull-down. As with the co-immunoprecipitation results, GST-APPC pull-down assays did 
not show a significant change in binding between Fe65QA and GST-APPC compared to 
Fe65WT (Figure 3.12B), although the non-significant trend in GST pull-downs did not 
match co-immunoprecipitation data. 
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These studies show that mutation of the four identified ERK1/2 phosphorylation sites of 
Fe65 to mimic permanent phosphorylation reduces its binding to APP in GST-APPC 
pull-down assays. However, mutation of these sites to preclude phosphorylation 
showed no significant effect on Fe65 binding to APP in either co-immunoprecipitation 
assays or GST-APPC pull-down assays. The results in this chapter support the 
hypothesis that BDNF negatively regulates the APP-Fe65 interaction by inducing 








Figure 3.11: The Fe65 phosphorylation mutants do not show changed binding to 
APP in co-immunoprecipitation assays. 
A) CHO-TrkB cells were transiently transfected with control vector (Ctrl), APP+Fe65WT 
APP+Fe65QA or APP+Fe65QE as indicated. Fe65 was immunoprecipitated using 
sc-19751 and bound APP was detected on western blots. Fe65 was detected using 
4H324 and APP using CT-17. Molecular mass markers are shown. B) Bar chart shows 
relative APP levels bound to Fe65 in immunoprecipitates. Signals on western blots 
were quantified by densitometry and bound APP signals were normalised to 
immunoprecipitated Fe65 signals. Data from BDNF treated cells were then normalised 
to APP+Fe65WT data and statistical analysis was carried out using Kruskal-Wallis test 
followed by Dunn’s multiple comparisons test (error bars show S.D., n.s. = p > 0.05,       






Figure 3.12: The Fe65 phospho-mimicking mutant has reduced binding to the 
cytoplasmic tail of APP. 
A) CHO-TrkB cells were transfected with CAT control vector (Ctrl), Fe65WT, Fe65QA or 
Fe65QE as indicated. Fe65 was pulled-down using GST-APPC and detected on western 
blots using 4H324. Molecular mass markers are shown. B) Bar chart shows relative 
Fe65 levels bound to GST-APPC. Signals on western blots were quantified by 
densitometry and data were normalised to Fe65WT. Statistical analysis was carried out 
using Kruskal-Wallis test followed by Dunn’s multiple comparisons test (error bars 








In this chapter, the effect of BDNF on Fe65 phosphorylation and APP-Fe65 binding 
was investigated. This was achieved by monitoring Fe65 phosphorylation and the 
APP-Fe65 interaction in response to BDNF treatment in CHO cells stably transfected 
with TrkB and rat cortical neurons. Fe65 phosphorylation was also investigated using 
phospho-mimicking and phospho-precluding Fe65 mutants in which, four known Fe65 
ERK1/2 phosphorylation sites were mutated to glutamic acid or alanine, respectively.  
 
BDNF treatment stimulated Fe65 phosphorylation in both CHO-TrkB cells and in 
cortical neurons. Fe65 phosphorylation was measured by a shift in its migration on 
SDS-PAGE, which has previously been reported to be indicative of Fe65 
phosphorylation state (Standen et al., 2003; Zambrano et al., 1997). BDNF-induced 
phosphorylation of Fe65 was reduced by inhibition of either the TrkB receptor by 
K252a or the MEK inhibitor U0126, which inhibits ERK1/2. Although TrkB inhibition did 
not completely abolish ERK1/2 activation, presumably because other signalling 
molecules can activate the ERK1/2 MAP kinase cascade (Yang et al., 2013), both 
inhibitors rescued the effect of BDNF on Fe65 phosphorylation as judged by its 
migration profile on SDS-PAGE. These experiments show that the shift in Fe65 
phosphorylation induced by BDNF involves ERK1/2, however they do not identify the 
specific Fe65 residues that are phosphorylated by BDNF-induced ERK1/2 
phosphorylation. 
 
Four ERK1/2 phosphorylation sites have been identified in Fe65 and these were 
mutated to either alanine (Fe65QA) or glutamic acid (Fe65QE; Standen et al., 2003). 
These Fe65 phosphomutants display changes in SDS-PAGE migration profiles that are 
similar (Fe65QE) or opposite (Fe65QA) to the migration profiles of BDNF treated cells. As 
such, these data further support the conclusion that the BDNF-induced Fe65 migration 
changes are due to ERK1/2 phosphorylation at these sites. While BDNF is known to 
activate the ERK1/2 MAP kinase cascade (Yang et al., 2013) and Fe65 has been 
identified as an ERK1/2 substrate (Standen et al., 2003), the link between these 
pathways had not previously been established. The findings presented here provide 
this novel connection by demonstrating that BDNF treatment can induce Fe65 
phosphorylation in an ERK1/2-dependent manner. More formal demonstration that 
BDNF-induced ERK1/2 phosphorylation of Fe65 involves the four known ERK1/2 sites 
(Ser175, Ser287, Ser347 and Thr709) could involve mass spectrometry analysis or 
alternatively, the generation of phospho-specific Fe65 antibodies to these sites. 
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To gain insight into the function of this BDNF-induced phosphorylation of Fe65, 
methods were established to measure the APP-Fe65 interaction. After optimisation, 
co-immunoprecipitations, GST-APPC pull-down assays and PLAs were all able to 
detect the interaction between APP and Fe65. Interestingly, in co-immunoprecipitation 
assays Fe65 antibodies successfully pulled-down APP, but in the reciprocal assay, a 
C-terminal APP antibody was unable to co-immunoprecipitate Fe65. One possible 
explanation for this observation is that the C-terminal APP antibody, which recognises 
the YENPTY Fe65-binding motif of APP, cannot bind to its epitope if Fe65 is bound to 
APP. Consequently, in co-immunoprecipitation assays, the APP antibody would be 
precipitating only APP that is not bound to Fe65. Since co-immunoprecipitations are 
carried out on total cell lysates, the cellular localisation of the proteins should not 
influence binding of the APP antibody. Similarly, both Fe65 and APP C-terminal 
antibodies detect proteins by western blotting. It is possible that use of an N-terminal 
APP antibody to immunoprecipitate APP might be more successful since it would not 
compete with Fe65 for APP binding. However, this might not be appropriate for 
detection of the APP-Fe65 interaction because Fe65 interacts with the C-terminus of 
APP and APP undergoes proteolytic cleavage to shed its N-terminal domain. An APP 
C-terminal antibody raised to an epitope that does not overlap with the Fe65 binding 
site would be useful in this context, but none have so far been characterised.  
 
Interestingly, the C-terminal APP antibody was able to detect the APP-Fe65 interaction 
in intact cells via the PLA technique. Although the reason for this is unclear, the PLA 
protocol involves paraformaldehyde fixation of cells prior to staining. This is a 
cross-linking method that can alter protein conformation and antigen availability 
(Hewitson et al., 2010). A common issue with cross-linked fixation is the masking of 
antigen sites, however, in this case cross-linking may alter the conformation of APP 
and/or Fe65 to expose the C-terminal APP antibody epitope and allow protein 
recognition. While paraformaldehyde cross-linking can modify protein conformation, it 
fixes proteins in place and would therefore not interfere with detection of the APP-Fe65 
interaction in the PLAs, which reveal protein interactions by measuring the proximity of 
the two proteins of interest. 
 
These three optimised protein interaction assays were used to determine how BDNF 
treatment affects the APP-Fe65 interaction. BDNF reduced binding of Fe65 to APP in 
proximity ligation assays, however this reduction failed to reach significance in 
co-immunoprecipitation assays and GST pull-downs although a consistent trend was 
seen. The co-immunoprecipitation assays revealed that BDNF induced a 16 % 
decrease in APP bound to Fe65, while the GST-APPC pull-down assays and PLAs 
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produced 43 % and approximately 40-50 % reductions in APP-Fe65 binding 
respectively (The PLAs showed 37 % and 49 % decreases in CHO-TrkB and cortical 
neurons respectively). The co-immunoprecipitation assays detected a smaller 
decrease than the GST-APPC pull-downs and PLAs, although only PLA studies 
reached statistical significance. One possibility for the less marked effect of BDNF on 
APP-Fe65 binding in the co-immunoprecipitation assays is that these involved co-
transfection of both APP and Fe65. This may increase the expression of these proteins 
to such levels that they could not be completely phosphorylated by endogenous levels 
of ERK1/2. Co-transfection of ERK1/2 as well as APP and Fe65 may induce a 
decrease in binding similar to that shown by the PLAs. The sample sizes tested in 
these experiments were small and as such, could not be tested for normality so non-
parametric tests had to be used. Larger sample sizes would give more power to these 
findings and may be able to resolve more subtle changes to APP-Fe65 binding than 
the studies discussed here. 
 
Overexpression of proteins can cause mislocalisation and accumulation in unusual 
cellular compartments. As such, the co-immunoprecipitation and GST-APPC pull-down 
assays used in this study are not as powerful as assays that detect the binding of 
endogenous proteins. Because of these limitations, the effect of BDNF on binding of 
endogenous APP to Fe65 was investigated using PLAs. In these assays, BDNF 
treatment resulted in a significant decrease in APP-Fe65 binding in both CHO-TrkB 
cells and rat cortical neurons and the scale of inhibition was similar in both cell types. 
One limitation of the PLA technique in cortical neurons is that only protein interactions 
in the cell body were analysed due to the difficulty of properly identifying neurites. To 
expand this experiment to include APP-Fe65 complexes in axons and dendrites, a 
counter-stain for a cytoskeletal component could be used.  
 
To determine how phosphorylation of Fe65 at the four known ERK1/2 sites altered its 
binding to APP, co-immunoprecipitation and GST-APPC pull-down assays were 
performed in CHO-TrkB cells transiently transfected with either Fe65WT, Fe65QA or 
Fe65QE (for the GST-APPC pull-down assays) or co-transfection of APP with either 
Fe65WT, Fe65QA or Fe65QE (for the immunoprecipitation assays). PLAs were not used 
to study the Fe65 phosphorylation mutants because these assays involve the analysis 
of individual cells. Transient transfection of cells does not result in uniform 
overexpression levels and cells expressing high levels of Fe65 are likely to produce 
higher PLA signals than those expressing low levels of protein. This could confound 
the interpretation of the effects of the mutants on APP binding. The use of 
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EGFP-tagged Fe65 constructs would allow normalisation of PLA signals to the level of 
Fe65 overexpression in individual cells, which would resolve this issue. 
The phospho-mimicking Fe65QE mutant showed a significant decrease in APP binding 
in GST-APPC pull-down assays and displayed a consistent but non-significant trend 
towards lower binding to APP than wild-type Fe65 in both co-immunoprecipitation 
assays. As with the BDNF studies, this effect was more pronounced when measured 
by GST pull-down assay compared to co-immunoprecipitation (35 % decrease and 15 
% decrease in relative protein binding respectively) and only the GST pull-down study 
reached significance. Interestingly, the phospho-precluding Fe65 mutant did not have a 
consistent effect on the APP-Fe65 interaction. It displayed non-significant and 
conflicting changes to binding in co-immunoprecipitation and GST-APPC pull-down 
assays. One possible explanation for this is that the phosphorylation mutants have 
amino acid substitutions at all four ERK1/2-responsive sites, but ERK1/2 may not 
phosphorylate all of these sites to an equal extent. Indeed, there is evidence that Thr709 
is more readily phosphorylated by ERK1/2 than the other three residues (Standen et 
al., 2003). If, in the CHO-TrkB cells used for these assays, the majority of Fe65 
remains unphosphorylated at these four ERK1/2-responsive sites, mutation of these 
sites to alanine would only have a minor effect on its interaction with APP compared to 
wild-type Fe65. Whatever the precise scenario, the results using these Fe65 
phosphorylation mutants complement and extend the data from BDNF treated cells, 
but again, possibly require larger sample sizes in order to reach statistical significance. 
They are consistent with BDNF-induced Fe65 phosphorylation by ERK1/2 causing a 
reduction in APP-Fe65 binding and confirm that this effect is due to phosphorylation of 
at least one of the four known ERK1/2-responsive sites.  
 
Although none of the ERK1/2-responsive residues are located within the protein 
interaction domains of Fe65, Ser287 is located two residues downstream of the WW 
domain and Thr709 is ten residues downstream of the PTB2 motif (Standen et al. 2003; 
Figure 1.5). One previously proposed mechanism for the regulation of Fe65 activity is a 
phosphorylation-induced conformational switch, in which, the N-terminal WW domain 
of Fe65 interacts with its own C-terminal domain (Cao and Südhof, 2004). As Ser287 
and Thr709 are situated close to the functional domains proposed to be involved in 
regulating Fe65 conformation, they may play a role in mediating this switch. 
Alternatively, due to its location, the addition of a phosphate group at Thr709 may render 
the PTB2 domain inaccessible to the binding domain of APP. Further investigation 
using individual phosphorylation mutants would help identify which phosphorylation 
sites are crucial to the inhibition of the APP-Fe65 interaction.  
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The results discussed so far show that BDNF activates ERK1/2 to induce Fe65 
phosphorylation to decrease binding between APP and Fe65. They also demonstrate 
that mutation of ERK1/2 phosphorylation sites on Fe65 to mimic permanent 
phosphorylation reduces the APP-Fe65 interaction. To show that the inhibitory effect of 
BDNF on this protein-protein interaction is via phosphorylation of Fe65 at one or more 
of these four sites, future studies that monitor binding between the Fe65 
phospho-precluding mutant (Fe65QA) and APP after BDNF treatment could be 
employed. If BDNF reduces APP-Fe65 binding via Fe65 phosphorylation at 
ERK1/2-responsive sites, this inhibitory effect should be rescued by the use of the 
Fe65QA mutant.   
 
BDNF is being investigated as a therapeutic approach for AD. This is because 
production of BDNF is impaired in AD and restoration of BDNF can improve memory 
deficits and rescue synapse loss and neuronal death in AD models (Ando et al., 2002; 
Arancibia et al., 2008; Blurton-Jones et al., 2009; Nagahara et al., 2013, 2009). In 
addition, BDNF shows neuroprotective effects against Aβ toxicity and reduces 
amyloidogenic processing of APP (Arancibia et al., 2008; Matrone et al., 2008). The 
exact molecular pathways involved in these beneficial effects of BDNF are unclear but 
several studies have shown that ERK1/2 signalling is required for BDNF-mediated 
neuroprotective effects and dendritic spine growth (Almeida et al., 2005; Alonso et al., 
2004; Han and Holtzman, 2000; Nguyen et al., 2009; Sun et al., 2008). The data 
presented in this chapter extend current knowledge by describing a BDNF-induced 
signalling pathway that activates ERK1/2 to phosphorylate Fe65 and inhibit APP-Fe65 
binding. As APP and Fe65 are thought to be involved in gene transcription, cell motility 
and APP processing (see sections 1.2.3, 1.3.2 and 1.3.3), part of the protective effect 
of BDNF may be linked to phosphorylation of Fe65 and its binding to APP. 
  
Although BDNF can protect cells against apoptosis, Aβ toxicity and rescue synapse 
loss (Ando et al., 2002; Arancibia et al., 2008; Blurton-Jones et al., 2009; Matrone et 
al., 2008; Nagahara et al., 2013, 2009), there are limitations to its use as a therapeutic 
molecule. One problem with using BDNF as a therapy for AD is that it does not easily 
cross the blood-brain barrier. In addition, the expression of the TrkB receptor is highly 
regulated so infusion of BDNF into the brain is not effective because local sites receive 
an acute dose of BDNF, which triggers a reduction in TrkB, while distal sites receive 
much lower doses (Frank et al., 1997). Viral vector delivery of BDNF has shown more 
promising results in animal models (Kells et al., 2004; Nagahara et al., 2013, 2009) and 
a synthetic TrkB agonist is able to cross the blood-brain barrier and shows similar 
efficacy to BDNF treatment (Devi and Ohno, 2012; Hsiao et al., 2014). Enhancing 
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endogenous BDNF expression is another avenue of BDNF treatment that is being 
explored and the AD-approved acetylcholinesterase inhibitor donepezil restores BDNF 
levels in AD patients to expression levels seen in control subjects (Leyhe et al., 2008). 
Other methods of augmenting endogenous BDNF include enhancing cAMP response 
element binding protein phosphorylation, which is involved in positively regulating 
BDNF expression, dietary supplements of zinc and the flavonoid rutin and low-level 
laser therapy (Caccamo et al., 2010; Corona et al., 2010; Meng et al., 2013; 
Moghbelinejad et al., 2014). 
 
In summary, this chapter shows that BDNF induces phosphorylation of Fe65 via 
induction of the ERK1/2 MAP kinase cascade, of which Fe65 is a known substrate. In 
addition to linking these pathways, the results presented here also show that 
phosphorylation of Fe65 at ERK1/2-responsive sites negatively impacts on the 
APP-Fe65 interaction. By being able to influence this interaction with an extracellular 
signalling molecule, it may be possible to regulate the functions of the APP-Fe65 
complex, one of which is mediating gene transcription. APP acts as a 
membrane-bound tether for Fe65 and prevents its translocation to the nucleus (Cao 
and Südhof, 2001; Minopoli et al., 2001). The evidence detailed here shows that BDNF 
inhibits the APP-Fe65 interaction and therefore may increase the amount of Fe65 
capable of translocating to the nucleus. This is consistent with evidence that the 
majority of Fe65 found in the nucleus is phosphorylated (Zambrano et al., 1998). 
Future analysis of subcellular fractions of BDNF treated cells would help to confirm 
whether more Fe65 is released for nuclear translocation in response to BDNF. The 
effect of an increase in available Fe65 on gene transcription would likely vary from 
gene to gene as previous research has shown that APP and Fe65 do not regulate all 
target genes by the same mechanism (see section 1.3.2). BDNF activates a variety of 
intracellular signalling pathways, so data collected from reporter gene assays, which 
have been used previously to measure changes to the transactivation function of Fe65 
(Bao et al., 2007; Belyaev et al., 2009; Bruni et al., 2002; Cao and Südhof, 2004, 2001; 
Kajiwara et al., 2009; Kim et al., 2003; Kinoshita et al., 2003; Lau et al., 2008; 
Pardossi-Piquard et al., 2005; Perkinton et al., 2004; Xu et al., 2011; Yang et al., 2006) 
in response to BDNF treatment would be difficult to attribute solely to Fe65 
phosphorylation. The formal identification of Fe65-regulated genes is required to 
characterise the role of BDNF-induced phosphorylation on any Fe65-mediated gene 
transcription. 
 
It has been previously established that the APP-Fe65 interaction is involved in the 
regulation of gene transcription, although the affected genes are not consistently 
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reported (see section 1.3.2). Chapter 4 of this thesis focuses on monitoring the effect of 
loss of Fe65 on transcription and the identification of novel genes that are regulated by 
Fe65. 
 
3.3.1 Limitations of the study 
1. Fe65 phosphorylation was assessed by changes in protein migration on SDS-PAGE. 
For the future, the generation and use of phosphorylation-specific antibodies to the 
sites under investigation would enhance the study. If these cannot be generated, then 
changes in phosphorylation could be monitored by mass spectrometry approaches. 
 
2. For both co-immunoprecipitation and GST pull-down assays, protein overexpression 
was required to detect the interaction between APP and Fe65. As overexpression can 
alter protein localisation in cellular compartments, this can detect interactions that, 
while physically compatible, do not occur endogenously. This limitation was addressed 
by the use of PLAs, which were carried out to measure interactions between 
endogenous proteins in intact, fixed cells. 
 
3. With the exception of PLAs, sample sizes used for these studies were small and 
often failed to reach statistical significance although consistent changes in protein 
interaction were seen. Increased sample sizes may reduce variability and allow 




CHAPTER 4: FE65 INDEPENDENTLY REGULATES FRIZZLED-1 




The interaction between APP and Fe65 is widely reported to be involved in regulating 
gene transcription (Alves da Costa et al., 2006; Bao et al., 2007; Belyaev et al., 2009; 
Bruni et al., 2002; Cao and Südhof, 2004, 2001; Kajiwara et al., 2009; Kim et al., 2003; 
Lau et al., 2008; Li et al., 2010; Ma et al., 2008; McLoughlin and Miller, 2008; Müller et 
al., 2007; Nakaya and Suzuki, 2006; Pardossi-Piquard et al., 2005; Perkinton et al., 
2004; Robinson et al., 2014; Schrötter et al., 2013; von Rotz et al., 2004; Xu et al., 
2011). The target genes for this transactivation complex are unclear as many of these 
studies utilise reporter gene assays. While these assays demonstrate that APP-Fe65 
signalling is capable of stimulating expression, they do not formally identify regulated 
genes. In fact, Fe65 is capable of translocating to the nucleus alone (Cao and Südhof, 
2001; Kim et al., 2003; Kinoshita et al., 2002) and can enhance reporter gene 
expression without APP overexpression (Cao and Südhof, 2001; Kajiwara et al., 2009; 
Lau et al., 2008; Perkinton et al., 2004; Yang et al., 2006). Despite this, the majority of 
research in this nuclear signalling function has focused on the role of APP and/or AICD 
in the regulation of gene expression, while the role of Fe65 has been less well studied.  
 
Prior to the start of this project, experiments were carried out by colleagues in 
collaboration with Dr Kwok-Fai Lau (Chinese University of Hong Kong) to try and 
identify genes regulated by Fe65. This involved Solexa next generation sequencing 
(NGS) of mRNA transcripts from Fe65KO mice and their non-transgenic littermates. 
The Fe65KO mice were kindly provided by Professor Suzanne Guénette 
(Massachusetts General Hospital) and have been previously described (Guénette et 
al., 2006). For these experiments, pooled mRNAs were prepared from the brains of 5 
Fe65KO and 5 WT male mice and reverse transcribed to cDNAs. These samples were 
then sequenced by Solexa sequencing and biostatistical analyses were carried out by 
Dr Lau using PANTHER (Protein Analysis Through Evolutionary Relationships; Mi et 
al. 2016). PANTHER identified several components of the wnt signalling pathway as 
showing different expression levels between Fe65KO and WT mouse brains. In 
particular, expression levels of the wnt receptor frizzled-1 (Fzd1), GSK3α and wnt3a 
were altered. As detailed in section 1.4.2, the wnt signalling pathway is one of the 
pathways that modulates the activation state of GSK3α and GSK3β, which are kinases 
that can phosphorylate tau in AD (Clevers and Nusse, 2012; Hernández et al., 2010; 
Hooper et al., 2008). In addition, wnt signalling regulates the degradation of 
neuroprotective β-catenin, which has also been previously proposed as a target for 
therapeutic intervention (Alvarez et al., 2004; Chacón et al., 2008; Clevers and Nusse, 
2012; Inestrosa and Varela-Nallar, 2014; Kimelman and Xu, 2006). As such, there is 
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increasing interest in the role of wnt signalling in AD (Inestrosa and Varela-Nallar, 
2014; Purro et al., 2014). 
 
Data generated by high-throughput techniques such as NGS should be validated using 
low-throughput methods. As such, one aim of the studies described in this chapter was 
to confirm the effects of Fe65 loss on Fzd1, GSK3α and wnt3a expression in the 
mouse brains. In addition, the effects of Fe65 loss on a number of related genes were 
also studied in this mouse model. These genes were LRP6, GSK3β, APP and tau. 
LRP6 is a co-receptor with Fzd1 for wnt ligands while GSK3β activity is regulated by 
canonical wnt signalling (Chacón et al., 2008; Clevers and Nusse, 2012). APP and tau 
were chosen for analysis because of their strong involvement in AD (see section 1.1). 
Finally, an alternative strategy for studying Fe65 and APP loss was established using 
Fe65 and APP siRNAs to reduce expression in cultured rat cortical neurons. This was 




4.2.1 Establishing animal and cellular models in which Fe65 and APP expression 
are reduced 
4.2.1.1 Fe65KO mice 
Fe65KO mice were generated by integration of a lacZ-neo cassette into exon 2 of the 
Fe65 gene (Guénette et al. 2006; Figure 4.1A). Fe65KO mice were maintained on a 
C57BL/6 genetic background and heterozygous KO individuals were bred to obtain 
homozygous Fe65KO pups and WT littermates. Brains were harvested from newborn 
mice and snap-frozen in liquid nitrogen for future use. Tissue was also harvested for 
genotypic analysis of the mice via PCR. PCR reactions were run on agarose gels to 
separate DNA fragments for analysis. The primers used in the PCR reactions generate 
a smaller PCR fragment when the WT allele is present and a larger PCR product when 
the modified transgene is present. In heterozygotes, two fragments can be observed 
on the gel as the samples contain one copy of each allele (Figure 4.1B). This means 
that the genotype of each sample can be determined by the migration pattern of the 
PCR signals. A no-template control run alongside samples did not contain any bands, 
demonstrating that signals detected on the gel were due to amplification of the 
genomic DNA template (Figure 4.1B). Using this method of genotyping, WT and 
homozygous Fe65KO brain samples were obtained for further studies. 
 
To confirm that Fe65 protein expression was absent in Fe65KO mice, brain 
homogenates from 5 WT and 5 Fe65KO brain samples were analysed via SDS-PAGE 
and western blotting. Blots were probed for Fe65 to measure Fe65 expression and 
GAPDH as a loading control. As expected, Fe65KO mice displayed a lack of Fe65 





Figure 4.1: Characterisation of Fe65KO mice 
A) Schematic showing the strategy for disruption of Fe65 by insertion of a lacZ-neo 
cassette into exon 2 (Figure taken from Guénette et al. 2006, not to scale). White 
arrowheads indicate the location of primers for PCR genotyping. B) PCR genotyping of 
DNA isolated and amplified from ear tissue of homozygous KO (-/-), wild-type (WT) and 
heterozygous KO (+/-) mice. Ctrl contains no DNA template. PCR reactions were 
separated by gel electrophoresis on 1.5% agarose gels containing ethidium bromide. 
C) Brain homogenates from 5 WT and 5 Fe65KO littermates were analysed by 
SDS-PAGE and western blotting. Fe65 was detected using sc-19751 and GAPDH 
(loading control) detected using 14C10. Molecular mass markers are shown. D) Bar 
chart shows relative Fe65 expression. Signals on western blots were quantified by 
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densitometry and Fe65KO expression levels were normalised to WT controls. 
Statistical analysis was carried out using a Mann-Witney test (error bars show S.D., ** 
= p < 0.01, n = 5).  
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4.2.1.2 Knockdown of Fe65 and APP in cultured rat cortical neurons using 
siRNAs 
Fe65 and APP siRNAs were obtained from Dharmacon. DIV 3 primary cortical neurons 
were treated with vehicle, non-targeting control siRNA, Fe65 siRNA or APP siRNAs at 
a concentration of 1 µM for 4 days. Cell lysates were prepared and analysed by 
SDS-PAGE and western blotting for Fe65, APP and GAPDH as a loading control. Fe65 
and APP siRNA treatment markedly reduced Fe65 and APP expression respectively. 
Control siRNAs had no effect on either Fe65 or APP protein levels, demonstrating the 




Figure 4.2: Fe65 siRNAs abolish Fe65 expression and APP siRNAs abolish APP 
expression in rat cortical neurons 
DIV 3 rat cortical neurons were treated with vehicle (untreated), control siRNA, A) Fe65 
siRNA or B) APP siRNAs at a concentration of 1 µM for 4 days. Cell lysates were 
analysed by SDS-PAGE and western blotting. Fe65 was probed with 4H324, APP with 
CT-17 and GAPDH (loading control) using 14C10. Molecular mass markers are shown.  
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4.2.2 Optimisation of RT-qPCR for analysis of gene expression 
The effect of Fe65 on the expression of seven potential target genes was investigated 
by carrying out RT-qPCR on brain mRNAs from 5 WT and 5 Fe65KO mice. The quality 
of the RNA isolated from the brain samples was determined by gel electrophoresis and 
analyses of 28s and 18s ribosomal RNAs. High quality RNA preparations display an 
approximate 2-fold greater signal of 28s compared to 18s signal. Analyses of the 
mRNA isolated for these studies revealed that all RNA samples were of high quality 
(Figure 4.3), so samples were further processed for RT-qPCR experiments.  
 
Relative quantification of mRNA levels by RT-qPCR requires normalisation of data 
across different treatment groups. As AD is known to affect the expression of a wide 
variety of genes, a reference gene should only be considered suitable if it shows low 
variation of expression both between samples within the same treatment group and 
between treatment groups (Selvey et al., 2001). In addition, more than one reference 
gene can be used to improve reliability. To address this, GeNorm reference gene 
analysis was carried out to test which putative reference genes had the most stable 
gene expression between WT and Fe65KO samples. The mRNA expression of  
12 commonly used reference genes (18S, ATP5B, ACTB, B2M, CANX, CYC1, EIF4A2, 
GAPDH, RPL13A, SDHA, UBH, and YWHAZ) were measured by RT-qPCR in 4 WT 
and 4 Fe65KO samples (Figure 4.4A).  
 
GeNorm is an algorithm that can be applied to Ct values of samples from different 
treatment groups to identify expression stability across groups. It measures the ratio of 
mRNA expression for each reference gene between treatment groups. The average 
variation (M) between these ratios for pairs of reference genes is then calculated and 
higher M values denote higher variation in reference gene expression between 
treatment groups. The two genes with the lowest M value are the most consistently 
expressed genes across the treatment groups (Gabrielsson et al., 2005; 
Vandesompele et al., 2002). ATP5B and GAPDH were identified by GeNorm analysis 
as the most stable reference genes for normalisation between WT and Fe65KO 
samples (Figure 4.4B). Consequently, these two genes were chosen as reference 
genes for data normalisation in further RT-qPCR experiments. 
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Figure 4.3: High quality RNA was isolated from WT and Fe65KO mouse brain 
samples 
RNA samples isolated from brain homogenates of 5 WT and 5 Fe65KO mice were 
separated by gel electrophoresis on a 1.5 % agarose gel containing ethidium bromide. 
28s (upper) and 18s (lower) species are clearly visible and signal analysis revealed 
that the 28s subunit was at least 2-fold greater than the 18s subunit. Molecular mass 




Figure 4.4: GAPDH and ATP5B are appropriate reference genes for normalisation 
in RT-qPCR analyses in WT and Fe65KO mice brains 
A) RT-qPCR was carried out on 4 WT and 4 Fe65KO samples to measure mRNA 
expression of 12 reference genes. Bar chart shows raw mean Ct values plotted for 
both samples for each gene (error bars show S.D.). B) GeNorm analysis was carried 
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out on the Ct values obtained in A) using Biogazelle qbase+ software, which ranks 
genes in order of expression stability across both samples.   
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4.2.3 Loss of Fe65 reduces Fzd1 mRNA levels but does not affect wnt3a, GSK3α, 
GSK3β, LRP6, APP or tau levels in Fe65KO brains 
To validate and extend the results of the Solexa sequencing, RT-qPCR was performed 
to measure differences in mRNA levels between Fe65KO and WT mice brains. As the 
data generated by Solexa sequencing identified Fzd1, GSK3α and wnt3a as genes that 
show altered expression in Fe65KO brains, the levels of mRNA for these genes were 
determined. In addition, the levels of GSK3β, LRP6, APP and tau mRNA were 
measured by RT-qPCR. These studies were performed on brain samples from 5 WT 
and 5 Fe65KO newborn male mice so the samples were the same as those used for 
Solexa sequencing. The levels of Fzd1 mRNA were significantly lower in Fe65KO 
mouse brain samples compared to WT littermates (Figure 4.5A). However, there were 
no changes seen in the levels of GSK3α, GSK3β, LRP6, wnt3a, APP or tau mRNA in 
Fe65KO mouse brains compared to WT littermates (Figure 4.5B-G), although a 
non-significant trend towards a decrease in mRNA expression was seen for GSK3α 
and GSK3β and an increase in LRP6. Increasing sample sizes may allow for greater 





Figure 4.5: Loss of Fe65 reduces Fzd1 mRNA expression in Fe65KO brains but 
does not affect GSK3α, GSK3β, LRP6, wnt3a, APP or tau mRNA levels in Fe65KO 
mouse brains 
Relative mRNA levels of A) Fzd1, B) GSK3α, C) GSK3β, D) LRP6, E) wnt3a, F) APP 
and G) tau were measured by RT-qPCR on brain homogenates of 5 WT and  
5 Fe65KO littermates. Relative quantification was calculated using the 2-ΔΔCt method 
(Livak and Schmittgen, 2001) using GAPDH/ATP5B as reference genes and samples 
were further normalised to the WT sample mean. Statistical analyses were performed 
 118 
using Mann-Witney tests on 2-ΔCt values (Livak and Schmittgen, 2001), bar charts were 
plotted using normalised 2-ΔΔCt values (error bars show S.D., * = p < 0.05, n.s. = not 
significant, n = 5). 
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4.2.4 Loss of Fe65 does not alter expression of GSK3α, GSK3β, LRP6, APP or tau 
protein levels in Fe65KO mouse brains and antibodies that detect Fzd1 or 
wnt3a proteins could not be identified 
The expression levels of mRNA transcripts do not always correlate with protein levels 
for the same gene. For example, a particular mRNA, although abundant, may not be 
translated, or may be translated inefficiently. Additionally, a protein may undergo rapid 
turnover despite being synthesised efficiently from high levels of mRNA. To address 
this, the levels of Fzd1, wnt3a, GSK3α, GSK3β, LRP6, APP and tau protein expression 
were analysed by SDS-PAGE and western blotting in WT and Fe65KO mouse brain 
samples. Consistent with mRNA RT-qPCR data, there were no significant differences 
in the levels of GSK3α, GSK3β, LRP6, APP or tau protein between Fe65KO and WT 
mice (Figure 4.6).  
 
Detection of Fzd1 and wnt3a proved difficult since no antibodies were identified that 
could convincingly detect these proteins on western blots. Three different Fzd1 
antibodies were tested in DIV3 rat cortical neurons treated with vehicle, control siRNA 
or Fzd1 siRNAs at a concentration of 1 µM for 4 days. These antibodies were sc-30428 
(Santa Cruz), AF1120 (R&D Systems) and pan Fzd sc-9169 (Santa Cruz). None of 
these antibodies specifically detected a species of 71 kDa (the predicted molecular 
mass of Fzd1) on western blots and there were no differences in labelling between 
vehicle, control or Fzd1 siRNA treated neurons (Figure 4.7A). 
 
Likewise, probing western blots of WT and Fe65KO brain samples with a wnt3a 
antibody detected multiple species, which is indicative of non-specific binding (Figure 
4.7B). Since no antibodies that could reliably identify Fzd1 or wnt3a protein were 




Figure 4.6: Loss of Fe65 does not alter expression of GSK3α, GSK3β, LRP6, APP 
or tau protein levels in Fe65KO mouse brains 
Brain homogenates from 5 WT and 5 Fe65KO mice were analysed by SDS-PAGE and 
western blotting. A) GSK3α was probed with 9338, C) GSK3β was probed with 610201, 
E) LRP6 was probed with C47E12, G) APP was probed with CT-17, and I) tau was 
probed with A0024. For all blots, GAPDH (loading control) was probed with 14C10 and 
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molecular mass markers are shown. B, D, F, H, J) Bar charts show relative protein 
expression. Signals on western blots were quantified by densitometry and Fe65KO 
expression levels were normalised to WT controls. Statistical analyses were carried out 





Figure 4.7: Antibodies that detect Fzd1 and Wnt3a proteins on western blot could 
not be identified  
A) DIV 3 rat cortical neurons were treated with vehicle (untreated), control siRNA or 
Fzd1 siRNAs at a concentration of 1 µM for 4 days. Cell lysates were analysed by 
SDS-PAGE and western blotting. Fzd1 was probed with sc-30428 (Fzd1 Santa Cruz), 
AF1120 (Fzd1 R&D) and pan Fzd using sc-9169. Tubulin (loading control) was probed 
with T6199. Molecular mass markers are shown. B) Brain homogenates from 5 WT 
and 5 Fe65KO mice were analysed by SDS-PAGE and western blotting. Blots were 
probed for wnt3a using 2721 and GAPDH (loading control) using 14C10. Molecular 
mass markers are shown.   
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4.2.5 Loss of Fe65 does not alter Fzd1 or APP mRNA levels in Fe65 siRNA treated 
rat cortical neurons and loss of APP does not affect Fzd1 or Fe65 mRNA 
levels in APP siRNA treated rat cortical neurons 
The data presented so far have shown that Fzd1 mRNA expression is impaired in 
Fe65KO mice. To complement these mouse studies, RT-qPCR analyses were carried 
out on rat cortical neurons treated with either Fe65 or APP siRNAs. The siRNA 
treatment achieved highly efficient knockdown of Fe65 or APP expression (Figure 
4.2.1.2). As Fzd1 was the only mRNA transcript to show significantly altered 
expression in Fe65KO mice, these further studies focused on confirming this result in 
siRNA treated cortical neurons. The effect of APP loss on Fzd1 expression was also 
investigated because APP and Fe65 are proposed to be involved in the same nuclear 
signalling pathway. Finally, APP itself has been proposed as a target of 
APP-Fe65-mediated gene transactivation (von Rotz et al., 2004). If loss of Fe65 altered 
APP levels, then any effect of Fe65 on Fzd1 expression could occur indirectly and be 
due to changes in APP expression. To address this, the effect of Fe65 loss on APP 
expression and the effect of APP loss on Fe65 expression were also monitored.  
 
For these experiments, DIV 3 rat cortical neurons were treated with control siRNAs or 
Fe65 siRNAs for 4 days. Cell lysates were analysed by RT-qPCR to monitor 
expression of Fzd1, APP and Fe65. Fzd1 mRNA levels showed a non-significant trend 
towards a decrease in neurons treated with Fe65 siRNAs (Figure 4.8A), which is 
consistent with the significant decrease in Fzd1 mRNA detected in Fe65KO mice 
compared to WT littermates. APP levels were unaffected by Fe65 siRNA treatment 
(Figure 4.8B). Treatment of cortical neurons with APP siRNAs again had no significant 
effect on the mRNA levels of either Fzd1 or Fe65 (Figure 4.8C, D), but showed a 





Figure 4.8: Loss of Fe65 does not alter Fzd1 or APP mRNA levels in Fe65 siRNA 
treated rat cortical neurons and loss of APP does not affect Fzd1 or Fe65 mRNA 
levels in APP siRNA treated rat cortical neurons 
DIV3 rat cortical neurons were treated with control, A, B) Fe65 siRNA or C, D) APP 
siRNAs at a concentration of 1 µM for 4 days. Relative mRNA levels of Fzd1, APP and 
Fe65 were measured by RT-qPCR of cDNA samples reverse transcribed from mRNAs 
isolated from cell lysates. Relative quantification was calculated using the 2-ΔΔCt method 
(Livak and Schmittgen, 2001) using GAPDH/ATP5B reference genes and samples 
were further normalised to the control siRNA sample mean. Statistical analysis was 
performed using Mann-Witney tests on 2-ΔCt values (Livak and Schmittgen, 2001), bar 
charts were plotted using normalised 2-ΔΔCt values (error bars show S.D.,  * = p < 0.05, 
n.s. = not significant, n = 3).  
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4.2.6 Loss of Fe65 has no significant effect on tau Ser202 phosphorylation or 
GSK3β Ser9 phosphorylation in Fe65KO brains 
The studies undertaken in this chapter were based upon findings from Solexa NGS 
analysis of Fe65KO mice which suggested that loss of Fe65 might impact the wnt 
signalling pathway by mediating changes in expression of Fzd1, GSK3α and wnt3a. 
Verification experiments in Fe65KO mice and siRNA treated neurons confirmed that 
loss of Fe65 expression results in altered Fzd1 expression but did not confirm a 
change in GSK3α or wnt3a expression. Because the canonical wnt signalling pathway 
regulates the activity of tau kinases GSK3α and GSK3β (Hernandez et al., 2012; 
Hooper et al., 2008; Kaidanovich-Beilin and Woodgett, 2011; Noble et al., 2013), these 
findings might reveal a new link between APP (via Fe65) and tau phosphorylation.  
 
To investigate this link, tau phosphorylation at an AD-relevant site and GSK3β activity 
were investigated in Fe65KO and WT mouse brains. Brain homogenates of 3 WT and 
3 Fe65KO mice were analysed by SDS-PAGE and western blotting. Blots were probed 
for phosphorylated tau using CP13, a phospho-specific tau antibody. CP13 recognises 
tau that has been phosphorylated at Ser202, a known GSK3β-responsive site (Goedert 
et al., 1995). Similarly, blots were probed for phosphorylated GSK3β using a 
phospho-specific antibody that detects GSK3β phosphorylation at Ser9. 
Phosphorylation at this site inhibits GSK3β activity so a higher proportion of 
phosphorylated GSK3β indicates a decrease in GSK3β activity (Kaidanovich-Beilin and 
Woodgett, 2011; Sutherland et al., 1993). 
 
As shown in Figure 4.6, levels of total tau expression were not significantly different in 
Fe65KO mice. However, the proportion of tau that was phosphorylated at Ser202 
showed a non-significant trend towards a decrease of phosphorylation in Fe65KO 
mouse brains (Figure 4.9A, B) There was also no significant difference in GSK3β Ser9 






Figure 4.9: Loss of Fe65 has no significant effect on tau phosphorylation or 
GSK3β phosphorylation in Fe65KO brains 
Brain homogenates from 3 WT and 3 Fe65KO mice were analysed by SDS-PAGE and 
western blotting. A) Blots were probed for tau phosphorylated at Ser202 with CP13.  
C) Blots were probed for GSK3β phosphorylated at Ser9 with 9336. GAPDH (loading 
control) was detected using 14C10. Molecular mass markers are shown. B, D) Bar 
charts show relative protein phosphorylation. Signals on western blots were quantified 
by densitometry and phosphorylated protein levels were normalised to total protein 
expression levels. Relative protein phosphorylation levels of Fe65KO samples were 
then normalised to WT controls and statistical analyses were carried out using 
Mann-Witney tests (error bars show S.D., n.s. = not significant, n = 3).  
  
 127 
4.2.7 Loss of Fe65 reduces tau phosphorylation and GSK3β activity in rat cortical 
neurons 
To complement the above studies, the effects of siRNA loss of Fe65 on tau 
phosphorylation and GSK3β activity (via Ser9 phosphorylation) using ELISAs were 
investigated. ELISAs provide quantitative data and compared to western blots, are 
more robust at detecting small changes. The tau ELISAs measured levels of total tau 
and tau phosphorylated on Ser199, another GSK3β-responsive site (Hanger et al., 
2009). The GSK3β ELISA measured both total GSK3β and GSK3β phosphorylated on 
Ser9  (inactive GSK3β). 
 
For these experiments, DIV 3 rat cortical neurons were treated with control siRNAs or 
Fe65 siRNAs for 4 days before cell lysates were analysed by the ELISAs. 
siRNA-induced loss of Fe65 had no effect on total tau expression, which is in 
agreement with the findings from the Fe65KO mice. However, consistent with the 
non-significant trend seen in the mouse data, tau phosphorylation (relative to tau 
expression) was significantly reduced in siRNA treated neurons (Figure 4.10A). siRNA 
knockdown of Fe65 had no effect on total GSK3β levels but a small but significant 
increase in GSK3β Ser9 phosphorylation was detected (Figure 4.10B). Because the 
effect of loss of Fe65 on GSK3β phosphorylation was so small, these experiments 
need to be repeated to confirm these findings. These results indicate that loss of Fe65 





Figure 4.10: Loss of Fe65 reduces tau phosphorylation and GSK3β activity in 
Fe65 siRNA treated rat cortical neurons 
DIV 3 rat cortical neurons were treated with either control siRNA or Fe65 siRNA at a 
concentration of 1 µM for 4 days. Cell lysates were analysed for tau phosphorylated on 
Ser199 and GSK3β phosphorylated on Ser9 using ELISAs. A) Bar chart showing tau 
Ser199 phosphorylation following normalisation of signals to total tau levels in the 
samples. B) Bar chart showing GSK3β Ser9 phosphorylation following normalisation of 
signals to total GSK3β levels in the samples. For both charts, samples were further 
normalised to the control siRNA sample mean and statistical analyses were carried out 
using Mann-Witney tests (error bars show S.D., * = p < 0.05, n = 6 for tau ELISA, n = 










In this chapter, the effect of loss of Fe65 on the expression of seven genes was 
investigated. This was achieved by monitoring mRNA and protein levels of genes of 
interest in WT and Fe65KO mice and siRNA-mediated Fe65 knockdown in rat cortical 
neurons. In addition, the effect of APP knockdown on the expression of two of these 
genes was also examined. Finally, the effect of loss of Fe65 on tau and GSK3β was 
studied. 
 
Regulation of gene transcription is thought to be one of the key roles for APP-Fe65 
nuclear signalling (see section 1.3.2). However, the exact target genes of this signalling 
complex are unknown and the relevance of this function has also been questioned 
(Hébert et al., 2006; Waldron et al., 2008). Due to the role of APP in AD, it is 
understandable that the majority of these studies have focussed on APP/AICD 
signalling with less attention on the role of Fe65. As discussed in section 1.3.2, APP 
was originally thought to act in a similar fashion to Notch, another type-1 membrane 
spanning protein that is cleaved by γ-secretase and involved in gene transcription. 
However, there are differences between AICD and the Notch intracellular domain, most 
notably the smaller size of AICD, which inhibits its ability to bind to multiple proteins 
that may be required for gene transcription. Fe65 on the other hand has several 
protein-protein interaction domains and has been shown to interact with a number of 
nuclear proteins including CP2/LSF/LBP1, Tip60 and SET (Cao and Südhof, 2001; Kim 
et al., 2003; Stante et al., 2009; Telese et al., 2005; Zambrano et al., 1998), so an 
alternative possibility is that the AICD-Fe65 complex recruits transcriptional proteins to 
perform a role similar to the Notch intracellular domain. The studies described in this 
chapter were aimed at exploring this possibility further. 
 
Initial experiments followed up data generated by a Solexa NGS study aimed at 
identifying genes that are regulated by Fe65. Bioinformatic analyses identified the wnt 
signalling pathway as a pathway that is regulated by Fe65. In particular, the wnt 
receptor Fzd1, GSK3α and wnt3a, which are all components of the canonical wnt 
pathway, were identified as genes with altered expression in the Fe65KO mice. While 
NGS allows the monitoring of mRNA expression for a high number of genes 
simultaneously, it is a high-throughput method that should be verified and validated 
using low-throughput techniques with higher accuracy. For NGS, the most common 
methods of validating data are measuring mRNA expression by RT-qPCR and protein 
levels by western blotting. To validate the Solexa findings, the expression levels of 
these genes were monitored by RT-qPCR in Fe65KO and WT littermate mouse brains. 
In addition, the expression of GSK3β and LRP6, which are also components of the wnt 
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signalling pathway, along with APP and tau were analysed. Of these seven genes, only 
Fzd1 expression was shown to be different in the Fe65KO mice brains, where loss of 
Fe65 led to a decrease in Fzd1 mRNA expression. The reduction of Fzd1 expression 
displayed by the Fe65KO mice suggests that Fe65 normally acts to positively regulate 
the expression of this gene. Because wnt signalling has a negative impact on GSK3α/β 
activity, enhancing Fzd1 levels may lead to reduced GSK3α/β activity. It should be 
noted that due to the low sample size and high variability of the samples, these studies 
are likely to be underpowered and therefore may be susceptible to Type 2 statistical 
error (failing to reject a null hypothesis). Increasing the sample size could help to 
reduce the variation and increase the sensitivity of the study to detect changes in gene 
expression. 
 
Changes in gene transcription do not always lead to changes in protein levels so it was 
important to determine whether loss of Fe65 also affects Fzd1 protein levels. However, 
despite using Fzd1 siRNAs to test several commercial antibodies, none were capable 
of detecting Fzd1. Since these studies were performed, my supervisor Professor Chris 
Miller has contacted Professor Patricia Salinas (University College London), who is an 
authority on the wnt signalling pathway and she has confirmed that currently there are 
no reliable antibodies that detect Fzd1 or other members of the Fzd family (personal 
communication). Because of this, measuring changes in Fzd1 protein levels after Fe65 
loss was not possible during this investigation.  
 
To complement these studies using an alternative approach, methods were 
established to knockdown Fe65 expression in cultured rat cortical neurons using 
siRNAs. Although siRNAs are a common route for reducing expression in cultured 
cells, achieving siRNA-mediated knockdown in neurons can be difficult (Gärtner et al., 
2006; Nakajima et al., 2012). Despite this, Accell siRNAs produced reliable and 
efficient knockdown of both Fe65 and APP expression in neurons. The siRNA studies 
confirmed the Fe65KO mouse findings that loss of Fe65 reduces Fzd1 expression in 
neurons. Interestingly, loss of Fe65 had no effect on APP expression and indeed, APP 
knockdown did not alter the expression of Fe65 or Fzd1. These results demonstrate 
the specificity of the effect of Fe65 on Fzd1 expression. In particular, the finding that 
APP loss had no effect on Fzd1 or Fe65 expression means it is unlikely that AICD is 
involved in Fe65-mediated regulation of Fzd1 expression. In addition, the siRNA 
experiments were carried out in neuronal cultures, indicating that these changes occur 
in neurons. This is consistent with Fe65 being predominantly expressed in neurons 
(Kesavapany et al., 2002), but does not eliminate the possibility that Fzd1 expression is 
affected in other cell types in the brain.  
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The results of RT-qPCR experiments in both Fe65KO mouse brains and Fe65 siRNA 
treated neurons confirm the Solexa NGS data for changes in Fzd1 expression. 
However, they do not corroborate changes seen in other genes linked to the wnt 
signalling pathway, specifically GSK3α or wnt3a. The reasons for this are unclear but it 
is possible that the sample sizes used were too small and high variation within the 
samples may have masked the effect of loss of Fe65 on gene expression. For future 
experiments, a larger sample size might allow better detection of differences between 
Fe65KO and WT mice. It would also be interesting to measure the changes in 
expression of the other genes of interest in the siRNA treated neurons, which typically 
showed less variation within treatment groups compared to the Fe65KO brain samples.  
 
To continue the investigation into the functional consequences of altered Fzd1 
expression, the activity of the wnt signalling pathway could be monitored. Activation of 
the canonical wnt pathway reduces the degradation of the nuclear signalling molecule 
β-catenin. As β-catenin accumulates in the nucleus, it binds to TCF/LEF transcription 
factors to enhance the transcription of target genes (Kaidanovich-Beilin and Woodgett, 
2011; Schuijers et al., 2014). Luciferase reporter assays using TCF/LEF reporter 
constructs have previously been generated to monitor wnt signalling (Smalley et al., 
1999) and could be used in both neurons from Fe65KO mice and Fe65 siRNA treated 
neurons. In addition, it would be interesting to determine whether overexpression of 
Fe65 has the opposite effect to loss of Fe65 and enhances Fzd1 expression. Again 
these experiments could be extended into monitoring wnt signalling in response to 
Fe65 overexpression via luciferase reporter assays.  
 
Loss of Fe65 causes a decrease in Fzd1 expression in both Fe65KO mouse brains 
and in Fe65 siRNA treated neurons. This reduction of Fzd1 expression suggests that 
Fe65 acts to positively regulate the expression of Fzd1, one of the receptors in the wnt 
signalling pathway. Since wnt signalling has a negative impact on GSK3α/β activity, 
reducing Fzd1 levels may lead to increased GSK3α/β activity. This is of particular 
interest in the field of AD because GSK3β is one of the key kinases involved in the 
hyperphosphorylation of tau (Killick et al., 2014; Scali et al., 2006; Stoothoff et al., 
2002; Wagner et al., 1997; Zhang et al., 2008). Indeed, defective wnt signalling has 
recently been linked to AD (Purro et al., 2014). To assess whether loss of Fe65 
affected tau phosphorylation, levels of total and phosphorylated tau protein were 
monitored. Both western blotting of Fe65KO mouse brains and ELISAs on siRNA 
treated neurons demonstrated that while loss of Fe65 had no effect on tau expression, 
it caused a decrease in tau phosphorylation at Ser202 and Ser199 respectively. These 
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residues are known to be hyperphosphorylated in AD and are targets of GSK3β 
(Hanger et al., 2009; Noble et al., 2013).  
 
Although one route of GSK3β activity regulation is via the wnt signalling pathway, 
another mechanism involves inhibitory phosphorylation on Ser9 (Kaidanovich-Beilin 
and Woodgett, 2011). To determine whether the reduced Ser199/202 tau phosphorylation 
induced by Fe65 loss coincided with a change in GSK3β activity via Ser9 
phosphorylation, western blots and ELISAs were performed on Fe65KO brain samples 
and Fe65 siRNA treated neurons, respectively. Fe65KO mice showed no change in 
GSK3β phosphorylation while siRNA-induced loss of Fe65 in neurons showed a small 
increase in GSK3β phosphorylation. This is consistent with a reduction in tau 
phosphorylation as increased GSK3β phosphorylation represents a decrease in 
GSK3β kinase activity. Again, the discrepancy between western blots of Fe65KO 
samples and ELISAs on siRNA treated neurons could be due to the higher sensitivity 
of the ELISA. These experiments need to be repeated to confirm the findings but they 
indicate that loss of Fe65 reduces GSK3β activity via Ser9 phosphorylation to reduce 
tau phosphorylation. While the change in GSK3β phosphorylation is small (3 % 
decrease) and the change in tau phosphorylation is much larger (46 % decrease in 
western blots and 36 % decrease in ELISAs), GSK3β is an enzyme so small changes 
in its catalytic activity may translate into larger changes in substrate phosphorylation, in 
this case tau. However, the relatively small sample size means that this study could be 
susceptible to Type 1 statistical error (incorrectly rejecting a null hypothesis) and this 
result should not be overinterpreted. Increasing the sample size would reduce the 
chance of Type 1 error and enable a proper confirmation of this result. 
 
The mechanisms behind this effect of loss of Fe65 on GSK3β are not clear but 
interestingly other studies have linked Fe65 with GSK3β. Overexpression of Fe65 
and/or AICD has been shown to increase GSK3β expression and tau phosphorylation 
and there is also evidence that Fe65 may bind directly to tau (Barbato et al., 2005; Kim 
et al., 2003; Perkinton et al., 2004). Clearly, further work is required in this area and it 
would be interesting to investigate whether Fe65 loss affects other tau phosphorylation 
sites (particularly, those that are targeted by GSK3α/GSK3β) and the expression or 
activity of other kinases that phosphorylate tau. Further studies should also include the 
investigation into how overexpression of Fe65 impacts tau and GSK3β phosphorylation 
in neurons. 
 
This investigation has shown that loss of Fe65 causes a reduction in the expression of 
Fzd1 and an increase in GSK3β and tau phosphorylation. More work needs to be done 
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to elucidate the exact mechanisms at play here and whether a single pathway or a 
more complex network of changes links these findings. Because Fzd1 is a receptor for 
wnt and activation of the wnt signalling pathway inhibits GSK3β, it was predicted that 
loss of Fe65-induced inhibition of Fzd1 expression would cause an increase in GSK3β 
activity and therefore an increase in tau phosphorylation. However, this is not the case 
and less Fzd1 expression occurs alongside decreased tau phosphorylation. There are 
two main models that could explain these results. The first is that while Fe65 loss 
reduces Fzd1, other Fzd isoforms compensate for the reduced receptor expression to 
rescue wnt signalling impairments. This is supported by the observation that there are 
10 Fzd receptors that can act in wnt signalling pathways. The complex relationship 
between different wnt and Fzd isoforms has yet to be fully characterised, but it is 
thought that there is some functional redundancy between the Fzd receptors (Clevers 
and Nusse, 2012). The second model is that Fe65 loss may reduce wnt signalling but 
also regulate another protein that is involved in tau phosphorylation and this second 
pathway is a more potent mechanism for regulating tau phosphorylation than wnt 
signalling. The increase in GSK3β Ser9 phosphorylation seen in Fe65 siRNA treated 
neurons suggests that the second model may be a better fit for the data because wnt 
signalling-mediated control of GSK3β is Ser9 phosphorylation-independent and is 
thought to instead rely on changes to protein localisation (Metcalfe & Bienz 2011). 
However, these models are not mutually exclusive. Monitoring changes in wnt 
signalling via luciferase reporter assays and measuring changes in protein expression 
and activity of other tau kinases in response to loss of Fe65 should help to shed light 
on this. 
 
Over the last 25 years, the amyloid cascade hypothesis has formed the major 
framework for studying pathogenic mechanisms in AD. Despite this, Aβ-targeting drugs 
have been unsuccessful and most APP animal models do not develop both neuritic 
plaques and neurofibrillary tangles (Elder et al., 2010; Herrup, 2015; Richardson and 
Burns, 2002). Definitively proving the link between APP and tau pathology has also 
proved elusive and a recent study involving human neurons generated from induced 
pluripotent stem cells from AD patients showed that familial AD-linked APP mutations 
cause increases in GSK3β and tau phosphorylation in an Aβ-independent manner 
(Israel et al., 2012). This finding suggests that tau hyperphosphorylation is linked to a 
different function of APP. AD-linked mutations that alter APP processing to increase Aβ 
production are likely to also alter APP function and may affect the amount of AICD 
generated by the amyloidogenic pathway, which has been shown to be the only 
transcriptionally active form (Belyaev et al., 2010; Goodger et al., 2009). The findings 
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reported in this chapter support this theory by providing evidence for an effect of Fe65, 
a known APP binding protein that is linked to APP function on tau phosphorylation. 
 
4.3.1 Limitations 
1. The mouse studies carried out in this chapter used small sample sizes and these 
carried high levels of variability. Because of this, some changes in protein expression 
may not have been detected, but could become apparent in larger study sizes. 
 
2. When performing western blots, specific antibodies that detect Fzd1 and wnt3 were 
not available so although RT-qPCR data detected a change in Fzd1 mRNA expression, 
this could not be confirmed at the protein level. 
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During the course of this PhD, my supervisors were contacted by Dr Kwok-Fai Lau 
from the Chinese University of Hong Kong, who also works on Fe65. Dr Lau had 
discovered that Fe65 binds to the GTPase protein ARF6 and enquired whether we 
would like to collaborate on investigating the interaction between Fe65 and ARF6. This 
was because his laboratory has little expertise on neuronal cell preparation and 
experimentation. I therefore became involved in this project, specifically in performing 
immunofluorescence and quantitative intensity correlation analysis to determine 
whether Fe65 and ARF6 colocalise in cultured rat cortical neurons.   
 
Small GTPases are involved in a wide range of cellular functions and ARF6 in 
particular has been reported to play a role in regulating the actin cytoskeleton, cell 
adherence, neurite development and endocytosis/exocytosis (Gillingham and Munro, 
2007). This is of particular interest since both Fe65 and APP are also believed to 
regulate cell motility and the actin cytoskeleton although the precise mechanisms by 
which they carry out these functions are unclear (Cheung et al., 2014; Ermekova et al., 
1997; Ma et al., 2008; Sabo et al., 2001; Wang et al., 2011), Neurite outgrowth and 
actin cytoskeletal dynamics are vital tasks for neuronal growth, survival and normal 
function. Abnormalities in these processes could contribute to impaired synapse 
formation or maintenance and impaired migration of neurons and neurite development. 
ARF6 acts upstream of other small GTPases Rac1 and RhoA that influence the actin 
cytoskeleton, although the exact pathway by which ARF6 interacts with these proteins 
is unknown (Gillingham and Munro, 2007). 
 
In this chapter, the interaction between Fe65 and ARF6 was investigated and the 
function of this interaction on axonal growth was studied. To achieve this, Fe65 
deletion constructs were used to determine which of the three protein-protein 
interaction domains of Fe65 mediated binding to ARF6, while immunofluorescence 






5.2.1 Fe65 interacts with ARF6 in CHO cells and rat brain lysate 
To validate the results of a yeast 2-hybrid screen, which indicated that ARF6 interacts 
with Fe65 (Cheung et al., 2014), co-immunoprecipitation assays were carried out on 
CHO cells transfected with either control vector (CAT; EV), Fe65 or Fe65+ARF6-myc 
plasmid vectors (see Table 2.2). ARF6 was immunoprecipitated with myc antibody 
9B11 and the presence of bound Fe65 was determined following SDS-PAGE and 
western blotting of the samples. Probing of total cell lysates for Fe65 and ARF6 
demonstrated that the cells were appropriately transfected and analyses of the 
immunoprecipitates confirmed that ARF6 bound to Fe65 (see Figure 5.1A). This 
interaction was also demonstrated between endogenous proteins by performing 






Figure 5.1: Fe65 interacts with ARF6 in CHO cells and rat brain lysates 
A) CHO cells were transiently transfected with CAT (EV), Fe65 or Fe65+ARF6-myc 
plasmid vectors. ARF6 was immunoprecipitated using 9B11 anti-myc antibody and 
bound Fe65 was detected by western blotting. B) ARF6 was immunoprecipitated from 
rat brain lysates using an in house generated ARF6 rat antibody and the precipitates 
were analysed via SDS-PAGE and western blotting. Molecular mass markers are 






5.2.2 ARF6 binds to the PTB1 domain of Fe65 
To identify which of the three Fe65 protein-protein interaction domains might mediate 
binding to ARF6, GST pull-down assays were carried out using a series of GST fusion 
proteins containing each of the three Fe65 interaction domains. CHO cells were 
transiently transfected with either CAT (EV), GST+ARF6-myc, GST-Fe65WW+ARF6-
myc, GST-Fe65PTB1+ARF6-myc or GST-Fe65PTB2+ARF6-myc plasmid vectors (see 
Table 2.2). GST pull down assays were then performed and these were analysed by 
SDS-PAGE and western blotting. Such analyses revealed that while all of the GST 
fusion proteins were pulled down by glutathione-Sepharose 4B beads, only 
GST-Fe65PTB1 also pulled down ARF6. This indicates that ARF6 interacts with the 
PTB1 domain of Fe65 (see Figure 5.2A).  
 
To complement these studies, co-immunoprecipitation assays were performed on CHO 
cells transiently transfected with either CAT (EV), Fe65+ARF6-myc or 
Fe65ΔPTB1+ARF6 plasmid vectors (see Table 2.2). Fe65ΔPTB1 is a deletion 
construct lacking the PTB1 domain of Fe65 (Cao and Südhof, 2001; Cheung et al., 
2014). SDS-PAGE and western blotting was used to detect whether both Fe65 and 
Fe65ΔPTB1 interact with ARF6. Probing of total cell lysates for Fe65 and ARF6 
indicated that the cells were appropriately transfected and that Fe65ΔPTB1 migrated at 
a lower molecular weight compared to Fe65. Analyses of the immunoprecipitated 
samples complemented the GST pull down assays and showed that Fe65 but not 
Fe65ΔPTB1 bound to ARF6 (see Figure 5.2B). Therefore, Fe65 binds to ARF6 and this 





Figure 5.2: ARF6 binds to the PTB1 domain of Fe65 
A) CHO cells were transiently transfected with either CAT (EV), GST+ARF6-myc, 
GST-Fe65WW+ARF6-myc, GST-Fe65PTB1+ARF6-myc or GST-Fe65PTB2+ARF6-
myc plasmid vectors. The GST/GST-Fe65 constructs were pulled down with 
glutathione sepharose 4B beads and bound ARF6 was analysed by western blotting. 
ARF6 was detected using an in house ARF6 rat antibody. B) CHO cells were 
transiently transfected with CAT (EV), Fe65+ARF6-myc or Fe65ΔPTB1+ARF6-myc 
plasmid vectors. Fe65ΔPTB1 is a deletion mutant that does not contain the PTB1 
domain of Fe65. ARF6 was immunoprecipitated using 9B11 anti-myc antibody and 
bound Fe65 was detected by western blotting. Fe65 was detected using sc-19751 and 




5.2.3 ARF6 is localised to perinuclear regions and colocalises with Fe65 in 
growth cones of rat cortical neurons 
 
Studies described in sections 5.2.1-5.2.2 revealed that Fe65 binds to ARF6. Both Fe65 
and ARF6 are reported to play a role in the dynamics of the actin cytoskeleton (Cheung 
et al., 2014; Ermekova et al., 1997; Ma et al., 2008; Sabo et al., 2001; Wang et al., 
2011). The actin cytoskeleton plays a major role in neurite outgrowth in growth cones 
(Gomez and Letourneau, 2014; Kessels et al., 2011). Developing rat cortical neurons 
were therefore immunostained for Fe65 and ARF6 to determine the subcellular 
locations of these proteins and to study whether Fe65 and ARF6 displayed any 
colocalisation. 
 
DIV 3 rat cortical neurons fixed and immunostained for ARF6 showed that ARF6 is 
predominantly a cytoplasmic protein concentrated in the perinuclear region. Staining 
for ARF6 was also detected along neurites and in growth cones (Figure 5.3). 
Co-staining for Fe65 revealed that Fe65 shows similar patterns of expression, including 
localisation to growth cones where Fe65-ARF6-mediated actin cytoskeletal 
rearrangement may occur (Figure 5.3). To quantify the level of colocalisation of these 
proteins, intensity correlation analyses (ICA) were performed. ICA determines not just 
whether pixels from the two labels colocalise but also whether the intensities of these 
pixel signals vary in synchrony. It therefore provides a more robust assay than simply 
comparing colocalisation of signals (Li et al., 2004). ICA generates an intensity 
correlation quotient (ICQ) value that can be statistically tested to identify the spatial 
relationship between the two proteins under investigation. ICQ = 0 describes random 
staining, -0.5 ≤ ICQ < 0 describes segregated staining and 0 < ICQ ≤ 0.5 describes 
colocalisation of staining. ICA analysis of Fe65 and ARF6 staining showed that the 
proteins significantly colocalise in growth cones of developing neurons (mean ± SEM; 




Figure 5.3: ARF6 is present in perinuclear regions and colocalises with Fe65 in 
the growth cones of developing neurites 
DIV 3 rat cortical neurons were fixed, permeabilised and immunostained for 
endogenous ARF6 using an in house rat antibody, Fe65 using sc-19751 and actin 
using Alexa Fluor-546-labelled phalloidin. Nuclei were labelled using DAPI. A) ARF6 is 
present in perinuclear regions and neurites. B) Fe65 and ARF6 show similar patterns 
of staining and are enriched in growth cones. Zoom box shows growth cone from the 





5.2.4 Fe65 and ARF6 enhance neurite outgrowth 
Fe65 and ARF6 are both reported to play a role in regulating the actin cytoskeleton. In 
addition, these proteins colocalise in the growth cones of developing neurites (section 
5.2.3). To determine whether Fe65 and ARF6 affected neurite outgrowth, DIV 2 rat 
cortical neurons were co-transfected with EGFP so as to facilitate measurements of 
neuron morphology and either CAT (EV), Fe65, Fe65ΔPTB1, Fe65ΔPTB2, ARF6, 
ARF6+Fe65, ARF6+Fe65ΔPTB1 or ARF6+Fe65ΔPTB2 plasmid vectors (see Table 
2.2). 24 hours later, the length of the longest neurite was measured in neurons from 
each transfection group. Transfection of Fe65 or ARF6 enhanced neurite outgrowth 
and this outgrowth was further enhanced in neurons transfected with plasmids for both 
proteins (Figure 5.4). Moreover, the stimulatory affect of Fe65 on neurite outgrowth 
was lost in neurons transfected with Fe65ΔPTB1 and partially lost in neurons 






Figure 5.4: Fe65 and ARF6 enhance neurite outgrowth 
DIV 3 rat cortical neurons were transiently co-transfected with EGFP along with CAT 
(EV), Fe65, Fe65ΔPTB1, Fe65ΔPTB2, ARF6, ARF6+Fe65, ARF6+Fe65ΔPTB1 or 
ARF6+Fe65ΔPTB2 plasmid vectors. The length of the longest neurite was measured 
24 hr after transfection as the distance between growth cone tip and cell body. A 
minimum of 40 cells were analysed per treatment group and statistical analyses were 
carried out using one-way ANOVA with Bonferroni post hoc test (error bars show S.D., 






In this chapter, the interaction between Fe65 and ARF6 was investigated. ARF6 was 
identified as a putative Fe65 binding protein via a yeast 2-hybrid screen in Kwok-Fai 
Lau’s research group (Chinese University of Hong Kong). Confirmation of the 
interaction was then achieved via a number of experimental approaches. These 
involved using co-immunoprecipitation assays of transfected proteins and endogenous 
proteins in brain, GST pull down assays and finally colocalisation studies in cultured rat 
neurons. The GST pull down assays demonstrated that binding of ARF6 to Fe65 
involved the PTB1 domain of Fe65; the Fe65 WW and PTB2 domains did not bind 
ARF6. Also co-immunoprecipitations using a deletion mutant of Fe65 lacking the PTB1 
domain (Fe65ΔPTB1) revealed that this mutant did not bind ARF6. 
 
To gain insight into the cellular localisation of both ARF6 and Fe65, 
immunofluorescence studies were carried out on fixed rat cortical neurons. These 
demonstrated that both ARF6 and Fe65 are present in cell bodies and neurites of 
developing neurons. Of particular interest was the observation that they were both also 
enriched in the growth cones of extending axons. Indeed, colocalisation assays of 
ARF6 and Fe65 in growth cones using ICA analyses revealed that they displayed 
significant colocalisation in growth cones. 
 
Both Fe65 and ARF6 are involved in mediating actin dynamics and actin is required in 
the growth cones of developing neurons for neurite outgrowth (Akiyama and Kanaho, 
2015; Cheung et al., 2014; Ermekova et al., 1997; Gillingham and Munro, 2007; 
Gomez and Letourneau, 2014; Kessels et al., 2011; Ma et al., 2008; Sabo et al., 2001; 
Wang et al., 2011). The affects of overexpression of Fe65 and ARF6 on neurite 
outgrowth in developing cultured rat neurons were therefore investigated. Both Fe65 
and ARF6 stimulated neurite outgrowth and this stimulation was enhanced in neurons 
expressing both proteins. Moreover, the effect of Fe65 on neurite outgrowth was lost in 
Fe65ΔPTB1 expressing cells; Fe65ΔPTB1 does not bind to ARF6. This indicates that 
the stimulatory effect of Fe65 on neurite outgrowth involves its binding to ARF6. 
 
Interestingly, expression of Fe65ΔPTB2 (Fe65 lacking the second PTB domain) was 
also less potent at promoting neurite outgrowth than wild-type Fe65. The Fe65 PTB2 
domain binds APP (see Table 1.1) and so it is possible that APP may also be involved 
in Fe65 and possibly ARF6 mediated neurite outgrowth. This could be tested by 
monitoring the effects on neurite outgrowth on overexpression of APP and mutants of 
APP in which the YENPTY motif that mediates binding to Fe65 have been altered to 
preclude the interaction.  
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Finally, BDNF is a neurotrophin and axon guidance molecule (Markus et al., 2002). 
The results presented in Chapter 3 demonstrate that BDNF induces phosphorylation of 
Fe65 by ERK. It would therefore be interesting to determine whether BDNF-mediated 
phosphorylation of Fe65 also alters the interaction between ARF6 and Fe65, and 
whether the phosphorylation mutants of Fe65 described earlier in this thesis alter the 
capability of Fe65 to promote neurite outgrowth. 
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS 
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6.1 Summary 
The amyloid cascade hypothesis has provided the dominant framework for studying 
AD and therapeutic targets. However, effective drugs that target Aβ production or 
clearance have so far proved elusive and this has prompted a re-appraisal of the 
hypothesis (Herrup, 2015; Karran and De Strooper, 2016). Alterations to APP 
processing that impact Aβ production are also likely to affect APP function and one 
possibility is that changes to this function might also contribute to AD. Fe65 is major 
binding protein of APP and the work described in this thesis is focused on the role of 
Fe65. In particular, it aimed to begin to test two related hypotheses. Firstly, that BDNF 
signalling, which leads to activation of ERK1/2 in neurons, induces phosphorylation of 
Fe65 by ERK1/2 to regulate its binding to APP. Secondly, that Fe65 regulates genes 
that are linked to GSK3α/β activity and tau phosphorylation. 
 
The studies in Chapter 3 were designed to further our understanding of the regulatory 
pathways that mediate the APP-Fe65 interaction. Firstly, BDNF was shown to induce 
Fe65 phosphorylation in an ERK1/2-dependent manner. Assays were then established 
to quantify APP-Fe65 binding. These were co-immunoprecipitation assays, GST 
pull-down assays using a GST-APPC fusion protein bait and finally PLAs. BDNF 
treatment consistently reduced the interaction between APP and Fe65 in both CHO 
cells stably expressing the BDNF receptor TrkB and cultured rat cortical neurons. To 
gain insight into whether the effect of BDNF on APP-Fe65 binding involved 
phosphorylation of Fe65 by ERK1/2, phospho-mimicking Fe65 mutants containing 
substitutions of the four known ERK1/2 phosphorylation sites to either alanine or 
glutamic acid were used. Mutation to alanine precludes phosphorylation while mutation 
to glutamic acid mimics permanent phosphorylation. The phospho-mimicking Fe65 
mutant showed less binding to APP in both co-immunoprecipitation and GST-APPC 
pull-down assays, confirming that this effect was due to the phosphorylation of one or 
more of four ERK1/2-responsive residues. These results show that a BDNF-induced 
signalling pathway activates ERK1/2 to phosphorylate Fe65 and inhibit APP-Fe65 
binding.  
 
There is evidence that BDNF treatment may have therapeutic value for AD as it shows 
a neuroprotective effect in models of AD (Ando et al., 2002; Blurton-Jones et al., 2009; 
Nagahara et al., 2009). The precise mechanism that underlies this effect is unknown 
but one possibility raised by the findings reported in Chapter 3 is that it might involve 
changes to Fe65 phosphorylation and its interaction with APP. 
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In Chapter 4, experiments were carried out to confirm results from next generation 
sequencing studies performed by others that compared gene expression in the brains 
of Fe65KO mice to their non-transgenic littermates. These experiments had identified 
several components of the wnt signalling pathway including Fzd1, GSK3α and wnt3a 
as showing altered gene expression. The wnt signalling pathway has been implicated 
in AD because it regulates the activity of GSK3β, which is strongly linked to AD as a 
tau kinase. In this thesis, Fe65KO mice and neurons treated with Fe65 siRNA, were 
used to investigate the role of Fe65 in regulating the expression of these three genes 
along with two other wnt signalling components, GSK3α and LRP6, and APP and tau, 
which have strong links to AD. Of the seven genes tested however, these experiments 
revealed that loss of Fe65 only affected Fzd1 expression. To test whether APP also 
contributes to the regulation of Fzd1, expression levels were measured in neurons 
treated with APP siRNAs. In contrast to loss of Fe65, APP knockdown had no effect on 
Fzd1 expression, indicating that Fe65 regulates Fzd1 expression in an 
APP-independent pathway. 
 
The studies discussed in Chapter 5 demonstrate an interaction between Fe65 and the 
small GTPase ARF6. They also show that Fe65-ARF6 complexes are present in the 
growth cones of developing neurons and play an important role in enhancing neurite 
outgrowth. The development and maintenance of synapses between neurons is a vital 
part of normal neuronal function. Disruption to neurite outgrowth may impair synaptic 
development and plasticity. The finding that loss of PTB1 (and therefore ARF6 binding) 
as well as loss of PTB2 domains of Fe65 can impair neurite outgrowth suggests that 
Fe65 might act as a bridge between ARF6 and a PTB2-interacting protein, such as 
APP, which has also been reported to regulate the actin cytoskeleton (Cheung et al., 
2014; Ermekova et al., 1997; Ma et al., 2008; Sabo et al., 2001; Wang et al., 2011),. 
 
To investigate other routes that might connect Fe65 to tau phosphorylation, the effect 
of loss of Fe65 in both Fe65KO mice and Fe65 siRNA-treated rat cortical neurons was 
studied. These revealed that loss of Fe65 decreased tau phosphorylation on Ser199 and 
Ser202, which are both phosphorylated by GSK3β in AD brains (Hanger et al., 2009). As 
well as regulation by the wnt signalling pathway, GSK3β is also regulated by inhibitory 
phosphorylation on Ser9, predominantly by the kinase Akt (Kaidanovich-Beilin and 
Woodgett, 2011). The effect of loss of Fe65 on GSK3β Ser9 phosphorylation was 
therefore investigated and was found to increase inhibitory GSK3β Ser9 
phosphorylation. This demonstrated that loss of Fe65 inhibits GSK3β activity via 
phosphorylation of its regulatory site Ser9 and leads to reduced tau phosphorylation on 
at least two known AD-linked sites. These are exciting findings since they demonstrate 
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that Fe65 can regulate tau phosphorylation and so reveal a new potential pathway in 
which APP, via its interaction with Fe65, might also influence tau phosphorylation. 
 
6.2 Future directions 
The findings presented in this thesis demonstrate that Fe65 binding is modulated by 
the ERK1/2 MAP kinase cascade and reveal a new target for Fe65-mediated regulation 
of gene transcription. They also provide evidence that Fe65 can regulate tau 
phosphorylation, possibly by altering GSK3β activity and may demonstrate a novel link 
between APP and tau. Some suggestions for future research directions are listed 
below. 
1. The use of Fe65 phosphorylation mutants revealed that four known phosphorylation 
sites targeted by ERK1/2 could mimic the impairment of APP-Fe65 binding displayed 
by BDNF treatment. It would be useful to identify whether all or just some of these four 
sites are responsible for the observed change in APP-Fe65 binding. This could be 
investigated using the biochemical assays employed in Chapter 3 on phosphorylation 
mutants that contain individual sites or combinations of sites mutated to mimic Fe65 
phosphorylation or preclude phosphorylation. It would also be interesting to perform 
these experiments using phosphorylation mutants combined with BDNF treatment to 
verify that the phosphorylation precluding mutants rescue the inhibition of APP-Fe65 
binding mediated by BDNF. This would confirm that no alternative, as yet unidentified, 
BDNF-responsive phosphorylation sites are involved. 
 
2. The studies in Chapter 3 demonstrate that BDNF induces Fe65 phosphorylation by 
ERK1/2 and reduces APP-Fe65 binding. It would be interesting to investigate what 
effect this has on the function of Fe65, particularly its role in nuclear signalling and 
gene transactivation. Subcellular localisation studies using immunofluorescence and 
biochemical techniques could determine whether the nuclear translocation of Fe65, or 
indeed APP are altered by BDNF treatment. In addition, since Fzd1 mRNA expression 
was shown to be regulated by Fe65 expression, Fzd1 mRNA levels could be used as a 
measure of the transcriptional activity of Fe65 after BDNF treatment. 
 
3. Fe65KO mice and Fe65 siRNA treated neurons showed reduced expression of 
Fzd1, a receptor of the wnt signalling pathway, which may be linked to AD because wnt 
signalling inhibits GSK3β activity. As there is suspected redundancy between the 
different Fzd receptor isoforms in the wnt signalling pathway (Clevers and Nusse, 
2012; Niehrs, 2012), it is important to ascertain whether Fe65 loss leads to 
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physiologically relevant changes to wnt signalling. This could be achieved using 
TCF/LEF reporter gene assays or monitoring of β-catenin protein levels.  
 
4. Loss of Fe65 also caused a decrease in GSK3β activity and a decrease in the level 
of tau phosphorylation at two AD-relevant sites. This demonstration of a relationship 
between Fe65 and tau phosphorylation may provide a link between APP and tau 
pathologies. This avenue of research could be explored further by monitoring levels 
how loss of Fe65 affects phosphorylation of other GSK3β-responsive phosphorylation 
sites in tau. It would also be interesting to determine whether overexpression of Fe65 
produces the opposite effect on tau phosphorylation. Since neurons transfect at low 
efficiency, lenti- or adeno-viral vectors could be used to overexpress Fe65 in neurons.  
5. Finally, it would be interesting to determine the role of APP in this pathway. This 
could be achieved by studying the effect of loss of APP and APP overexpression in 
combination with Fe65 on tau and GSK3β Ser9 phosphorylation in neurons.  
 
To summarise, the finding that loss of Fe65 alters GSK3β activity (via Ser9 
phosphorylation) and tau phosphorylation might be of particular relevance to AD. This 
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ABSTRACT FE65 is an adaptor protein that binds to
the amyloid precursor protein (APP). As such, FE65 has
been implicated in the pathogenesis of Alzheimer’s
disease. In addition, evidence suggests that FE65 is
involved in brain development. It is generally believed
that FE65 participates in these processes by recruiting
various interacting partners to form functional com-
plexes. Here, we show that via its first phosphotyrosine
binding (PTB) domain, FE65 binds to the small GTPase
ADP-ribosylation factor 6 (ARF6). FE65 preferentially
binds to ARF6-GDP, and they colocalize in neuronal
growth cones. Interestingly, FE65 stimulates the activa-
tion of both ARF6 and its downstream GTPase Rac1, a
regulator of actin dynamics, and functions in growth
cones to stimulate neurite outgrowth. We show that
transfection of FE65 and/or ARF6 promotes whereas
small interfering RNA knockdown of FE65 or ARF6
inhibits neurite outgrowth in cultured neurons as com-
pared to the mock-transfected control cells. Moreover,
knockdown of ARF6 attenuates FE65 stimulation of
neurite outgrowth and defective neurite outgrowth
seen in FE65-deficient neurons is partially corrected by
ARF6 overexpression. Notably, the stimulatory effect
of FE65 and ARF6 on neurite outgrowth is abrogated
either by dominant-negative Rac1 or knockdown of
Rac1. Thus, we identify FE65 as a novel regulator of
neurite outgrowth via controlling ARF6-Rac1 signal-
ing.—Cheung, H. N., Dunbar, C., Mórotz, G. M.,
Cheng, W. H., Chan, H. Y., Miller, C. C., Lau, K.-.F.
FE65 interacts with ADP-ribosylation factor 6 to pro-
mote neurite outgrowth. FASEB J. 28, 337–349 (2014).
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FE65 is an adaptor protein that interacts with the
intracellular C terminus of the Alzheimer’s disease
amyloid precursor protein (APP; ref. 1–3). The inter-
action between FE65 and APP can influence APP
processing and production of amyloid-! (A!) peptide
that is deposited in the brains of Alzheimer’s disease
patients (4–8). In addition, FE65 and APP participate
in nuclear signaling (9, 10) and DNA repair after
damage (11, 12) and these functions have also been
linked to Alzheimer’s disease (for reviews, see refs.
13–15).
However, along with these nuclear functions, FE65 is
also believed to have cytoplasmic roles in neurons and
in particular in neurodevelopmental processes and
synaptic function. Evidence to support this notion
comes from a number of findings. First, FE65 is devel-
opmentally regulated in the brain and has been linked
to neurogenesis (16, 17). Also, FE65-knockout mice
display defective brain development (5). Second, FE65
regulates actin-based membrane motility and localizes
in actin-rich mobile structures within the growth cones
(18, 19). Finally, learning and memory deficits have
been reported in FE65-knockout mice, and these are
linked to synaptic changes (8, 20). However, the precise
mechanisms by which FE65 regulates neuronal devel-
opment and synaptic function are not properly under-
stood.
Here, we show that FE65 binds to ADP-ribosylation
factor 6 (ARF6). ARF6 is a ubiquitously expressed Ras
superfamily GTPase that is involved in both endocytic
membrane trafficking and actin cytoskeletal rearrange-
ments. These functions are regulated by cycling of ARF6
between GTP (active) and GDP (inactive) states that
are modulated via the actions of guanine nucleotide
exchange factors (GEFs) and GTPase-activating pro-
teins (GAPs) (for review, see ref. 21). In the nervous
system, ARF6 has been shown to regulate early neuro-
nal morphogenesis (for review, see ref. 22) and axon
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development (23, 24). The effect of ARF6 on neural
development involves, at least in part, Rac1, which is a
regulator of actin dynamics (for reviews, see refs. 25,
26). In this report, we characterize FE65-ARF6 interac-
tion and demonstrate that FE65 and ARF6 promote
neurite outgrowth and regulate the activation of Rac1.
MATERIALS AND METHODS
Yeast 2-hybrid system
Yeast 2-hybrid screens were performed essentially as de-
scribed previously (27). Briefly, sequence encoding the hu-
man FE65 phosphotyrosine binding (PTB) 1! 2 domains (aa
361–676 of FE65) was subcloned into the yeast “bait”
pGBKT7 vector and then transformed into yeast Y2H Gold.
To perform the library screen, the bait-containing yeast Y2H
Gold was mated with yeast Y187 pretransformed with a
human brain cDNA library (Clontech, Mountain View, CA,
USA). After selection, vigorously growing clones were
subjected to freeze-fracture "-galactosidase assays. Candi-
date library pACT2 plasmids were rescued by transforming
into Escherichia coli DH5#, and the brain library cDNA
inserts were then sequenced.
Cell culture and transfection
Chinese hamster ovary (CHO) and SH-SY5Y cells were cul-
tured as described previously (27, 28). Primary rat cortical
neurons were dissected from E18 embryos and grown on glass
coverslips coated with poly-d-lysine in Neurobasal medium
with B27 supplement (Life Technologies, Grand Island, NY,
USA).
For plasmid transfection, CHO cells were transfected with
FuGene 6 (Roche, Perzberg, Germany), and SH-SY5Y and rat
cortical neurons were transfected with Lipofectamine 2000
(Life Technologies) according to the manufacturers’ instruc-
tions and as described previously (29). All siRNAs were
obtained from Dharmacon ThermoScientific (Rockford, IL,
USA). For CHO and SHSY5Y cells, siRNAs were transfected
using Lipofectamine RNAiMAX (Life Technologies). For
cultured neurons, cells were incubated with Accell siRNAs
previously described (27, 29). For cytochalasin D (CytoD; Life
Technologies) treatment, neurons were incubated with 0.25
$g/ml CytoD (in DMSO) for 24 h.
Plasmids
A mammalian expression vector of glutathione S transferase
(GST) was prepared by cloning GST cDNA into pCI-neo
(Promega, Madison, WI, USA) to form pCIneo-GST. The
GST fusion protein constructs of pCIneo-GST-FE65 WW,
pCIneo-GST-FE65 PTB1, and pCIneo-GST-FE65 PTB2 were
made by subcloning of the FE65 corresponding cDNAs (WW
domain, aa 248–290; PTB1 domain, aa 361–514; and PTB2
domain, aa 531–676) into pCIneo-GST, respectively. The
GST fusion protein constructs of pCIneo-GST-ARF6, pCIneo-
GST-ARF6 1–80, pCIneo-GST-ARF6 28–175, pCIneo-GST-
ARF6 48–175, and pCIneo-GST-ARF6 73–175 were made by
subcloning of the ARF6 corresponding cDNAs into pCIneo-
GST, respectively. Mammalian expression constructs for wild-
type FE65, myc-tagged FE65, myc-tagged FE65 %PTB1, and
APP were as described previously (9, 10, 30). Wild-type Rac1
and N17Rac1 were as described previously (31). V12Rac1
mutant was generated by using QuikChange II site-directed
mutagenesis kit (Agilent Technologies, Santa Clara, CA,
USA). Myc/His- and GST-tagged wild-type ARF6 constructs
were generated by subcloning the full-length ARF6 cDNA
into pcDNA3.1/myc-His vectors (Life Technologies) and
pGEX-6P-1 (GE Healthcare Biosciences, Pittsburgh, PA, USA),
respectively. Myc/His-tagged mutant ARF6 T27N and Q67L
were generated by site-directed mutagenesis.
Antibodies
Mouse (9B11) and rabbit (71D10) anti-myc antibodies were
purchased from Cell Signaling Technology (Boston, MA,
USA). Rabbit anti-#-tubulin and mouse anti-#-tubulin (DM1A)
were from Abcam (Cambridge, MA, USA) and Sigma (St.
Louis, MO, USA), respectively. Anti-polyHistidine (HIS-1)
and anti-GST were purchased from Sigma. Rabbit anti-#-
tubulin was from Abcam. Anti-Rac1 (23A8) was obtained
from Millipore (Billerica, MA, USA). Rat polyclonal antibody
against ARF6 (AR3) was created by immunization of a rat with
GST-ARF6 fusion protein. Anti-ARF6 antibodies 3A-1 and
6ARF01 were purchased from Santa Cruz Biotechnology
(Dallas, TX, USA) and Millipore, respectively). Rabbit anti-
FE65 was as described previously (32); goat anti-FE65 (E20)
was obtained from Santa Cruz Biotechnology, and mouse
anti-FE65 (4H324) was from Abcam. FE65 is reported to be
phosphorylated by several kinases at various residues, which
can lead to reduction in electrophoretic mobility of FE65 (10,
33, 34). Therefore, multiple FE65 bands would be seen in
Western blot analysis. Since the phosphorylation status of
FE65 might vary from different samples, different banding
patterns might be observed.
GST fusion protein binding assays
The GST-ARF6 and GST-FE65 PTB1 were expressed in E. coli
BL21 and captured by glutathione-Sepharose 4B (GE Health-
care Biosciences) according to the manufacturer’s instruc-
tions. GST pulldown assays were performed essentially as
described previously (32). In ARF6 pulldown assays, GST and
GST-ARF6 baits were used to pull down FE65 from trans-
fected cell lysates. Cells were harvested in ice-cold lysis buffer
(50 mM Tris/HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; 1%
Triton X-100; and Complete protease inhibitor; Roche).
Following lysis, cells were cleared by centrifugation at 14,000
g at 4°C. The lysates were incubated with the baits at 4°C for
1 h. The captured proteins were boiled in SDS-PAGE sample
buffer and then analyzed by SDS-PAGE and Western blotting.
For mammalian GST fusion protein binding assays, CHO
cells were transfected with GST ! ARF6, GST-FE65 WW !
ARF6, GST-FE65 PTB1 ! ARF6, or GST-FE65 PTB2 ! ARF6.
Cells were harvested in ice-cold lysis buffer as described
above. Lysates were incubated with glutathione-Sepharose at
4°C for 1 h. The captured proteins were then analyzed by
SDS-PAGE and immunoblotting. Similar assays were also
performed for cells transfected with GST-FE65 PTB1! ARF6,
GST-FE65 PTB1 ! ARF6 T27N, or GST-FE65 PTB1 ! ARF6
Q67L. Mammalian GST-ARF6 fusion protein pulldown of
FE65 were also performed by the method as described above.
To perform direct protein-binding assay, His6-ARF6 was ex-
pressed in E. coli BL21, purified by Ni-NTA agarose (Qiagen,
Hilden, Germany), and incubated with purified GST or
GST-FE65 PTB1 baits in ice-cold lysis buffer. The protein
complexes were captured by glutathione-Sepharose 4B and
analyzed by SDS-PAGE.
To determine the state of ARF6 (i.e., ARF6-GDP or ARF6-
GTP) that interacts with FE65, bacterial GST-FE65 PTB1 was
used to pull down dominant negative ARF6 T27N and con-
stituently active ARF6 Q67L mutants from transfected CHO
338 Vol. 28 January 2014 CHEUNG ET AL.The FASEB Journal ! www.fasebj.org
cell lysates. In brief, ARF6-transfected cells were harvested in
ice-cold lysis/binding/wash buffer (25 mM Tris-HCl, pH 7.2;
150 mM NaCl; 5 mM MgCl2; 1% Nonidet P-40; 5% glycerol;
and protease inhibitor cocktail) and then cleared by centrif-
ugation. The lysates were incubated with the bacterial GST-
FE65 PTB1 baits at 4°C for 1 h. The captured proteins were
boiled in SDS-PAGE sample buffer and then analyzed by
SDS-PAGE and Western blotting.
To further confirm the state of ARF6 that interacts with
FE65, wild-type ARF6-transfected cell lysates were loaded with
either GDP or GTP by incubating with 1 mM GDP or 10 mM
nonhydrolyzable GTP!S, respectively, at 30°C for 15 min and
then followed by bacterial GST-FE65 PTB1 pulldown assays as
described above.
Coimmunoprecipitation assays
CHO cells transfected with either FE65, FE65 " myc-tagged
ARF6, or FE65#PTB1 " myc-tagged ARF6 were harvested in
ice-cold lysis buffer. Myc-tagged ARF6 was immunoprecipi-
tated from cell lysates by 9B11 anti-myc antibody at 4°C for 16
h. The antibody was captured by protein A-agarose (Sigma) at
4°C for 2 h. The immunoprecipitates were washed 3 times
with ice-cold lysis buffer and then boiled in SDS/PAGE
sample buffer for 10 min. Proteins in the immunoprecipitates
were analyzed by SDS-PAGE and Western blotting. For en-
dogenous interaction between FE65 and ARF6, the rat brain
was homogenized in ice-cold lysis buffer and cleared by
centrifugation as described above. ARF6 was immunoprecipi-
tated from the lysate and was detected by 3A-1 anti-ARF6
antibody, whereas FE65 was detected by E20 anti-FE65 anti-
body.
ARF6 activation assays
ARF6 activation was determined using an active Arf6 pull-
down kit (Cell Biolabs, San Diego, CA, USA). The principle of
the kit is based on the fact that active ARF6 (i.e., ARF6-GTP)
binds specifically to the protein-binding domain (PBD) of
GGA3 (33). To determine the ARF6-GTP level, cells were
harvested in ice-cold lysis/binding/wash buffer and then
cleared by centrifugation. The cleared lysates were incubated
with GST-GGA3-PBD bait (i.e., GST-GGA3-PBD fusion protein
coupled on glutathione-Sepharose that is supplied with the
kit) at 4°C for 3 h. The amounts of ARF6-GTP pulled down by
the bait and total ARF6 in the lysates were analyzed by
immunoblotting using 6ARF01 mouse monoclonal antibody.
Rac 1 activation assays
Rac1-GTP levels in cells were determined by using a Rac1
activation assay (ThermoScientific). In this assay, only Rac1-
GTP interacts with GST-PAK1-PBD bait (34, 35). In brief, cells
were harvested in assay/lysis buffer (25 mM HEPES. pH 7.5,
150 mM NaCl; 1% Nonidet P-40; 10 mM MgCl2; 1 mM EDTA;
2% glycerol; and protease inhibitor cocktail) and followed by
centrifugation. The cleared lysates were incubated with GST-
PAK1-PBD bait (i.e., GST-PAK1-PBD fusion protein coupled
on glutathione-Sepharose that is supplied with the kit) to pull
down Rac1-GTP. The levels of Rac1-GTP pulled down by the
bait and total Rac1in the cell lysates were detected by Western
blotting using 23A8 mouse monoclonal antibody.
Immunofluorescence studies and neurite length
measurements
Neurons grown on coverslips were fixed in 4% (w/v) para-
formaldehyde in PBS for 10 min, permeabilized in 0.1%
Triton X-100 in PBS, blocked with 5% fetal bovine serum
(FBS) in PBS for 30 min, and then probed with primary
antibodies in 5% FBS/PBS. For FE65 and ARF6 colocalization
studies, FE65 was detected using goat anti-FE65 (E20) and rat
anti-ARF6. Primary antibodies were detected using Alex-
aFluor-coupled secondary Igs and nuclei labeled with 4=,6-
diamidino-2-phenylindole (DAPI) (all from Invitrogen). Cov-
erslips were mounted in Fluorescence Mounting Medium
(Dako, Carpinteria, CA, USA). For intensity correlation anal-
ysis, images were captured using a Zeiss LSM510Meta confo-
cal microscope equipped with a $63, Plan-Apochromat 1.4
NA objective (Zeiss, Oberkochen, Germany), and analyzed
using ImageJ (U.S. National Institutes of Health, Bethesda,
MD, USA) with the intensity correlation analysis plug-in
essentially as described by us and others (29, 36, 37). Further
calculations and statistical analyses were performed using
Excel (Microsoft Corp., Redmond, WA, USA) and SPSS 15
(IBM, Chicago, IL, USA). Light-microscopy was performed
using a Leica DM5000B microscope with $63 HCX PL
Fluotar phase objective.
For neurite length measurements, we employed a widely
used approach that involves cotransfecting enhanced green
fluorescent protein (EGFP)-expressing plasmid [pEGFP-C1
(Clontech) in this study] into neurons (31, 38, 39). Since GFP
has a uniform distribution throughout neurons, it therefore
was used to determine cell shape and also act as a marker for
transfected neurons. In brief, pEGFP-C1 was cotransfected
with different constructs and/or with different siRNAs into
2-day in vitro (DIV) primary rat cortical neurons. All GFP-
expressing neurons were immunostained for cotransfected
protein to confirm expression. Healthy neurons were distin-
guished based on their morphologically normal nuclei
stained by DAPI. The longest neurite of the transfected
neurons was analyzed after 24 h for each treatment. Three
independent experiments, with !40 neurons each, were
performed in a blind manner. The lengths were determined
as the distance from the growth cone tip to the periphery of
the cell body and quantified using ImageJ with NeuronJ
plug-in (40). Statistical analyses were performed using 1-way
ANOVA test with Bonferroni post hoc test. Differences were
considered significant at P % 0.05.
RESULTS
FE65 interacts directly with ARF6 through the PTB1
domain
From a yeast 2-hybrid screen of a human brain cDNA
library using FE65 PTB1" 2 domain as bait, we isolated
a cDNA clone encoding the small GTPase ARF6. The
FE65-ARF6 interaction in yeast was confirmed using
LacZ liquid assays (data not shown).
To further analyze the FE65-ARF6 interaction, bacte-
rially expressed GST and GST-ARF6 fusion proteins
were used as baits to pull down FE65 from transfected
cells. In this assay, GST-ARF6, but not GST, interacted
with FE65 (Fig. 1A). We next tested the FE65-ARF6
interaction using immunoprecipitation assays from
transfected cells. FE65 was transfected either alone or
cotransfected with myc-tagged ARF6 and ARF6 then
immunoprecipitated via the myc tag. FE65 was present
in immunoprecipitates from the FE65 " ARF6 but not
FE65 singly transfected control cells (Fig. 1B). To
demonstrate that endogenous FE65 interacts with en-
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Figure 1. FE65 interacts with ARF6 via its PTB1 domain. A) ARF6 binds
to FE65 in GST pulldown assays. E. coli-expressed GST and GST-ARF6
were used as baits in pulldown assays from FE65-transfected cells. FE65 in
the cell lysates and pulldowns were detected using a goat anti-FE65.
Coomassie blue gel showed the GST and GST-ARF6 baits. B) FE65 and
ARF6 interact in immunoprecipitation assays from transfected cells.
Immunoprecipitations were performed from CHO cells transfected with FE65 or FE65 ! myc-tagged ARF6. ARF6 was
immunoprecipitated using anti-myc antibody 9B11. Immunoprecipitated FE65 and ARF6 were detected by a goat
anti-FE65 and a rat anti-ARF6, respectively. Symbols " and ! indicate the absence or presence of myc antibody 9B11
in the immunoprecipitations. C) FE65 interacts endogenously with ARF6. ARF6 was immunoprecipitated from rat
brain lysate using anti-ARF6 (3A-1). ARF6 was detected using rat anti-ARF6 antibody and FE65 using goat anti FE65
antibody. Immunoprecipitated FE65 and ARF6 were detected by a goat anti-FE65 and a rat anti-ARF6, respectively.
Symbols " and ! indicate the absence or presence of anti-ARF6 (3A-1) in the immunoprecipitations. D) ARF6
(continued on next page)
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dogenous ARF6, we immunoprecipitated ARF6 from
rat brain and probed these immunoprecipiates for
FE65. FE65 was present in the ARF6 immunoprecipi-
tates (Fig. 1C). Thus, FE65 and ARF6 interact in yeast
2-hybrid, GST pulldown, and immunoprecipitation as-
says, and endogenous FE65 interacts with endogenous
ARF6 in immunoprecipitation assays from rat brain.
We next determined which domain of FE65 interacts
with ARF6. To do so, we cotransfected CHO cells with
full-length ARF6 and mammalian expression constructs
encoding GST or GST fused to different domains of
FE65. The domains were the WW domain, the first PTB
domain (PTB1), and the second PTB domain (PTB2).
GST pulldowns from the cell lysates were performed,
and these were then probed on immunoblots for ARF6.
These assays revealed that only GST-FE65 PTB1 inter-
acted with ARF6 (Fig. 1D). Furthermore, FE65!PTB1
mutant could not interact with ARF6 in coimmunopre-
cipitation assay (Fig. 1E). To determine the region in
ARF6 that mediates FE65-ARF6 interaction, we pulled
down FE65 from transfected cell lysate using various
GST-ARF6 deletion mutants. FE65 could be pulled
down by GST-ARF6 28–175 (also ARF6 1–80 and
full-length ARF6) but not ARF6 48–175 (Fig. 1F). This
result suggests that aa 28–47 of AFR6 (a region that
contains the guanine nucleotide binding switch I, resi-
dues 36–47, of ARF6) are critical for the interaction
with FE65. To examine whether this interaction is
direct (and not mediated by some other intermediary
protein), we incubated E. coli purified His-ARF6 with E.
coli purified GST or GST-FE65 PTB1 baits. Similar to
the assays above, His-ARF6 was pulled down by GST-
FE65 PTB1 but not GST (Fig. 1G). Taken together,
these results demonstrate that ARF6 interacts directly
with the FE65 PTB1 domain.
FE65 preferentially binds to the inactive ARF6-GDP form
Similar to other small GTPases, ARF6 exists in a GTP-
bound active and a GDP-bound inactive state. These
two states have distinct structures that alter the interac-
tions between ARF6 and its binding proteins (for
reviews, see refs. 21, 22). Therefore, it is possible that
FE65 binds differentially to these two states of ARF6. To
test this possibility, ARF6 Q67L and T27N mutants,
which mimic the GTP- and GDP-bound states, respec-
tively (for reviews, see refs. 21, 22), were utilized in both
mammalian and bacterial GST-FE65 PTB1 pulldown
assays (Fig. 2A, B). In the mammalian GST pulldown
assay, GST-FE65 PTB1 was cotransfected with either
wild-type ARF6 or the ARF6 mutants. GST-FE65 PTB1
was pulled down from the transfected cell lysates, and
the amounts of bound ARF6 were detected by immu-
noblotting. FE65 PTB1 domain interacted more
strongly with ARF6 T27N than wild-type ARF6 but did
not interact with ARF6 Q67L (Fig. 2A). Likewise, simi-
lar pulldown assays using bacterial expressed GST-FE65
PTB1 as bait revealed that FE65 PTB1 domain bound
strongly to ARF6 T27N but not ARF6 Q67L (Fig. 2B).
The specificities of the ARF6 mutants were confirmed
by GST-GGA3 pulldown assay in which the bait prefer-
ably binds to ARF6 Q67L mutant (Fig. 2B), which is
similar to those published elsewhere (41, 42). To further
preclude the possibility that this differential binding is
an artifact of using the artificial mutants, we treated the
wild-type ARF6 transfected cell lysates with either GDP
or nonhydrolyzable GTP"S to load either GDP or GTP
nucleoside triphosphates onto ARF6 and then tested
binding of GDP- and GTP-bound ARF6 to FE65 in
pulldown assays. The GDP-bound and GTP-bound
states of ARF6 were confirmed by performing ARF6
GTPase activation assays; GTP bound ARF6 interacts
more strongly with GGA3 in these assays (Fig. 2C,
bottom panel). In line with the assays involving mutants
of ARF6, GDP-ARF6 interacted stronger than GTP-
ARF6 with FE65 PTB1 domain (Fig. 2C, top panel).
Thus, FE65 preferentially interacts with GDP- but not
GTP-bound ARF6.
FE65 activates both endogenous ARF6 and Rac1
Typically, ARF effectors bind to ARF-GTP, and this sug-
gests that FE65 does not function downstream of ARF6 as
an effector protein. We therefore speculated that FE65
functions upstream to regulate ARF6 activation in some
fashion. To test this possibility, we monitored the effect of
modulating FE65 expression on the ARF6 activation.
Overexpression of FE65 increased endogenous ARF6
activation (as detected using GGA3 pulldown ARF6 as-
says), whereas FE65 siRNA knockdown reduced ARF6
activation (Fig. 3A, B). These findings implicate that
although it preferentially binds to ARF6-GDP form, FE65
promotes the activation of ARF6.
A large body of evidence indicates that the small
interacts with FE65 via FE65 PTB1 domain. Myc-tagged ARF6 was cotransfected with GST, GST-FE65 WW, PTB1, or PTB2
domains into CHO cells. GST-FE65 fusion proteins were then pulled down, and the samples were probed on immunoblots for
ARF6 and the GST baits as indicated. Approximately 12% of ARF6 in the input lysate was pulled down by GST-FE65 PTB1.
E) FE65 PTB1 domain is essential for the interaction. Myc-tagged ARF6 was cotransfected with FE65 or FE65!PTB1 into CHO
cells. ARF6 was immunoprecipitated from the lysates using myc antibody 9B11. ARF6 and FE65 in the precipitates were detected
using rat anti-ARF6 antibody and FE65 using goat anti FE65 antibody, respectively. Symbols # and $ indicate the absence or
presence of myc antibody 9B11 in the immunoprecipitations. F) Residues 28 to 47 of ARF6 is important for FE65-ARF6
interaction. Myc-tagged FE65 was cotransfected with GST, GST-ARF6, ARF6 1–80, ARF6 28–175, ARF6 48–175, or ARF6 73–175
into CHO cells. GST-ARF6 fusion proteins were then pulled down and the samples probed on immunoblots for FE65 and the
GST baits as indicated. Schematic diagram shows the ARF6 mutants. G) FE65 PTB1 domain interacts directly with ARF6. E.
coli-expressed GST and GST-FE65 PTB1 were used to pull down purified His-tagged ARF6. Left panel: Coomassie-stained gel of
the recombinant proteins. Right panel: pulldown assays.
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GTPase Rac1 is a downstream effector of ARF6 activa-
tion (refs. 43–47; for review, see ref. 48). The above
observations prompted us to investigate whether FE65
also activates endogenous Rac1. We therefore per-
formed Rac1 activation assays (which involved assaying
binding of Rac1 to its effector PAK1 in pulldown assays)
in cells in which FE65 expression was modulated.
Overexpression of FE65 by transfection increased Rac1
activation, whereas siRNA knockdown of FE65 reduced
Rac1 activation in these assays (Figs. 3C, D). To deter-
mine whether this stimulatory effect of FE65 on Rac1
activation involved ARF6, we performed similar Rac1
activation assays in cells in which ARF6 levels were
depleted using siRNAs. In control siRNA-transfected
cells, overexpression of FE65 again increased Rac1
activation but this stimulatory effect was abolished in
ARF6 knockdown cells (Fig. 3E). Thus, FE65 acts
upstream of ARF6 to regulate Rac1 activation.
FE65 and ARF6 colocalize in neuronal growth cones
Rac1 regulates actin dynamics within neurons, and
during development, Rac1 controls neurite outgrowth
via effects on the actin cytoskeleton within growth
cones (for reviews, see refs. 49–51). Since FE65 regu-
lates Rac1 activity, we therefore enquired whether FE65
and ARF6 colocalize in developing neurons and in
particular, whether they colocalized in growth cones.
Immunostaining for ARF6 revealed that it was princi-
pally a cytoplasmic protein in neurons that was en-
riched in perinuclear regions but also present in pro-
cesses and growth cones (Fig. 4A, B). To determine
whether FE65 and ARF6 colocalize in growth cones, we
immunostained neurons and utilized intensity correla-
tion analyses (ICAs; ref. 37) to determine whether
there was significant overlap in the distribution of the
two proteins in growth cones. ICA compares the scatter
plots of 2 stains against the product of the difference of
the pixel intensities of each of the two stains from their
respective means. Thus, ICA determines whether the
pixel intensities from 2 signals vary in synchrony and as
such is superior to many other methods for determin-
ing the extent of colocalization of proteins in cells and
tissues. The values obtained from the analyses can be
reported as an intensity correlation quotient (ICQ),
which is a statistically testable, single value assessment
of the relationship between 2 stained protein pairs: for
random staining, ICQ ! 0; for dependent staining
(colocalization), 0 " ICQ ! #0.5; and for segregated
staining, $0.5 ! ICQ " 0. Both ARF6 and FE65 were
enriched in growth cones of developing rat cortical
neurons (Fig. 4B), and ICA revealed that they colocal-
ized to a highly significant level within this subcellular
compartment (mean%sem ICQ!0.225%0.01, P"0.001;
n!36 cells).
FE65 and ARF6 stimulate neurite outgrowth
Since Rac1 regulates neurite outgrowth and we demon-
strated that FE65 and ARF6 regulate Rac1 activity, we
determined the effects of modulating FE65 and ARF6
expression on neurite outgrowth in rat cortical neu-
Figure 2. FE65 preferentially binds to GDP bound ARF6. A) Mammalian expression construct of GST-FE65 PTB1 was
cotransfected with ARF6, ARF6 T72N (mimicking ARF6-GDP), or ARF6 Q67L (mimicking ARF6-GTP). FE65 was pulled down
using the GST tag, and the amounts of bound ARF6 were detected by immunoblotting. Samples of both the input lysates and
pulldowns are shown. GST-FE65 PTB1 bait pulled down 10, 23, and 2% of ARF6, ARF6 T27N, and ARF6 Q67L from the
corresponding input lysates, respectively. B) E. coli-expressed GST-FE65 PTB1 domain was used as bait in pulldown assays from
CHO cells transfected with myc-tagged ARF6, ARF6 T27N, or ARF6 Q67L. ARF6 in the input lysates and pulldowns was detected
by anti-myc 9B11. Coomassie blue gel (third panel) showed GST-FE65 PTB1 baits used in the pulldowns. GST-FE65 PTB1 bait
pulled down 12, 27, and 0.7% of ARF6, ARF6 T27N, and ARF6 Q67L from the corresponding input lysates, respectively. Control
pulldowns using GST-GGA3 as bait were performed in which the bait preferably binds to ARF6 Q67L mutant. EV-transfected cell
lysates are included in panels A and B to demonstrate overexpression of ARF6. C) E. coli-expressed GST-FE65 PTB1was used as
baits in pulldown assays from myc-tagged ARF6-transfected lysates incubated with either GDP or GTP&S (to load either GDP or
GTP onto ARF6). ARF6 was detected by anti-myc 9B11. Also shown is an ARF6 activation assay (bottom panels) to demonstrate
activation of ARF6 (increased binding to GST-GGA3 bait) in GTP&S-treated lysates.
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rons. We first tested the effect of overexpressing FE65
and/or ARF6 on neurite outgrowth. To do so, we
transfected DIV2 rat cortical neurons with either FE65;
FE65 lacking PTB1 (FE65!PTB1, which does not bind
ARF6); or FE65 lacking PTB2 (FE65!PTB2) together
with ARF6 and monitored neurite outgrowth, as de-
Figure 3. FE65 stimulates both endogenous ARF6 and Rac1 activation. A, B) FE65
stimulates ARF6 activation. CHO cells were either transfected with EV or
FE65 (A), or treated with either control (Ctrl) or FE65 siRNAs (B).
Endogenous active ARF6 was pulled down from the transfected cell lysates
using GST-GGA3-PBD bait (supplied in the active ARF6 pulldown kit; Cell
Biolabs) that interacts specifically with ARF6-GTP. ARF6-GTP bound to the
bait was analyzed on immunoblots. Immunoblots showing FE65, ARF6, and
"-tubulin levels as a loading control in the cell lysates are also shown. FE65 was
detected using anti-FE65 E20, ARF6 using anti-ARF6 6ARF01 and anti-"-tubulin
DM1A. Overexpression of FE65 stimulates (A, top panel) while siRNA knock-
down of FE65 inhibits (B, top panel) ARF6 activation. Longer exposures
revealed the presence of ARF6 in the GGA3 pulldowns in control transfected
cells in panel A. C, D) FE65 stimulates Rac1 activation. CHO cells were either EV
transfected or transfected with FE65 (C) or treated with either control or FE65
siRNAs (D). Endogenous active Rac1 was pulled down from the transfected cell
lysates using GST-PAK1 PBD bait [supplied in the Rac1 activation assay (Ther-
moScientific), which binds Rac1-GTP]. Rac1-GTP bound to the bait was
analyzed on immunoblots using anti-Rac1 23A8. Immunobots showing FE65,
Rac1, and "-tubulin levels as a loading control in the cell lysates are also shown. Overexpression of FE65 stimulates (C, top
panel) while knockdown of FE65 inhibits (D, top panel) Rac1 activation. E) Rac1 activation by FE65 requires ARF6. CHO cells
were treated with control or ARF6 siRNAs and transfected with either EV or FE65. Rac1 activation assays were then performed.
Top panel: immunoblot of the amounts of Rac1 in the PAK1 PBD pulldown assays. Also shown are immunoblots for FE65,
ARF6, Rac1, and "-tubulin levels as a loading control in the cell lysates. Overexpression of FE65 did not trigger Rac1 activation
in ARF6 knockdown cells (top panel, lane 2 vs. lane 4).
Figure 4. ARF6 is present in perinuclear regions
and processes in developing neurons and colo-
calizes with FE65 in growth cones. Rat cortical
neurons were immunostained at DIV2 for en-
dogenous ARF6, FE65, and actin (via Alex-
aFluor-546 labeled phalloidin) and nuclei la-
beled using DAPI. A) Perinuclear and neurite
labeling of ARF6. B) FE65 and ARF6 are pres-
ent in both the cell bodies and processes but
show a high level of colocalization in growth
cones. Zoomed area of box with growth cone is
shown. Scale bars # 10 $m.
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scribed previously (31). Expression of FE65 or ARF6
both stimulated neurite outgrowth, and this effect was
more pronounced in FE65 ! ARF6 cotransfected neu-
rons. However, the effect of FE65 was lost in neurons
expressing FE65"PTB1 that does not bind ARF6 (Fig. 5A).
Intriguingly, the stimulatory effect of FE65 was also
markedly decreased when the PTB2 domain was de-
leted (Fig. 5A). This suggests that FE65 PTB2 domain
also plays a role in mediating neurite extension.
We next tested how loss of ARF6 or FE65 influenced
neurite outgrowth. Analyses of these neurons revealed
that siRNA knockdown of either ARF6 or FE65 both
reduced neurite outgrowth (Fig. 5B, C). However,
overexpression of FE65 did not rescue the effect of
ARF6 knockdown (Fig. 5B) and FE65 knockdown did
not influence the stimulatory effect of ARF6 on neurite
outgrowth (Fig. 5C). Immunoblots revealed that both
the FE65 and ARF6 siRNAs induced efficient knock-
down in the neurons (Fig. 5D). These results support
the notion that FE65 acts upstream of ARF6 to promote
neurite outgrowth and are thus complementary to the
biochemical studies (Figs. 2 and 3), which place FE65 as
an upstream regulator of ARF6 and Rac1.
Rac1 is indispensible for FE65 and ARF6 stimulation
of neurite outgrowth
As shown in the biochemical assays, FE65 stimulates
ARF6-Rac1 signaling (Fig. 3C, D). It is therefore possi-
ble that the effect of FE65 on neurite outgrowth
involves Rac1. To test this possibility, we monitored the
stimulatory effect of FE65 ! ARF6 expression on
neurite outgrowth in cells expressing a dominant-
negative Rac1 (N17Rac1; ref. 31). Overexpression of
wild-type Rac1 enhanced neurite outgrowth in FE65 !
ARF6 cotransfected neurons. However, N17Rac1 blocked
Figure 5. FE65 and ARF6 both stimulate neurite outgrowth, but the effect of FE65 is lost in the absence of ARF6. A–C) Rat
cortical neurons were transfected with EGFP as a cell morphology marker and different combinations of EV control plasmid,
FE65, FE65"PTB1, FE65"PTB2, ARF6, and either control, FE65, or ARF6 siRNAs as indicated. All transfections received the
same amounts of DNA. The length of the longest neurite was then determined 24 h later. Bar charts show fold changes in mean
neurite length for the longest neurite. Also shown are representative images of the different transfected cells. A) FE65 and ARF6
but not FE65"PTB1 stimulate neurite outgrowth. On the other hand, FE65"PTB2 induces a small increase in neurite extension.
B) Knockdown of ARF6 inhibits neurite outgrowth, and this affect is not influenced by overexpression of FE65. C) Knockdown
of FE65 inhibits neurite outgrowth, but this effect is rescued by overexpression of ARF6. Data were obtained from !40
cells/transfection, and the experiments were repeated 3 times. Error bars# sd. Scale bars# 10 $m. *P% 0.001. D) Immunoblot
demonstrating siRNA knockdown of FE65 and ARF6; also shown is an immunoblot for actin as a loading control.
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this effect of FE65! ARF6 (Fig. 6A). In agreement with
this, the stimulatory effect of FE65 and ARF6 on neurite
extension was markedly reduced in Rac1-knockdown
neurons (Fig. 6B). On the other hand, expression of
constitutively active Rac1 (V12Rac1) alone was sufficient to
stimulate neurite outgrowth (Fig. 6A, C). Knockdown
of either FE65 or ARF6 induced small decrease in
neurite extension of the V12Rac1 transfected neurons
(Fig. 6C). Such a reduction in neurite outgrowth might
due to the inactivation of endogenous Rac1 in the FE65
and ARF6 knockdown cells. Nevertheless, Rac1 appears
to be essential for the effect of FE65 and ARF6 on
neurite outgrowth.
To test if the effect of Rac1 on neurite outgrowth is
via actin-modeling, rat cortical neurons were treated
with actin-destabilizing agent CytoD. Decrease of neu-
rite outgrowth was observed in the empty vector (EV)-
transfected neurons treated with CytoD (Fig. 6D). The
stimulatory effect of V12Rac1 on neurite extension was
suppressed in the presence of CytoD (Fig. 6D). This
suggests that Rac1 stimulates neurite outgrowth in rat
cortical neurons, at least in part, via actin modeling.
DISCUSSION
In this study, we identify the small GTPase ARF6 as a
binding partner for the neuronal adaptor protein
FE65. FE65 contains a number of protein-protein inter-
action domains, including an N-terminal WW domain
and 2 C-terminal PTB domains, and we show that
binding of ARF6 is mediated via the first (N-terminal)
PTB1 domain. FE65 also binds to 2 nuclear proteins,
the histone acetyl transferase Tip60, and the transcrip-
tion factor CP2/LSF/LBP1 via PTB1 (9, 52, 53). Since
ARF6 is a cytoplasmic protein (Fig. 4A), it is unlikely to
compete CP2/LSF/LBP1 for binding to FE65. How-
ever, it is not known whether Tip60 competes with
ARF6 for FE65 PTB1, as a splice variant of Tip60, PLA2
interacting protein, localizes to both cytoplasm and
nucleus (54). In addition, several low-density lipopro-
tein receptor family members, including LRP1, ApoER2,
and VLDLR, have been shown to interact with FE65
PTB1 (55–60). Of note, LRP1 has been recently shown
to act as a myelin-associated glycoprotein receptor to
inhibit neurite outgrowth (61), ApoER2 functions as a
Reelin receptor to regulate neurite motility (62), and
VLDLR has also been implicated in neurite develop-
ment (63). Since we show here that binding of ARF6 to
FE65 PTB1 promotes neurite outgrowth, it is possible
that changes in binding of these different FE65 PTB1
ligands is a mechanism for regulating and fine-tuning
neurite outgrowth in different neuronal populations
during development. Indeed, such mechanisms may
also be conserved in the adult to regulate plasticity.
The mechanisms for binding of PTB domains with
their ligands has now been characterized in a number
of studies (for review, see ref. 64). Many PTB domain
ligands interact via canonical C-terminal NPXY or
NXXY sequences in which the tyrosine can be either
phosphorylated or nonphosphorylated (64). Although
ARF6 does not contain such sequences, the PTB do-
mains are now known to interact with ligands that do
not contain NPXY/NXXY sequences. For example,
binding of Deleted in liver cancer-1 to the tensin2 PTB
domain has recently been shown to involve a novel
interface and not the classical NPXY/NXXY sequence
(65). Association of ARF6 with the FE65 PTB1 domain
thus appears to resemble this less well-characterized
mode of interaction.
Since FE65 interacts with the guanine nucleotide
binding switch I of ARF6, this may provide an explana-
tion for the fact that FE65 preferably binds to the
ARF6-GDP as switch I undergoes conformational reor-
ganization during GDP/GTP cycle of ARF6 (66, 67).
Notably, such FE65-ARF6-GDP interaction stimulates
ARF6 activation. The mechanism that underlies this
stimulatory effect is unclear; certainly FE65 does not
structurally resemble any known GEF. Of note, several
ARF-interacting adaptor proteins that lack of intrinsic
GEF and GAP activities have been shown to alter ARF
activity. For example, Arfaptin1 was found to inhibit
ARF even though it binds to constitutively active mutant
of ARF (68, 69). As an adaptor protein, it seems likely
that FE65 may somehow mediate the recruitment of
other proteins (perhaps ARF6 GEFs) to modulate ARF6
activity. Indeed, there are precedents for such a model.
For example, GULP1 binds to ARF6 and the ARF6-GAP
ACAP1 to stimulate ARF6 activation (70).
ARF6 regulates a number of physiological processes,
including endocytosis, secretion, phagocytosis, cell ad-
hesion, and cell migration; in neurons, ARF6 also
regulates axon and neurite outgrowth (refs. 21, 22,
71–73; and results described here). This role in neurite
outgrowth is mediated, at least in part, via Rac1 depen-
dent actin remodeling in the growth cone; ARF6 local-
izes to the plasma membrane and recruits Rac1 to the
cell surface (for reviews, see refs. 21, 22). Interestingly,
APP is also present within growth cones and functions
in axonal outgrowth (19, 74–76), but the mechanisms
that underlie this function are not properly under-
stood. Both APP and FE65 have been implicated in
various cytoplasmic and nuclear processes (14). Of
note, APP has been shown to function as a cytosolic
docking site to retain FE65 in the cytoplasm through
the interaction between FE65 PTB2 and APP intracel-
lular domain (77). Therefore, it is possible that the role
of APP in axonal outgrowth may be to recruit FE65 to
growth cone membranes where it can then interact
with ARF6 via PTB1. In support of this notion, the
stimulatory effect of FE65 on neurite outgrowth was
significantly reduced when the PTB2 domain was de-
leted (i.e., FE65"PTB2). Since FE65"PTB2 remains
concentrated at the growth cone (Supplemental Fig.
S1), such recruitment of FE65 by APP may occur after
FE65 entry to growth cones. Once recruited, the FE65-
ARF6 interaction might then stimulate the activation of
ARF6 and downstream Rac1 so as to modulate actin
dynamics. Interestingly, FE65 also binds via its WW
domain to mammalian enabled (Mena), a member of
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Figure 6. Rac1 is indispensable for FE65 and ARF6 stimulation of neurite
outgrowth. A, B) Stimulation of neurite outgrowth by FE65 and ARF6 is abrogated
in cells coexpressing a dominant-negative Rac1 (A) or transfected with Rac1
siRNA (B). A) Rat cortical neurons were transfected with EGFP and either EV,
FE65 ! ARF6, FE65 ! ARF6 ! Rac1, FE65 ! ARF6 ! N17Rac1 (dominant-
negative Rac1), or V12Rac1 (constitutively active Rac1). B) Rat cortical neurons were transfected with EGFP and
either EV, FE65 ! ARF6 ! control siRNA, and FE65 ! ARF6 ! Rac1 siRNA. C) Immunoblot shows siRNA
knockdown of Rac1. Constitutively active Rac1 stimulates neurite outgrowth. Rat cortical neurons were transfected
with EGFP and either EV, V12Rac1 ! control siRNA, V12Rac1 ! FE65 siRNA, or V12Rac1 ! ARF6 siRNA. In panels
A–C, the length of the longest neurite was determined 24 h later. D) Effect of constitutively active Rac1 on neurite
outgrowth is suppressed in the presence of CytoD. Rat cortical neurons were transfected with EGFP and either EV
or V12Rac1. Neurons were treated with either DMSO or 0.25 "g/ml CytoD for 24 h. Length of the longest neurite
was then measured. Bar charts show fold changes in mean neurite length for the longest neurite. Also shown are
representative images of the different transfected cells. Data were obtained from !40 cells/transfection, and the
experiments were repeated 3 times. Error bars # sd. Scale bars # 10 "m. *P $ 0.001.
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the Ena/Vasp family of actin regulatory proteins (78).
Furthermore, FE65 and Rac1 have been shown to
interact in a coimmunoprecipitation assay (79). Thus,
FE65 may perform critical functions within growth
cones to recruit various molecules and integrate a
variety of signaling cascades that control axon out-
growth.
In our study, actin-destabilizing agent CytoD abol-
ished the stimulatory effect of V12Rac1 on neurite
extension (Fig. 6). It may suggest that destabilization of
actin has an inhibitory effect on the process. However,
the role of actin depolymerization in neurite develop-
ment remains controversial (80–90). The causes for
such contradictory data are not fully understood; how-
ever, they may due to the differences of neuron types,
ages, animal strains, culture conditions, and experi-
mental approaches employed. Further studies are re-
quired to find out the reasons for such conflicting
observations.
Many of the cellular mechanisms that regulate axon
and dendritic outgrowth during development are con-
served in the adult and function at the synapse to
control plasticity. As such, the FE65-ARF6-Rac1 interac-
tion we describe here may also function in synapses.
Synaptic dysfunction and loss are key features of Alz-
heimer’s disease. Disruption to ARF6 function has
recently been implicated in the pathogenesis of
Alzheimer’s disease via ARF6 control of BACE1 traf-
ficking; BACE1 processing of APP is required for
production of A! (91). Our findings suggest that
perturbation of FE65/ARF6 function might also dis-
rupt synaptic function via alterations in Rac1 depen-
dent actin remodeling.
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